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ABSTRACT
THE DISCOVERY AND CHARACTERIZATION OF SMALL MOLECULE
INHIBITORS OF PYRUVATE CARBOXYLASE
Brittney N. Wyatt
Marquette University, 2018
Pyruvate carboxylase is a metabolically important enzyme that has been implicated in a
wide range of diseases and infections such as cancer, diabetes and listeriosis. Despite the
importance of pyruvate carboxylase in these diseases and infections, there are no
selective and potent small molecule effectors available to study pyruvate carboxylase
both in vitro and in vivo. Effective small molecule effectors of pyruvate carboxylase will
expand the biochemical toolkit to facilitate the investigation of the structure, regulation
and specific cellular role of pyruvate carboxylase. To discover small molecule effectors
of pyruvate carboxylase, a novel fixed time assay was developed. The assay is based on
the reaction of the diazonium salt, Fast Violet B, with the final product of the pyruvate
carboxylase catalyzed reaction, oxaloacetate. This robust assay was validated and was
used to screen numerous compounds in a high throughput format. In addition to highthroughput screening, a structure-based drug design project was implemented to
specifically target the unique carboxyltransferase domain of pyruvate carboxylase,
leading to the discovery of potent competitive inhibitors with respect to pyruvate. These
compounds provide the foundation for chemical probes that target pyruvate carboxylase
and have the potential to benefit a wide range of in vitro and in vivo studies that are
investigating the role of pyruvate carboxylase in cancer, diabetes and listeriosis.
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CHAPTER 1: INTRODUCTION
1.1. The Metabolic Context of Pyruvate Carboxylase
Pyruvate carboxylase (PC) was first discovered in liver homogenates by Utter and
Keech in 1959, when it was established that pyruvate could become carboxylated to form
oxaloacetate (OAA) in the presence of Mg2+, ATP, acetyl CoA and CO2 (Utter and Keech
1960). PC is an important anaplerotic enzyme that replenishes OAA as it is withdrawn
from the TCA cycle to become a precursor in lipid and amino acid biosynthetic pathways
(Jitrapakdee et al. 2008). PC catalyzes the first step of gluconeogenesis in a wide range of
organisms including prokaryotes and eukaryotes (Zeczycki, St. Maurice, and Attwood
2010). PC is primarily located in the mitochondria in eukaryotes and in the cytosol of
prokaryotes (Zeczycki, St. Maurice, and Attwood 2010). In eukaryotic gluconeogenesis,
as pyruvate enters the mitochondria, it is carboxylated to OAA by PC (Jitrapakdee et al.
2008). Depending on the levels of NADH in the mitochondria and cytoplasm, OAA is
converted to either malate or phosphoenolpyruvate (PEP) (Jitrapakdee et al. 2008). If
there are high levels of NADH in the mitochondria and low levels of NADH in the
cytoplasm, malate dehydrogenase (MDH) converts OAA to malate (Jitrapakdee et al.
2008). Malate is subsequently transported out of the mitochondria and converted back to
OAA with the reduction of NAD+ to NADH (Jitrapakdee et al. 2008). Cytosolic
phosphoenolpyruvate carboxykinase (PEPCK) catalyzes the conversion of OAA to PEP
which is accordingly converted back to pyruvate, allowing the cycle to replenish NADH
levels in the cytoplasm (Jitrapakdee, Vidal-Puig, and Wallace 2006, Jitrapakdee et al.
2008, Yang, Kalhan, and Hanson 2009). The accumulation of NADH in the cytoplasm
promotes the reduction of 1,3-bisphosphoglycerate to glyceraldehyde 3-phosphate as part
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of gluconeogenesis (Jitrapakdee et al. 2008). If there are low levels of NADH in the
mitochondria, OAA is converted to PEP by mitochondrial PEPCK and transported by the
tricarboxylic acid anion carrier system to the cytoplasm where it is sequentially converted
to glucose in the reverse pathway of glycolysis (see Figure 1-1).
Individuals who are born with mutated versions of PC and are PC deficient have
shorter lifespans with symptoms ranging from severe lactic acidaemia, hypoglycemia and
mental retardation (Marin-Valencia, Roe, and Pascual 2010, Robinson 2006). As there is
a reduction in pyruvate carboxylation to OAA in PC deficient individuals, the buildup of
pyruvate is converted to lactate by lactate dehydrogenase (LDH) resulting in lactic
acidaemia (Habarou et al. 2015). Hypoglycemia results from the lack of OAA production
and subsequent gluconeogenesis, reducing the amount of glucose available to the body
(Owen, Kalhan, and Hanson 2002). Additionally, reduced OAA pools impact fatty acid
synthesis, as OAA is an essential precursor to lipid biosynthesis, resulting in a plethora of
developmental issues including mental retardation (Jitrapakdee et al. 2008). Aberrant PC
expression has been implicated in diseases such as diabetes and cancer, and in certain
bacteria where the metabolic function of PC is essential to maintain infection (see Table
1-1 for an overview).
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Figure 1-1. The Role of PC in Gluconeogenesis

Figure 1-1. The role of PC in gluconeogenesis. PC catalyzes the conversion of
pyruvate to OAA in the TCA cycle. This reaction replenishes TCA cycle intermediates
that are withdrawn for other biosynthetic pathways. PC plays an important role in
gluconeogenesis (indicated in purple). In conditions where cytosolic NADH levels are
low, OAA is converted to malate by MDH and shuttled out of the mitochondria,
represented by the double blue circle, to the cytosol via the malate transporter,
represented by the green cylinder, where it is subsequently converted back to OAA. OAA
in the cytosol is converted to PEP by PEPCK to continue the cycle of NADH generation
in the cytosol. In conditions where cytosol NADH levels are high, mitochondrial PEPCK
will convert OAA to PEP in the first committed step of gluconeogenesis, represented by
the dashed purple line. OAA is transported to the cytosol by the tricarboxylic acid anion
carrier system, represented by the dotted purple lines.
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1.1.1. Diabetes
Pancreatic b-cells are responsible for secreting insulin to maintain glucose
homeostasis within the body (Henquin 2000). Diabetes results when there is an
insufficient amount of insulin secreted to meet the demands of increased glucose in the
blood or due an inadequate systemic response to circulating insulin (Henquin 2000).
Alternatively, hypoglycemia results when too much insulin has been released (Henquin
2000). This signaling mechanism between glucose levels and insulin secretion is
regulated by anaplerotic processes (Flamez et al. 2002, Farfari et al. 2000). Despite being
incapable of carrying out gluconeogenesis due to PEPCK (MacDonald et al. 1992,
MacDonald et al. 2005) and fructose-1,6-bisphosphatase deficiency (MacDonald et al.
2005), pancreatic b-cells express PC at levels that are almost equivalent to those in the
gluconeogenic tissues of the liver and kidneys. PC is responsible for converting almost
half of the pyruvate that enters pancreatic b-cells to OAA in rats (Khan, Ling, and
Landau 1996), but that role appears to be decreased 20-30% in human islet cells
compared to the rodent model (MacDonald et al. 2011). PC is an important enzyme that
facilitates the anaplerotic control mechanism of insulin secretion (Jensen et al. 2006).
OAA that is formed by the PC-catalyzed reaction is important in pyruvate cycling where
it is converted to malate, citrate or isocitrate through various mitochondrial and cytosolic
enzymes (Lu et al. 2002). This pyruvate cycling generates a high NADPH: NADP and
ATP:ADP ratio that regulates glucose-stimulated insulin secretion (Xu et al. 2008, Hasan
et al. 2008). Studies have found that PC expression is decreased in type 2 diabetes and is
correlated to an impairment of glucose-induced insulin release (MacDonald, Efendic, and
Ostenson 1996, Han and Liu 2010, Fransson et al. 2006). Not only does PC regulate
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insulin release in the pancreas, it also controls hepatic gluconeogenesis (Lao-On,
Attwood, and Jitrapakdee 2018). In conditions of insulin resistance, excessive lipolysis in
white adipose tissue results in the accumulation of free fatty acids in the plasma that are
oxidized in the liver (Wallace, Easterbrook-Smith, and Keech 1985). Acetyl CoA is
generated through this oxidation process and acts as an allosteric activator of PC,
increasing PC activity (Kumashiro et al. 2013). An increase in PC activity results in an
increase of gluconeogenesis, leading to hyperglycemia (Kumashiro et al. 2013).
Hyperglycemia impairs insulin secretion from the pancreas (Jitrapakdee, Vidal-Puig, and
Wallace 2006).
1.1.2 Cancer
A classic hallmark of cancer is the ability of cancer cells to reprogram their
metabolism (Pavlova and Thompson 2016, DeBerardinis and Chandel 2016). An example
of this reprogramming is demonstrated by the Warburg effect. The Warburg effect is a
common observation that cancer cells will predominately utilize glycolysis for pyruvate
production that is converted to lactate by LDH, even under aerobic conditions (Kim and
Dang 2006). Additionally, cancer cells adapt to increase their nutrient intake to support
proliferation and biomass formation. With the increased demand for energy, cancer cells
alter the way in which they direct glycolytic and TCA cycle intermediates for the
biosynthesis of fatty acids, amino acids, nucleotides and the production of NADPH
(Vander Heiden, Cantley, and Thompson 2009). Consequently, anaplerotic routes play an
important role in sustaining the TCA cycle while many of its intermediates are withdrawn
(Cheng et al. 2011). However, the preference for particular anaplerotic routes, such as
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pyruvate carboxylation by PC, is specific for different types of cancer (Pavlova and
Thompson 2016).
1.1.2.1 Breast Cancer
The leading cause of cancer related death for women is breast cancer (Jemal et al.
2011). A majority of those deaths are a result of breast cancer metastasis to the blood,
bone or brain (Scully et al. 2012). PC is abundantly expressed in breast cancer cells that
are highly invasive such as MDA-MB-435 and MDA-MB-231 cell lines, but is not
abundant in non-aggressive cell lines such as MCF-7 and SKBR3 (Phannasil et al. 2015).
Cell lines that are highly invasive and aggressive depend on the anaplerotic mechanisms
of PC (Phannasil et al. 2015) whereas cell lines such as MCF-7 are more dependent on
glutamine-dependent anaplerosis (Forbes et al. 2006). Furthermore, it was found that the
size and motility of tumors are related to the expression of PC in breast cancer cells.
When PC was overexpressed in MCF-7 cells, the cells increased in size, motility and
invasion (Phannasil et al. 2015). Alternatively Christen et al. suggested that PC
expression in cancer cells is controlled by the in vivo microenvironment in certain types
of tissues (Christen et al. 2016). For example, the authors compared primary breast
cancer cells located in the breast tissue and the same type of cells that had metastasized to
the lung, noting that there was an increase in PC expression and PC-dependent
anaplerosis in the lung metastases (Christen et al. 2016). While it is still unclear how PC
expression is regulated and the exact role of PC-dependent anaplerosis in breast cancer,
recent studies suggest that PC is important in the metastasis of certain types of breast
cancer cells (Christen et al. 2016).
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1.1.2.2 Lung Cancer
Similarly to breast cancer, PC expression levels have been found to be increased
in lung cancer tissue (Fan et al. 2009). In particular, PC expression has been found to be
3- to 10-fold higher in early stages of non-small-cell lung cancer (NSCLC) than when
compared to noncancerous lung tissue (Sellers et al. 2015). NSCLC accounts for the most
frequent type of lung cancer in non-smokers and constitutes 80-85% of all lung cancer
cases (Ettinger et al. 2017). Sellers et al. confirmed that when PC expression was reduced
via shRNA in NSCLC cell lines, there was a decrease in cell proliferation with a
reduction in nucleotide and lipid biosynthesis, consistent with a decrease in PCdependent anaplerosis (Sellers et al. 2015).
1.1.2.3 Succinate Dehydrogenase-Deficient Cancer
As it was stated previously, cancer cells adapt to increase their nutrient intake to
support proliferation and biomass formation by altering the way in which they direct
glycolytic and TCA cycle intermediates. Succinate dehydrogenase (SDH) oxidizes the
conversion of succinate to fumarate in the TCA cycle and is important in maintaining a
fully functional TCA cycle (Rutter, Winge, and Schiffman 2010) Mutations in SDH lead
to an increase in succinate and surprisingly have been associated with certain types of
cancers such as neuroendocrine neoplasms, gastrointestinal tumors and renal carcinomas
(Cardaci et al. 2015, Lussey-Lepoutre et al. 2015). Cancer cells that are SDH deficient
have an interrupted TCA cycle and despite the deficiencies in aspartate, citrate and
malate, are still capable of sustaining cellular proliferation to establish an oncogenic
phenotype (Lussey-Lepoutre et al. 2015). Due to this metabolic interruption, cancer cells
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metabolically reprogram anaplerotic routes that are important in replenishing TCA cycle
intermediates. SDH deficiency, in particular, results in a critical dependency on PC
anaplerosis (Cardaci et al. 2015, Lussey-Lepoutre et al. 2015). SDH-deficient cancer cells
increase the carboxylation of pyruvate through PC that generates OAA to replenish TCA
cycle intermediates and to supply OAA for aspartate synthesis (Cardaci et al. 2015,
Lussey-Lepoutre et al. 2015). The interrupted TCA cycle in SDH-deficient cancers are
solely dependent on PC for aspartate biosynthesis (Cardaci et al. 2015, Lussey-Lepoutre
et al. 2015). Cardaci et al. demonstrated that silencing of PC expression significantly
reduced cellular growth in SDH-deficient cancer cell in vitro while having little effect on
the wild-type cells (Cardaci et al. 2015), highlighting the metabolic vulnerably of SDHdeficient cancer cells and the potential of PC to be targeted for SDH-deficient cancers.
1.1.3 Viral Infections
PC is an important metabolic host enzyme and scaffold for certain viral infections
(Lao-On, Attwood, and Jitrapakdee 2018). Herpes simplex virus type I (HSVI)
reprograms host cells to increase PC expression for viral nucleic acids and protein
synthesis (Vastag et al. 2011, Grady et al. 2013). Influenza A H1N1 reprograms host cell
metabolism to not only increase PC-dependent anaplerosis but glutamine-dependent
anaplerosis as well (Janke et al. 2011). Not only is PC expression increased by certain
viruses but there is also evidence that PC physically interacts with and acts as a scaffold
for the nonstructural NS5A protein of hepatitis C virus (HCV) (Yim et al. 2013). NS5A
interacts with the biotin carboxylase domain of PC (described in Section 1.4) and downregulates PC expression (Yim et al. 2013). While counterintuitive, Yim et al.
hypothesizes that NS5A may act as an on/off switch for PC activity so that HCV can
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control host metabolism towards virus replication (high PC expression) or viral assembly
(low PC expression) (Yim et al. 2013). Interestingly, PC is also important in activating an
antiviral immune response against RNA viruses such as Influenza A, human enterovirus
71 (EV71) and vesicular stomatitis virus (VSV) (Cao et al. 2016). PC suppresses the
replication of RNA viruses by targeting the mitochondrial antiviral signaling protein
(MAVS) signalosome and triggers the release of nuclear factor kappa B (NF-kB),
resulting in increased interferon and cytokine levels (Cao et al. 2016). The interaction of
MAVS with PC seems to be due to structural scaffolding that is independent of PC
activity (Cao et al. 2016), highlighting the importance of PC as a structural scaffold in
cellular systems.
1.1.4 Bacterial Infections
PC is found in a wide range of bacteria, but not in enteric bacteria that utilize
phosphoenolpyruvate carboxylase (PEPC) to convert PEP directly to OAA thus
excluding the need for PC (Jitrapakdee et al. 2008). In particular, PC is important in the
growth of Bacillus subtilis (Diesterhaft and Freese 1973), Pseudomonas aeruginosa
(Choi et al. 2016, Kukavica-Ibrulj et al. 2008, Phibbs, Feary, and Blevins 1974)
Staphylococcus aureus (Benton et al. 2004), Listeria monocytogenes (Schar et al. 2010,
Whiteley et al. 2017) and Lactococcus lactis (Choi et al. 2017). S. aureus and L.
monocytogenes are pathogenic bacteria that can cause serious infections such as
antibiotic-resistant skin infections (Choo and Chambers 2016) and listeriosis (Cossart and
Lebreton 2014), respectively. Studies have linked bacterial metabolism to virulence for
microbes such as S. aureus and L. monocytogenes (Eisenreich et al. 2010, Schar et al.
2010, Sureka et al. 2014, Whiteley et al. 2017). This relationship between metabolism
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and pathogenicity is well exemplified in L. monocytogenes (Schar et al. 2010, Sureka et
al. 2014, Whiteley et al. 2017). L. monocytogenes has an interrupted citric acid cycle
much like SDH deficient cancer cells, except L. monocytogenes does not encode for aketoglutarate dehydrogenase. PC is crucial for L. monocytogenes growth inside host cells
during infection as it is the predominate source of OAA generation within the bacterium.
L. monocytogenes cannot utilize host OAA as the bacterium apparently lacks OAA
permease (s) (Schar et al. 2010). Due to the interrupted TCA cycle, L. monocytogenes is
metabolically vulnerable, and PC deficient bacteria are attenuated in mouse sepsis models
(Schar et al. 2010).
Table 1-1. Summary of the Importance of PC in Disease and Infection
Disease/Infection

Tissue/Organism

PC Expression

Type 2 Diabetes

Pancreatic b-cells

Decreased

Type 2 Diabetes

Liver/Kidneys

Increased

Breast Cancer

Metastasized tumors

Increased

Non-Small Cell Lung Cancer

Lungs

Increased

*SDH Deficient Cancers

Various

Essential

*Listeriosis

L. monocytogenes

Essential

*Indicates interrupted TCA cycle
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1.2 Pyruvate Carboxylase Structure and Function
PC is a multifunctional, biotin dependent enzyme that exists predominately in the
a4 form which consists of four identical polypeptide chains organized together to form a
homotetramer of ~500kDa (Jitrapakdee et al. 2008) . Each subunit contains a biotin
carboxylase (BC), biotin carboxyl carrier protein (BCCP), carboxyltransferase (CT) and
allosteric domain. The homotetramer is organized such that there are two layers, each
containing two subunits with CT/CT and BC/BC domain interface interactions between
the top and bottom layer (St Maurice et al. 2007) (see Figure 1-2A). The MgATPdependent carboxylation of pyruvate by HCO3- to form OAA occurs in two distinct active
sites, the BC domain and the CT domain (Jitrapakdee et al. 2008). Biotin, which is
covalently attached to a specific lysine residue in the BCCP domain, is carboxylated in
the BC domain to form carboxybiotin (Jitrapakdee et al. 2008). The carboxybiotin is
subsequently transferred via the BCCP domain to the CT domain where pyruvate is
carboxylated to form OAA (Jitrapakdee et al. 2008) (see Figure 1-2B).
The BC domain structures are conserved across biotin dependent enzymes (Tong
2013) and have similar structural architectures that contain an ATP-grasp fold
(Jitrapakdee et al. 2008). It is assumed that all biotin dependent enzymes catalyze the
first partial reaction of the MgATP-dependent carboxylation of biotin from HCO3through similar mechanisms (Menefee and Zeczycki 2013). For the first partial reaction
of the PC domain that results in the carboxylation of biotin, the BC domain requires free
Mg2+, MgATP, HCO3-, and biotin to be bound in the BC domain (Menefee and Zeczycki
2013). The binding of the BC domain substrates induces a closed conformation for biotin
carboxylation to occur through the formation of carboxyphosphate and biotin enolate
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intermediate. After biotin has been carboxylated to carboxybiotin, it is transferred to the
CT domain for the second partial reaction where pyruvate is carboxylated to form OAA.
The core structure of the CT domain consists of a TIM-barrel that forms a funnellike structure (Jitrapakdee et al. 2008). Centered at the base of the funnel is an essential
catalytic Mn2+/Zn2+ metal ion that was proposed to stabilize the enolpyruvate
intermediate through a bidentate interaction (Mildvan, Scrutton, and Utter 1966, YongBiao et al. 2004), but recent crystal structures demonstrate that this interaction does not
occur (Lietzan and St Maurice 2013b). Before pyruvate binds, the CT domain is in an
open conformation and upon pyruvate binding, the CT domain adopts a closed
conformation that promotes the carboxylation of pyruvate to form OAA (Lietzan and St
Maurice 2013a). The transition between this open and closed state is centered within the
flexible loop region of Arg621-Asn630 (RePC residue numbering). Based on the overlay
structures of RePC (St Maurice et al. 2007), RePCDBCDBCCP (Lietzan and St Maurice
2013a, b), LmPC (Sureka et al. 2014), and SaPCDBC (unpublished) without pyruvate
present, Arg621 is either disordered or occupies multiple conformations. When pyruvate
binds, the position of Arg621 becomes fixed through a salt bridge with the carboxyl
moiety of pyruvate and the guanidinium side-chain of the arginine, while Gln552 and
Arg548 are within hydrogen bonding distance of the carbonyl oxygen of pyruvate (Lietzan
and St Maurice 2013b) (see Figure 1-3A). Additionally, crystal structures of PC with
pyruvate bound in the CT domain demonstrate that Tyr628 rotates to form a hydrogen
bond with Asp590 (Xiang and Tong 2008a, Lietzan and St Maurice 2013b, a) (see Figure
1-3B). The carbonyl oxygen of pyruvate is oriented toward the tightly bound metal ion
and this positioning of pyruvate with respect the metal ion is observed to be bridged by a
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water molecule (Lietzan and St Maurice 2013a). The binding mechanism has been
proposed to induce the closed conformation of the CT domain such that Arg621, Gln552
and Arg548 are responsible for stabilizing the enolpyruvate intermediate while Tyr628 and
Asp590 are responsible for establishing a substrate-induced binding pocket for
carboxybiotin (Lietzan and St Maurice 2013a). Once bound, carboxybiotin is
subsequently decarboxylated to form an anionic enol intermediate that is stabilized by
Gln844, Ser884 and Lys866 (Zeczycki et al. 2009). Thr882 acts as general acid to protonate
the biotin enol intermediate and as a general base to shuttle a proton from pyruvate to
biotin, forming the enolpyruvate intermediate (Zeczycki et al. 2009). The enolpyruvate
intermediate is subsequently carboxylated to form OAA.
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Figure 1-2. The Structure and Function of a4 PC

Figure 1-2. The structure and function of a4 PC. A) Surface representation of the
homotetramer of SaPC (pdb i.d. 3bg5). The top layer or “top face” of the homotetramer is
composed of two individual subunits. The bottom layer or “bottom face” is also
composed of two individual subunits (yellow surface representation). Each subunit
contains a BC domain (cyan), allosteric domain (blue), CT domain (green), and BCCP
domain (gray). One subunit of the homotetramer has been outlined in black. B) Cartoon
representation of one subunit of the homotetramer and the general scheme of the BC and
CT domain reaction. The BC domain catalyzes the MgATP- and HCO3- -dependent
carboxylation of biotin. The carboxybiotin is subsequently transferred to the CT domain
by the swinging arm movement of the BCCP domain where pyruvate is carboxylated to
form OAA.
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Figure 1-3. Comparison of the Closed and Open Conformation of the Six Key
Catalytic Amino Acids, Arg621, Gln552, Arg548, Tyr628 and Asp590 in the CT Domain of
SaPC

Figure 1-3. Comparison of the closed and open conformation of the six key catalytic
amino acids, Arg621, Gln552, Arg548, Tyr628 and Asp590 in the CT domain of SaPC (pdb i.d.
3bg5) A) Upon the binding of pyruvate, the CT domain adopts a closed conformation
where the carboxyl moiety of pyruvate forms a salt bridge with the guanidinium sidechain of Arg621 and the carbonyl oxygen of pyruvate is within hydrogen bonding distance
of Arg548 and Gln552. These residues are responsible for stabilizing the enolpyruvate
intermediate. In the closed conformation, Tyr628 forms a hydrogen bond with Asp590. B)
The contrast between the open (light purple) and closed conformation (green) can be seen
with the 90° rotation of Tyr628 and the uncoordinated (open) vs coordinated position of
Arg621.
1.3 Existing Methods to Study the Role of Pyruvate Carboxylase in Disease and
Infection
The studies described in Section 1.1 highlight the importance of PC expression in
diabetes, cancer and listeriosis that are sustained as a result of aberrant or essential PC
expression. PC has been implicated in these diseases and infections primarily through
genetic tools such as knockouts, antisense oligonucleotides, and siRNAs that target the
PC gene. For example, the essential role of PC in listeriosis was determined by genome
sequence analysis (Glaser et al. 2001) and insertional mutagenesis of pycA, the gene
encoding PC, in L. monocytogenes (Schar et al. 2010). Pyruvate carboxylation by PC was
shown to be the exclusive route of OAA formation in L. monocytogenes (Schar et al.

16
2010). Without PC, the bacterium could no longer effectively replicate inside host cells,
leading to an attenuated rate of virulence in mouse sepsis models (Schar et al. 2010).
Additionally, genetic manipulation of the pycA gene in L. monocytogenes when
compared to wild-type L. monocytogenes, was shown to have reduced glucose
metabolism as indicated by the downregulation of glycolysis genes, but the authors were
unable to identify the exact cause of this observation (Schar et al. 2010). PC is an
important scaffold for other metabolic enzymes such as MDH and aspartate
aminotransferase (Fahien, Davis, and Laboy 1993). The differential regulation of
glucose-controlled genes in the pycA mutant could have been a consequence of removing
PC as a scaffold for MDH and aspartate aminotransferase or as direct consequence of
removing the catalytic activity of PC from L. monocytogenes.
As a result of not only the catalytic, but structurally relevant role of PC as a
scaffold, genetic tools such as knockouts, siRNAs and ASO that reduce PC expression
levels are likely to impact multiple cellular systems. It is difficult to know the exact role
that PC activity has in cancer, diabetes or bacterial infections, independent of PC
expression. In other words, attempts to study the role of PC activity using genetic tools
also impact PC expression. Small molecule effectors of PC have the potential to
circumvent issues that arise with genetic manipulation of PC. The advantage of small
molecule regulation as compared to gene knockout or silencing is that small molecules
can alter specific catalytic functions without eliminating the gene product from the
cellular system, thus precluding unintentional effects, such as a change in MDH or
aspartate aminotransferase activity in the cell. Currently, there are no known specific and
potent small molecules that can regulate PC activity without affecting other enzymes in
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the cellular context. For example, in certain bacteria like L. monocytogenes and L. lactis,
cyclic-di-AMP (c-di-AMP) is a recently discovered allosteric regulator that decreases PC
activity with a KD value of 8 µM (Sureka et al. 2014, Choi et al. 2017), making it one of
the most potent inhibitors of PC to be documented. However, even with a compound like
c-di-AMP that has been used both in vivo and in vitro to elucidate the importance of PC
in bacterial metabolism, it is difficult to assess the direct and specific role of PC. This is
due to c-di-AMP not being specific for PC and binding to a broad range of proteins
(Commichau et al. 2015). Experiments that have utilized L. monocytogenes PC knockouts
to study the relationship between c-di-AMP and PC in the cellular context of bacterial
metabolism are still subject to off target effects and to the possible downstream
consequences of disrupting other enzymatic systems. For example, upon cellular
infection of host cells, L. monocytogenes releases c-di-AMP that has a wide range of
consequences not only for L. monocytogenes, but for the host cell as well (Radoshevich
and Cossart 2018, Woodward, Iavarone, and Portnoy 2010). Specific and potent small
molecules that can regulate PC activity without affecting other enzymes in the cellular
context would be able to specifically activate and inhibit PC activity, while avoiding
disruption of PC expression.
1.4 Methods for Small Molecule Probe Discovery
There are many screening approaches that can be taken to discover novel, potent
and specific small molecule effectors of PC. These methods vary by the primary assay
that is applied in the screen, the type of molecules that are being screened against, the
detection system and the sampling availability of small molecules (Keseru and Makara
2006). The type of small molecules that can be screened against can be broadly classified
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as drug-like or fragment-like compounds (Rees et al. 2004, Lamoree and Hubbard 2017,
Keseru and Makara 2006). Drug-like compounds have molecular weights that average in
the low 300s and have drug-like physicochemical and structural properties (Lipinski
2004, Carr and Jhoti 2002). Drug-like compounds are typically associated with highthroughput screening (HTS) procedures where large libraries of up to 10,000-100,000
compounds can be assessed per day with miniaturized screening assays and automatic
robotic systems (Mayr and Bojanic 2009). Fragment-like compounds are smaller and are
more likely to bind to a wider range of targets due to the lack of additional functional
groups that may spatially prevent binding (Lamoree and Hubbard 2017). Fragment-like
compounds are useful in fragment-based lead discovery or structure-based drug design
(SBDD) that can further improve fragment hits for selectivity and potency by adding
functional groups to the fragment (Lamoree and Hubbard 2017).
Fragment-like and drug-like compounds can be used in bioassay-based screening,
affinity screening or in silico screening. Bioassay-based screening includes the rigorous
development and validation of an analytical method that measures a biological process
(Janzen 2014). These screening assays are typically biochemical assays that measure
enzyme activity or cell-based assays that screen for phenotypes in cells, tissues and whole
organisms (Janzen 2014). Zebrafish are an example of a whole organisms that have been
utilized successfully in cell-based screening assays. Zebrafish larvae in particular, are
ideal whole organisms for screening as they are small enough to be dispensed in 96-well
plates, are permeable to compounds and are transparent for non-invasive imaging
(Mathias, Saxena, and Mumm 2012). Bioassay-based screening that is utilized in HTS
can be beneficial for discovering compound hits that are more specific for a biological
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process, but assay optimization and hit confirmation can be difficult in biological systems
(Janzen 2014).
Affinity or biophysical assays are based on physical interactions between the
screened compound and selected target rather than the effect on a biological system (Carr
and Jhoti 2002). Techniques for affinity assays include nuclear magnetic resonance
(NMR) (Carr and Jhoti 2002), mass spectrometry (MS) (Jonas, LaMarr, and Ozbal 2009)
and X-ray crystallography (Caliandro et al. 2013). NMR and X-ray crystallography in
particular, are useful for SBDD and fragment-based screening approaches (Carr and Jhoti
2002). The advantage with affinity assays is the structural information that is discovered
through the screening process. For example, structure activity relationships (SAR) in
NMR studies can assess where a ligand is binding, and X-ray crystallography can provide
binding orientations of molecular fragments. X-ray crystal structures in particular, greatly
enhance the ability to generate lead compounds (Carr and Jhoti 2002). Fragment-like
compounds can be screened individually or as cocktails (combination of 4-8 compounds)
by soaking the compounds with crystals and observing for electron density in the binding
site for any small molecules (Carr and Jhoti 2002). However, X-ray crystallography is
resource intensive and the number of compounds that are able to be screened with this
method are limited.
In silico assays, or computational assays, require a knowledge-driven approach
based on available structural information of either the desired ligands or known target
selection (Congreve, Murray, and Blundell 2005). In silico assays are beneficial due to
their ability to screen numerous diverse compounds computationally and can be utilized
for quantitative structure-activity relationships (Ekins, Mestres, and Testa 2007). This
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method involves docking compounds into a known active site (ligand-based screening) or
screening for a target that will computationally bind to a compound that is of interest
(target-based screening) (Ekins, Mestres, and Testa 2007). Target-based screening is
more limited as there are not as many protein structures available as there are compound
structures (Ekins, Mestres, and Testa 2007). However, in silico assays may be limited by
the ability to test the predictive targets or compounds in biological assays.
Acetyl CoA carboxylase (ACC) is an example of a biotin dependent enzyme that
has been targeted in a variety of screening methods, one of which has resulted in the
successful discovery of potent small molecule inhibitors (Marjanovic et al. 2010,
Harriman et al. 2016). ACC catalyzes the conversion of acetyl CoA to malonyl CoA
through two distinct half reactions, the carboxylation of biotin with HCO3- in the BC
domain and the subsequent transfer of the carboxyl group by the BCCP domain to
carboxylate acetyl CoA in the CT domain (Li and Cronan 1992). This reaction catalyzes
the first committed step in fatty acid biosynthesis (Li and Cronan 1992). While there are
several examples of assays that have been developed to detect ACC activity in a highthroughput manner in cell-based (Marjanovic et al. 2010), biochemical (Kroeger,
Zarzycki, and Fuchs 2011, Marjanovic et al. 2010) and in silico assays (Vyas et al. 2017)
only one will be discussed further. A validated HTS assay has been developed that
specifically targets the CT domain of ACC based on a modified coupled enzyme assay
that measures the reverse reaction of the CT domain in which biocytin reacts with
malonyl CoA to form carboxybiotin and acetyl CoA. Citrate synthase was coupled to this
reaction and catalyzed the reaction of acetyl CoA to CoA and citrate. CoA levels were
detected by 5,5-Dithiobis(2-nitrobenzoic acid) (DTNB) and the signal was measured at
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412 nm (Santoro et al. 2006). In addition to the development of screening assays for
ACC, a potent allosteric inhibitor (ND-630) for ACC, was identified through SBDD
(Harriman et al. 2016). This compound disrupts the protein-protein interactions at the BC
dimerization site of ACC and inhibits enzyme activity (Harriman et al. 2016). ND-630
has been transitioned to in vivo studies where it reduced weight gain and improved
insulin sensitivity in diet-induced obese rats (Harriman et al. 2016).
ACC is an excellent example of a biotin dependent enzyme that has been the
target of a variety of screening approaches and demonstrates the success of developing
HTS assays, compound development and validation of lead compounds applied to in vivo
studies. It demonstrates that similar methods can be taken to discover novel small
molecule effectors of PC. We have taken two approaches to discover novel, potent and
specific small molecule effectors of PC that will be discussed further in this dissertation:
1) HTS and 2) SBDD. HTS is a method that can find small molecule effectors that have
novel binding sites or modes of action, and lead to new insights into the regulation and
mechanism of PC. SBDD in contrast, is a rational approach that takes advantage of small
molecule effectors bound to PC. Based on available structural information, we can
discover and design small molecules to be more potent and specific for PC.
1.5 Overview
PC is metabolically important enzyme that has been implicated in a wide range of
diseases and infections such as cancer, diabetes and listeriosis. Despite the importance of
PC in these diseases and infections, there are no specific and potent small molecule
effectors available to study pyruvate carboxylase both in vivo and in vitro. Small
molecule effectors of pyruvate carboxylase can benefit studies that investigate the
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structure, regulation and specific cellular role of PC in diseases and infections. To
discover small molecule effectors of PC, a novel fixed time assay has been developed.
The assay is based on the reaction of the diazonium salt, Fast Violet B (FVB), with OAA,
the final product of the PC catalyzed reaction. The assay is robust, validated and has been
applied to screen numerous compounds in a high throughput format. SBDD was
implemented to specifically target the unique CT domain of PC, and lead to the discovery
of potent inhibitors that are competitive with respect to pyruvate. These compounds can
provide the foundation for chemical probes development that specifically targets PC.
These compounds have the potential to benefit a wide range of in vivo and in vitro studies
that investigate the role of PC in cancer, diabetes and listeriosis.
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CHAPTER 2: MATERIALS AND METHODS
2.1 General Protein Purification Method
Rhizobium etli PC (RePC) was co-expressed from a modified pET-17b-(His)9
vector (Chapman-Smith et al. 1994) with a pCY216 vector (St Maurice et al. 2007)
encoding E. coli biotin protein ligase (BirA) in E. coli BL21Star(DE3) cells. S. aureus PC
(SaPC) (Xiang and Tong 2008b), SaPC truncations with the removal of the BC and/or
BCCP domain (SaPCDBC and SaPCDBCDBCCP) and L. monocytogenes (PC) LmPC
were co-expressed from a pET-28a vector with a pCY216 vector in E. coli
BL21Star(DE3) cells. RePC, LmPC, SaPC, SaPCDBC and SaPCDBCDBCCP were
purified using Ni2+-affinity and anion exchange chromatography as previously described
(Lietzan et al. 2011). In all cases, harvested cells were re-suspended in a lysis buffer
containing 20 mM Tris (pH 7.8), 5 mM imidazole, 200 mM NaCl, 0.5 mM EGTA, 6 mM
2-mercaptoethanol, lysozyme (300 µg/mL), 1 mM phenylmethane-sulfonyl fluoride
(PMSF), 1 µM pepstatin A, and 5 µM proteinase inhibior E-64. Cells were disrupted by
sonication and the cell lysate was cleared by centrifugation at 4°C prior to loading onto a
10 mL Ni2+-NTA Profinity resin column (Bio-Rad Laboratories). The column was
washed with 150 mL of lysis buffer followed by 150 mL of wash buffer (20 mM Tris (pH
7.8), 20 mM imidazole, 200 mM NaCl, 0.5 mM EGTA, 6 mM 2-mercaptoethanol). The
RePC enzyme was eluted from the column in elution buffer (20 mM Tris (pH 7.8), 250
mM imidazole, 200 mM NaCl, 0.5 mM EGTA, 6 mM 2-mercaptoethanol) with an 88 mL
gradient of 20 mM imidazole wash buffer to 250 mM imidazole elution buffer. For SaPC,
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SaPCDBC, SaPCDBCDBCCP and LmPC, the enzymes were eluted in a single step
elution with 25 - 30 mL elution buffer.
All purified protein samples were pooled and dialyzed overnight in 1 L of QSepharose buffer containing 20 mM triethanolamine (pH 8.0), 50 mM NaCl, 1 mM
EGTA, and 2 mM DTT at 4°C in preparation for anion exchange chromatography.
Protein was loaded on a 10 mL column of Q-Sepharose Fast Flow resin (GE Healthcare)
and the column was washed with 60 mL of Q-Sepharose buffer. The RePC protein was
eluted from the resin in Q-Sepharose buffer using a linear gradient from 50 mM to 1 M
NaCl over 88 mL. For SaPC SaPCDBC, SaPCDBCDBCCP and LmPC, the enzymes were
eluted in a single step elution with 25 - 30 mL of Q-sepharose buffer containing 1 M
NaCl. Fractions were pooled and dialyzed against a storage buffer consisting of 10 mM
Tris (pH 7.8), 150 mM KCl, 3 mM MgCl2, 5% (v/v) glycerol and 2 mM DTT. An
Amicon stirred cell with a 30,000-molecular weight cutoff filter was used to concentrate
protein preparations to a range of 3 - 12 mg/mL. Concentrated protein was flash-frozen in
liquid nitrogen prior to storage at -80 °C.
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CHAPTER 3: THE DEVELOPMENT OF A HIGH-THROUGHPUT SCREENING
ASSAY FOR PYRUVATE CARBOXYLASE
3.1 Introduction
As described in Chapter 1, recent studies have linked aberrant PC activity to
several diseases and infections, such as type 2 diabetes, listeriosis, and certain types of
cancers (Cheng et al. 2011, Christen et al. 2016, Farfari et al. 2000, Jensen et al. 2006,
Phannasil et al. 2015, Schar et al. 2010, Xu et al. 2008, Lao-On, Attwood, and
Jitrapakdee 2018). Studies focused on the role of PC in insulin secretion and tumor cell
proliferation have revealed a strong correlation between reduced PC expression/activity
and decreased insulin release, while enhanced PC expression and activity has been
associated with tumor cell proliferation and breast cancer metastases (Hasan et al. 2008,
Phannasil et al. 2015, Cheng et al. 2011, Christen et al. 2016). Additionally, PC is the
primary enzyme that produces OAA in L. monocytogenes, a facultative intracellular
bacterium, and has been shown to be vital for the bacterium's pathogenicity as PCdeficient L. monocytogenes mutants are unable to replicate in host cells (Whiteley et al.
2017, Schar et al. 2010, Sureka et al. 2014).
While there is a growing realization that PC activity is implicated in a wide range
of diseases and infections, at present, there are no specific and potent small molecule
effectors available to study altered PC activity in vitro or in vivo. A number of small
molecules are known to alter PC activity (Zeczycki, Maurice, and Attwood 2010, Choi et
al. 2017, Zeczycki, St. Maurice, and Attwood 2010), but none of these demonstrate good
binding affinities and many of them are promiscuous, binding to multiple targets in
addition to PC. Oxalate for example, is an inhibitor of PC with a Ki value of 12 µM

26
(chicken liver PC (Zeczycki, St. Maurice, and Attwood 2010)), but is also a known metal
chelator (Makkar, Siddhuraju, and Becker 2007) that inhibits LDH (Novoa et al. 1959)
and transcarboxylase (Northrop and Wood 1969). Specific and potent small molecule
effectors of PC have great potential to be used as biochemical tools to aid in delineating
the structure, mechanism, and regulation, as well as its role in infection and disease. The
development of a high-throughput assay is an important prerequisite in discovering new
and potent effectors of PC activity.
Several well-established coupled-enzyme assays are available to study PC activity
(Zeczycki, Menefee, Adina-Zada, et al. 2011, Attwood and Cleland 1986a), but none of
these are well suited to HTS of small molecule effectors. The carboxylation of pyruvate
in PC is typically measured by coupling the formation of the product, OAA, to the MDH
catalyzed reduction of OAA to malate and oxidation of NADH to NAD+ (Attwood and
Cleland 1986b) (see Figure 3-1). This can be readily observed by measuring the change
in absorbance of NADH at 340 nm (Attwood and Cleland 1986a). In addition, there are a
variety of other coupled-enzyme assays that can measure the specific half-reactions
catalyzed in either the BC or CT domains. For example, an LDH-coupled assay can be
used to determine the rate of OAA decarboxylation in the CT domain by the NADHdependent reduction of pyruvate to lactate. Similarly, a glucose-6-phospate
dehydrogenase / phosphoglucomutase / phosphorylase coupled assay system can be used
to determine the rate of MgATP cleavage in the BC domain (Zeczycki, Menefee, AdinaZada, et al. 2011). These coupled-enzyme assays are generally inappropriate for
screening large libraries of small molecules. For instance, the inclusion of secondary
coupling enzymes raises the potential for small molecules to target the coupling enzyme

27
instead of, or in addition to, the target enzyme. While counter-screens of small molecules
against the coupling enzyme are routinely implemented in HTS programs, these represent
an additional step that must be performed to eliminate false positives (Glickman 2004,
Acker and Auld 2014). Furthermore, the vast majority of coupled-enzyme assays make
use of redox enzymes that act on NAD/NADH, requiring absorbance changes to be
monitored at 340 nm. This wavelength is suboptimal for the small assay volumes typical
of HTS assays, where short path lengths and low extinction coefficients limit the signal
window in a multi-well plate format (Inglese et al. 2007, Simeonov and Davis 2004,
Simeonov et al. 2008). Additionally, absorbance at 340 nm is subject to interference from
small molecules, dust particles and standard assay components (Inglese et al. 2007,
Simeonov et al. 2008), resulting in a decreased signal to noise ratio and an increased
number of false positives.
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Figure 3-1. Use of Malate Dehydrogenase to Assay Pyruvate Carboxylation

Figure 3-1. Use of malate dehydrogenase to assay pyruvate carboxylation. MDH reduces
OAA to malate while oxidizing NADH to NAD+. Initial velocities of PC are measured
through the decrease in absorbance of NADH at 340 nm. PC and MDH have been
highlighted to demonstrate the ability of small molecules to not only target PC, but also
to cross-react with MDH. Thus, a counter-screen for MDH would have to be established
if this assay was to be used as a primary screening assay.
To overcome the limitations associated with using coupled-enzyme assays, a
novel fixed-time assay has been developed (Wyatt, Arnold, and St Maurice 2018). After
the assay was optimized in a 96-well plate format, it was subsequently modified to a 384well plate format to decrease the demand on materials while increasing the efficiency
with which small molecules could be tested. The assay is based on the reaction of OAA,
the product of the PC-catalyzed reaction, with Fast Violet B, a diazonium salt which
produces a colored adduct with an absorbance maximum at 530 nm (see Figure 3-2).
Diazonium salts have previously been used to detect OAA formation in other enzymatic
systems such as phosphoenolpyruvate carboxylase and glutamic oxalacetic transaminase
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(Sax and Moore 1967, Cockburn et al. 1990, Lombarts and Peters 1971, Norris,
Atkinson, and Smith 1975, Babson et al. 1962a) , but FVB has never been applied to
determine PC activity. This chapter outlines the development of a fixed-time, FVB-based
assay to detect PC activity in a manner that is amenable to analyzing numerous small
molecule effectors of PC. The assay readout is stable for an extended time period and
accurately reports on enzyme activity from a single data point. The FVB fixed-time assay
is reproducible, sensitive and responsive to known effectors of PC. The assay was used to
screen a series of small molecule libraries that established the FVB assay as an excellent
primary assay to use in a concerted HTS program against PC in the future.
Figure 3-2. Proposed Mechanism for the Reaction of Oxaloacetate with Fast Violet
B

Figure 3-2. Proposed mechanism for the reaction of oxaloacetate with Fast Violet B.
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3.2 Materials and Methods
3.2.1 Preparation of Assay Reagents and Solutions
All assay reagents and solutions were prepared separately and maintained at 22 °C
for the full duration of the experiments. All substrates, effectors and enzyme were freshly
dissolved and diluted in assay buffer containing 50 mM Bis-Tris (pH 7.7), 150 mM KCl,
3.0 mM MgCl2, 0.5% triton X-100, and 1% DMSO. The final concentrations of enzyme,
substrates and effectors are in total assay volume (100 µL) before the addition of EDTA
and FVB. The final concentration of enzyme in the assay was 10 µg/mL, except for
LmPC where the final concentration of enzyme in the assay was 50 µg/mL. Where noted,
oxalate and acetyl coenzyme A (Crystal Chem Inc., Elk Grove, IL) were included in the
assay at a final concentration of 5 mM and 0.25 mM, respectively. The substrate solution
containing NaHCO3, pyruvate and ATP was added to the assay at a final concentration of
25 mM, 2 mM, and 1 mM, respectively. EDTA was prepared in assay buffer and served
to inactivate the enzyme-catalyzed reaction at a final concentration of 12.7 mM. Fast
Violet B Salt (FVB; Santa Cruz Biotechnology) was prepared at a stock concentration of
46 mM in DMSO. After vortexing the FVB stock solution to dissolve the dye, it was
centrifuged at 9,300 ×g for one minute and the clarified supernatant was separated from
the salt pellet. The resulting FVB stock solution was protected from light exposure until it
was introduced into the assay.
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3.2.2 Assay Procedures
For all experiments other than the evaluation Library of Pharmacologically
Active Compounds (LOPAC, Sigma) screens, the Microsource Discovery and Prestwick
screens (University of Wisconsin-Milwaukee (UWM)) and the National Cancer Institute
Developmental Therapeutics Program (NCI DTP) screen, 30 µL enzyme stock solution
was added to each well in 96-well, flat clear bottom, polystyrene microplates (Santa Cruz
Biotechnology) followed by the addition of 10 µL of the effectors (oxalate for inhibition,
acetyl CoA for activation, assay buffer for the un-inhibited or un-activated reaction, and
EDTA for measurement of the background signal). To initiate the enzyme-catalyzed
reaction, 60 µL of a substrate stock solution containing pyruvate, HCO3- and ATP in
assay buffer was added to each well. After one hour, the enzyme reaction was inactivated
by the addition of 10 µL of EDTA, followed by the addition of 10 µL of FVB for a total
volume of 120 µL. The plates were sealed with microseal ‘B’ adhesive seals (Bio-Rad)
and incubated for 2 hours at 22 °C, prior to measuring absorbance values at 530 nm with
a multi-well plate reader. All plates and reagents were kept at 22 °C for the duration of
the experiments. Reagents were dispensed using an automated liquid handling system
(MultiFlo FX, Biotek) except for the effectors which were manually added using a handheld, multi-channel micropipette. The 96-well plate format was modified to a 384-well
plate format and all of the steps described above are identical except that the volumes
were decreased by half so that the final volume was 60 µL. For the screens performed at
UWM (the LOPAC and Microsource Discovery Prestwick screens), the procedure was
slightly modified to incorporate a pintool (V&P Scientific) in combination with an Evo
system (Tecan Life Sciences) to transfer the controls. After the addition of the controls,
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70 µL of the substrate stock solution was added to the wells to initiate the enzyme
reaction.
The screen provided by the NCI DTP, contained a mechanistic (1 mM stock of
compounds), oncology (10 mM stock of compounds), natural product (10 mM stock of
compounds) and diversity (10 mM stock of compounds) set for a total of 2,954
compounds that were screened in the 384-well plate format. Slight modifications were
made to the 384-well plate FVB assay procedure in screening compounds from the DTP.
After the addition of 15 µL of enzyme, 5 µL of controls and compounds were added to a
final concentration of 100 µM for the mechanistic set in the screen. For the natural
products, oncology and diversity set, 1 µL of controls and compounds were added to a
final concentration of 200 µM in the screen. After the addition of the controls, 30 µL of
the substrate stock was added for the mechanistic set while 34 µL of the substrate stock
was added for the natural products, oncology and diversity set to initiate the enzyme
reaction. After one hour, the enzyme reaction was inactivated by the addition of 5 µL of
EDTA, followed by the addition of 5 µL of FVB for a total volume of 60 µL. Reagents
were dispensed using an automatic liquid handling system (MultiFlo FX, Biotek) except
for the controls and compounds, which were manually added using a hand-held, multichannel micropipette.
3.2.3 Data analysis
The assay signal quality was statistically evaluated using the Z-factor value as
described by Equation 1 (Zhang, Chung, and Oldenburg 1999), where ss and sc represent
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the standard deviations for the sample and control, respectively, and µs and µc represent
the means for the sample and control, respectively.
Z= 1 −

(&'() &'+ )

[1]

|-( . -+ |

A Z-factor between 0.5 and 1.0 indicates that the signals in the assay have a large
signal difference between the sample and the control, in addition to low standard
deviations. Z-factors in this range indicate that an assay is excellent for screening. To
determine the agreement of the assay in measuring PC activity, a kcat and KM for pyruvate
were determined by the following method:
1. An OAA standard curve was established to relate absorbance values at 530 nm to
the OAA concentration: y = a + bx, where y is absorbance, a is the intercept, b is
the slope of the line and x is OAA concentration. Rewritten:
Abs = a + b[OAA]
Solving for [OAA]:
[OAA]=

9:;.<
:

[2]

The standard curve that was used for these calculations was the standard curve
that was linear with 0-400 µM of OAA (described in the results) as the
absorbance range to determine kcat and KM was well within that range.
2. To determine the kcat and KM values using the FVB assay, the enzyme-catalyzed
reaction at varying concentrations of pyruvate was inactivated at different time
intervals. The absorbance values were then converted to [OAA] using equation
[2] determined from the standard curve. Initial velocities ([OAA]/minute) were
determined for each substrate concentration and plotted against pyruvate
concentration. The following equations were used to determine kcat and KM values,
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where [E]T represents the total enzyme concentration, vi represents initial velocity,
Vmax represents the maximum velocity and [S] represents the substrate
concentration:
𝑣> =

?@AB [C]

[3]
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The validation experiments were designed and evaluated according to the
recommendations of the “Assay Guidance Manual” from the National Center for
Advancing Translational Sciences (NCATS), which includes all necessary pre-configured
spreadsheets for analysis of the inter-plate and inter-day experiments (Sittampalam et al.
2012).
For the LOPAC screen, percent activation and percent inhibition were calculated
according to the equations [5] and [6], where µC, µE and µR represent the means for the
control (addition of acetyl CoA or oxalate), effector (screened small molecule), and
reaction (the unaffected reaction), respectively:
W –W

Percent activation = 100 − UV WX .W Z \ × 100]
X

[

W –W

Percent inhibition = 100 − UV WZ .W X \ × 100]
[

X

[5]

[6]

To determine the potency of specific effectors, the FVB assay was performed at
varying effector concentrations. The dose-dependent response curves were evaluated
using IC50 and EC50 equations, according to equation [7]:
Hab.:aHHac

Y = bottom + d)de(fghiXjk lB) ∗ noff pfgqr)

[7]
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Curve fitting was performed using the software programs KaleidaGraph and Graphpad
Prism.

3.3 Results
To accelerate the discovery of novel small molecule effectors of PC, it was
necessary to establish an assay that can accurately measure PC activity in a highthroughput manner. Several diazonium salts have previously been utilized to detect OAA
formation (Babson et al. 1962a, Cockburn et al. 1990, Norris, Atkinson, and Smith 1975,
Sax and Moore 1967), but to the best of our knowledge, they have never been applied to
assay PC activity. Consequently, we sought to develop and validate a novel fixed-time
assay to measure PC activity via the formation of a colored adduct between the reaction
product, OAA, and the diazonium salt, FVB.
3.3.1 Optimization and Validation of the Fast Violet B (FVB) Assay
FVB formed a colored adduct with OAA with an absorbance maximum at 530
nm, consistent with what has been reported in previous studies (see Figure 3-3A) (Sax
and Moore 1967, Cockburn et al. 1990). None of the other assay components (HCO3-,
pyruvate, ATP) contributed substantially to the absorbance at 530 nm in the presence of
FVB, resulting in a large signal to noise ratio for OAA under all assay conditions. The
absorbance at 530 nm was linear over a wide range of OAA concentrations between 1 ~
400 µM, but deviated from linearity at OAA concentrations greater than ~ 400 µM (see
Figure 3-3B). This deviation from linearity has previously been reported (Sax and Moore
1967). Because of this deviation, the accuracy of the assay is expected to decrease at
concentrations of OAA in excess of 400 µM. As such, the assay was designed to maintain
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an upper limit of OD530 ~1 to maximize the signal window while ensuring accuracy. In
this range, the assay is both reliable and sensitive in measuring OAA formation as a
function of PC activity.
An assay procedure was developed according to the schematic described in Figure
3-4. Assay conditions were optimized for a 120 µL reaction volume in a 96-well format.
The assay comprises three overall steps: 1) a PC catalyzed reaction, 2) PC inactivation
with EDTA, and 3) incubation with FVB. PC was first added to the wells, followed by
the addition of the small molecule effector before the addition of substrates. The addition
of the small molecules in this order facilitated the pre-incubation of the enzyme with
effector molecules to account for potential slow-binding activators or inhibitors
(Glickman 2004). The reagent volumes at each step were carefully considered in order to
maximize the amenability of the assay for automated systems and HTS procedures
(Glickman 2004). The assays were established and optimized primarily using hand-held
multi-channel pipettes, with the ultimate goal of transitioning these steps over to
automated liquid dispensing systems. The enzymatic reaction was initiated by the
addition of a large volume of substrates, to facilitate rapid and complete mixing in each
well. EDTA was used to inactivate the reaction. EDTA is a metal ion chelating agent that
sequesters essential Mg2+ ions from the BC domain active site of PC, immediately
rendering the enzyme inactive (Osmani 1984) (see Figure 3-5). Previous studies have
also demonstrated that EDTA assists in preventing diazonium salt precipitation (Sax and
Moore 1967). Following enzyme inactivation, FVB was added and absorbance was
measured at 530 nm following a 2-hour incubation.
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Figure 3-3. FVB Absorbance Spectrum and OAA Standard Curve

Figure 3-3. Absorbance spectrum and OAA standard curve in the presence of 4 mM
FVB. A) The background absorbance (yellow) in the assay was measured by the addition
of the substrates (2.0 mM pyruvate, 1.0 mM ATP and 25 mM HCO3- and assay buffer.
The absorbance spectra recorded in assay buffer in the presence of 2.0 mM pyruvate, 1.0
mM ATP and 25 mM HCO3- at varying concentrations of OAA are shown for 0.3 mM
(pink), 0.6 mM (red) and 1.2 mM (purple) OAA. B) The absorbance (530 nm) of the
FVB-OAA adduct responds linearly to OAA concentrations between 1-400 µM (solid
line, R2=0.99), while the dependence of absorbance on concentration begins to deviate
from linearity at concentrations greater than 400 µM. This deviation can be approximated
by a second standard curve between 400 – 800 µM (dashed line, R2=0.96). The error bars
represent the standard deviation of the signal across eight wells.
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Figure 3-4. 96-Well Fixed-Time Assay Procedure

Figure 3-4. 96-well fixed-time assay procedure. The PC-catalyzed reaction is initiated by
the addition of substrates (2 mM pyruvate, 1 mM ATP, and 25 mM NaHCO3). After one
hour, the PC-catalyzed reaction is inactivated by the addition of 12.7 mM EDTA. FVB is
subsequently added to a final concentration of 4 mM for two hours prior to reading the
absorbance of the FVB-OAA colored adduct at 530 nm. The procedure for 384-well
plates is identical except that the volumes for each step are reduced by half, to a final
volume of 60 µL. This procedure can be performed with manual pipettes or an automated
liquid handling system.
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Figure 3-5. Immediate Inactivation of the PC Catalyzed Reaction with EDTA

Figure 3-5. Immediate inactivation of the PC catalyzed reaction with EDTA. EDTA
inactivation was assessed using the malate dehydrogenase coupled enzyme assay (see
Figure 3-1). EDTA (5mM) was added to a PC reaction with 12 mM pyruvate, 3.0mM
ATP, 25 mM HCO3- , and 10 units/mL MDH after 350 seconds (PC Reaction + EDTA)
for a noticeable immediate inactivation of the reaction. A control for the PC reaction was
determined with the addition of assay buffer at 400 seconds (PC Reaction + AB). In
order to determine if the addition of EDTA inactivated malate dehydrogenase (MDH),
EDTA (5 mM) was added to a MDH reaction with 12 mM pyruvate, 3.0mM ATP, 25
mM HCO3- , 3 mM OAA and 0.1 units/mL MDH. MDH was added at 200 seconds to
initiate the reaction, followed by the addition of EDTA at 250 seconds as demonstrated
by the break in curvature. (MDH Reaction + EDTA). Continuation of the MDH reaction
past 250 seconds indicated that MDH was not affected by 5 mM EDTA, thus the
inhibition demonstrated in the coupled enzyme assay was due to PC inactivation of
EDTA.
To test the ability of the assay to detect activators and inhibitors of PC, the assay
procedure was validated by measuring the FVB-OAA colored adduct in the presence of
acetyl CoA (activator) and oxalate (inhibitor). The background reaction was measured in
the presence of inactivating EDTA and resulted in similar absorbance values (~0.2 Abs)
as the inhibited reaction in the presence of 5 mM oxalate. The activated reaction in the
presence of 0.25 mM acetyl CoA resulted in an increase in absorbance (~1.0-1.2 Abs)
when compared to the unaltered reaction without any small molecule effectors added
(~0.5-0.6). These results strongly support that the FVB assay can be simultaneously
utilized to screen for both activators and inhibitors in a HTS program (see Figure 3-6).
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Figure 3-6. FVB Assay Optimization

Figure 3-6. FVB assay optimization. The FVB assay can be used to measure both
inhibition and activation of the PC-catalyzed reaction. A) Visual representation of an
inhibited, unaltered and activated PC reaction, indicating the corresponding relative
levels of OAA production and FVB-OAA formation. B) The primary assay method was
evaluated in the presence of established effectors of PC activity. The “background” signal
was determined from the reaction of PC in the in the presence of 12.7 mM EDTA. The
“reaction” signal was determined from the reaction of PC in the absence of any effectors.
The “activation” signal was determined from the reaction of PC in the presence of the
activator, acetyl CoA (0.25 mM). The “inhibition” signal was determined from the
reaction of PC in the presence of the inhibitor, oxalate (5 mM). The error bars represent
the standard deviation of the signal across eight wells. The differences between the group
means were statistically significant, as determined by one-way ANOVA (F (3, 28)
=5956, p<0.0001)
To confirm the reliability of this assay, steady-state kinetic constants were
determined for Rhizobium etli PC (RePC). RePC was used to optimize the 96-well plate
assay due to well-established protein purification procedures that afford relatively high
yields of protein. Additionally, RePC has been extensively structurally and kinetically
characterized in the presence of both oxalate and acetyl CoA, serving as an ideal model
system for validation. The KM value for pyruvate (1.5 ± 0.3 mM) and the kcat value (120 ±
20 min-1) were determined for RePC (see Figure 3-7) and were consistent with previously
reported values (Zeczycki, Menefee, Jitrapakdee, et al. 2011, Zeczycki et al. 2009).
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Figure 3-7. FVB Determined Steady State Kinetic Parameters for R. etli PC

Figure 3-7. Steady state kinetic parameters for R. etli PC determined using the FVBbased fixed-time assay. A) Initial velocities for the PC catalyzed reaction measured at
varying concentrations of pyruvate, 0.47 mM (light blue), 0.95 mM (green), 1.9 mM
(purple), 2.5 mM (red), 3.4 mM (blue), 4.5 mM (pink) and 6 mM (black). Solid lines
represent initial velocity and the dashed lines represent the fit to the overall data. B) A
plot of initial velocities as a function of pyruvate concentration yields a KM value for
pyruvate of 1.5 ± 0.3 mM and a kcat value of 120 ± 20 min-1. The error bars represent the
standard deviation of the initial velocities determined in panel A in triplicate.
Oxalate (inhibitor) and acetyl CoA (activator) are established small molecule
effectors of PC. These were used to test the reliability and signal window of the assay as
a prerequisite for its application in small molecule dose-dependent measurements. The
IC50 value for oxalate (97 µM) and the EC50 value for acetyl CoA (45 µM) were
determined for RePC (see Figure 3-8). These values are consistent with published KD and
KA values, 130µM (Lietzan and St Maurice 2013b) and 10 µM (Adina-Zada, Zeczycki,
and Attwood 2012) respectively), thus further confirming the reliability of this method.
Additionally, successful use of the assay in a dose-dependent response manner
demonstrates the potential of the assay to be utilized as a secondary assay in screening, as
steep dose-response curves can be informative in eliminating promiscuous aggregators
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(Shoichet 2006). This will be beneficial to use for elimination of false-positives and to
further investigate more potent small molecule effectors.
Figure 3-8. Dose Dependent Response with Known Effectors of RePC

Figure 3-8. Dose dependent response with known effectors of RePC. In all plots, the error
bars represent the standard deviation of the signal across eight wells. A) Titration of
acetyl CoA gives an EC50 value for acetyl CoA of 42 µM. B) Titration of oxalate gives an
IC50 value for oxalate of 95 µM.
Assays that are transitioned to HTS need to not only be reliable, accurate and
sensitive but also robust, reproducible and statistically validated (Zhang, Chung, and
Oldenburg 1999). To assess the quality of the assay to be transitioned to a HTS platform,
PC was statistically evaluated in the presence of both acetyl CoA and oxalate. Z-factors
can be utilized to compare, evaluate and validate the suitability of an assay for HTS. A Zfactor score of 0.5-1.0 indicates that the assay has a high dynamic range and low
variation in the signal measurements and is an excellent assay. Z’-factors are used to
determine the overall quality of the assay without interference from small molecule
effectors. Alternatively, Z-factors take into account the signal separation and error of the
assay when used with small molecule activators or inhibitors. In order to determine the
robustness and quality of the assay, Z-factors and Z’-factors were calculated for RePC,
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LmPC and SaPC (see Table 3-1). PC enzymes from multiple source organisms were
selected to determine the suitability of various bacterial PC enzyme for HTS. The
excellent Z-factors for RePC, LmPC and SaPC demonstrate that this assay is amenable to
high-throughput screening for both activators and inhibitors of PC enzymes from a range
of organisms. The results suggest, however, that assay conditions may need to be
individually optimized for PC enzymes from different species, as demonstrated by the
increased enzyme concentration (50 µg/mL) required to obtain high Z-factors in the assay
catalyzed by LmPC.
Table 3-1. Z- Factors Determined for the Assay of Bacterial PC Enzymes
Enzyme
[]
µg/mL

Z'Factor

Z-Factor
Activation

Z-Factor
Inhibition

Assay
Score

Rhizobium etli

10

0.86

0.85

0.87

Excellent

Listeria monocytogenes

50

0.70

0.77

0.70

Excellent

Staphylococcus aureus

10

0.87

0.87

0.87

Excellent

PC Origin

In consideration of using this assay in a HTS context, a series of additional
optimization and validation tests were performed using automatic liquid dispensing
protocols. These tests included DMSO compatibility, reagent stability and signal
variability across multiple days for the assay. Most small molecules from screening
libraries are dissolved in DMSO and are added at fixed concentrations in the screening
assays. Thus, it was necessary to evaluate the tolerance of PC for DMSO (Sittampalam
et al. 2012). PC activity was not affected by the presence of 1% DMSO (see Figure 3-9)
and our laboratory has commonly observed that PC activity is unaffected by 5% DMSO.
Additionally, it was beneficial to establish the stability of the reagents and assay signal
for future HTS procedure implementation of large libraries that may take up to 8 hours to
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screen (Sittampalam et al. 2012). Optimal conditions for reagent stability were tested for
solutions kept at 22 °C and on ice (see Figure A1). All reagents were stable at 22 °C for
up to 8 hours, and the final measured absorbance values were stable between 2-5 hours of
incubation with FVB (see Figure 3-10).
A series of plate uniformity tests were performed to assess the signal variability of
the FVB assay across multiple days with various plate templates that evaluate the
maximum, mid-point and minimum signals of the inhibited and activated PC reaction.
While Z-factors are used to determine the suitability and robustness of an assay to be
transitioned to HTS, plate uniformity assessments determine the reproducibility of the
assay that includes the reproducibility of the Z-factors. Plate uniformity assessments can
indicate whether or not the signal windows, Z-factors and spatial uniformity of each plate
will be sufficient to detect potential activators and inhibitors during the screening
process. A three-day plate uniformity assessment using the interleaved-signal format
(Sittampalam et al. 2012) was performed in the presence of the inhibitor, oxalate, and
demonstrated that the signal windows, Z-factors and spatial uniformity met the criteria
for consistent plate readouts across multiple plates and days (see Figure 3-10A). A twoday validation test was performed for activation in the presence of acetyl CoA and also
demonstrated consistent plate readouts across multiple plates and days (see Figure 3-10B)
(see Table A1 for statistical parameters).
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Figure 3-9. Pyruvate Carboxylase Tolerance of 1% DMSO.

Figure 3-9. Pyruvate carboxylase tolerance of 1% DMSO. The background signal (black)
is the inactivated PC reaction in the presence of 12.7 mM EDTA. The reaction signal
(grey) is the PC reaction in the absence of added effectors. The activation signal (green)
is the PC reaction in the presence of the activator, acetyl CoA (0.25 mM). The
inactivation signal (blue) is the PC reaction in the presence of the inhibitor, oxalate (5
mM). Pyruvate carboxylase activity, measured using the FVB-based assay, is unaffected
by the presence of 1% DMSO. The error bars represent the standard deviation of the
signal across eight wells.
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Figure 3-10. Reagent and Signal Stability for the FVB-Based Assay

Figure 3-10. Reagent and signal stability for the FVB-based assay. In all plots, the
background signal (black) represents the inactivated PC reaction in the presence of 12.7
mM EDTA. The reaction signal (grey) represents the PC reaction in the absence of
effectors. The activation signal (green) represents the PC reaction in the presence of the
activator, acetyl CoA (0.25 mM). The inactivation signal (blue) represents the PC
reaction in the presence of the inhibitor, oxalate (5 mM). The error bars represent the
standard deviation of the signal across eight wells. A) All reagents used in the FVB-based
assay are stable under all conditions for up to 8 hours at 22 °C. Time 0 represents the first
assay that was ran with freshly prepared reagents and the measured absorbance values are
consistent for all reactions for up to 480 minutes when using the reagents that were
prepared at time 0. B) Incubation times between 120 and 300 minutes yield consistent
absorbance measurements, indicating that the FVB-OAA color adduct is stable for an
extended time period, permitting the measurement of plates at any time between 2 - 5
hours post-incubation with FVB.
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Figure 3-11. Plate Uniformity Validation Tests for RePC with Oxalate and Acetyl
CoA

Figure 3-11. Plate uniformity validation tests for RePC with oxalate and acetyl CoA.
Both plate uniformity tests reveal consistent signals across all plates and across multiple
days. Well number 0-96, 97-192 and 193-288 refer to Day 1, Day 2 and Day 3,
respectively. No edge or drift effects were observed, and all statistical measures are
acceptable. A) 3-day inhibition plate uniformity assessment with 5 mM oxalate for the
minimal signal (blue diamonds), 90 µM oxalate for the IC50 signal (pink squares) and the
uninhibited PC reaction for the maximal signal (green triangles). B) 2-day activation
plate uniformity assessment with 250 µM acetyl CoA as the maximal signal (green
triangles), 50 µM acetyl CoA for the EC50 signal (pink squares) and the uninhibited PC
reaction as the minimal signal (blue diamonds).
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The FVB assay was used to screen RePC against a LOPAC library to validate the
responsiveness of the assay to a library of well-characterized bioactive compounds. RePC
was screened against the LOPAC library on three separate occasions and reproducibly
identified two inhibitors in all three iterations of the screen (see Figure 3-12D).
Consistent activation and inhibition signals were obtained for individual plate controls
across all 16 plates and all plates had excellent Z-factors (see Figure 3-12 A and B). The
screen identified several compounds that resulted in 70-91% inhibition (see Figure 3-12
D). The two hit compounds, cisplatin and pyriplatin, were confirmed by dose-dependent
response assays, yielding IC50 values of 22 µM and 30 µM respectively (see Figure 3-13).
While the steep dose-response curve for both of these compounds suggests that they are
likely acting as non-specific alkylating agents (Pujol, Carestia, and Daurès 2000, Porrata
and Adjei 2001) or promiscuous aggregators (Shoichet 2006), the results from the pilot
screen nevertheless indicate that the assay can reproducibly and reliably identify an
appropriate number of potential inhibitor hit compounds. The LOPAC pilot screen did
not identify any potential activators for RePC, indicating that a larger, more diverse
library is required to screen for activators (see Figure 3-12 C). All optimization and
validation results indicate that the assay is reproducible, reliable and sufficiently sensitive
to detect a range of small molecule effectors of PC in screening libraries.
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Figure 3-12. LOPAC (Library of Pharmacologically Active Compounds) Screen
Results for Inhibitors and Activators of Rhizobium etli PC

Figure 3-12. LOPAC (Library of Pharmacologically Active Compounds) screen results
for inhibitors and activators of Rhizobium etli PC. A) Absorbance signals for individual
plate controls. The maximal signal is determined in the presence of 250 µM acetyl CoA
(pink squares), the normal PC reaction is determined in the absence of effectors (purple
squares) and the inhibited reaction is determined in the presence of 5 mM oxalate (blue
squares). The error bars represent the standard deviation of the signal across eight wells.
B) Z-factors fall in a range considered to be excellent (0.6 – 0.8) and are consistent across
all 16 plates. C) Results of the percent of activation of Screen 1 from the LOPAC screen
D) Combined inhibition data from three individual LOPAC screens (Screen 1, Screen 2
and Screen 3). The dashed line represents a threshold of 3× the standard deviation for the
combined data, equivalent to 45% inhibition. Two compounds consistently exceeded this
threshold across all three screens.
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Figure 3-13. Hit Compound Dose Dependent Response

Figure 3-13. Dose dependent response for the two inhibitors, cisplatin and pyriplatin,
identified in the LOPAC screen. The error bars represent the standard deviation of the
signal across eight wells. A) Dose-dependent response for the inhibition of R. etli PC in
the presence of cisplatin results in an IC50 value of 22 µM. B) Dose-dependent response
for the inhibition of R. etli PC in the presence of pyriplatin results in an IC50 value of 30
µM. C) Chemical structures of the hit compounds and the percent of inhibition measured
in each of the three independent screens.
3.3.2 Screening of Compound Libraries
A small molecule library consisting of ~10,000 compounds was available to
screen against RePC at the Milwaukee Institute for Drug Discovery at the UWM. The
screen consisted of unique compounds synthesized at UWM and compounds from the
LOPAC, Microsource Discovery and Prestwick library collection. While the library
contained unique compounds, it also had built in redundancy from the LOPAC screen to
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cross validate the performance of the assay with multiple libraries. Due to the large
number of compounds in the library, a 96-well plate screening format would have
required an unwieldy ~125 plates. To reduce the resource demands associated with
screening larger compound libraries, the 96-well plate format was transitioned to a 384well plate format, optimized and validated for RePC (see Table A1 and Figures A2-A4).
The validated 384-well plate FVB assay was used to screen the small molecule library at
UWM against RePC (see Figure A5). Z-factor scores were excellent across all plates and
the individual plate controls had consistent absorbance values. Despite the larger number
of compounds in the library, the screen did not reveal any hits for RePC activation (see
Figure A5). The screen did however, result in two potential inhibitors (see Figure A6).
Based on the previous hit rate from the LOPAC screen (~1 hit/500 compounds), it was
notable that this larger screen resulted in a much lower hit rate (~1 hit/5,000 compounds).
Since it had previously been established that the FVB assay could be utilized with
other PC enzymes such as SaPC and LmPC (see Table 3-1), the screen performed at
UWM was transitioned to screen against LmPC with the goal of establishing a higher
compound hit rate. Additionally, it had become evident from the SBDD project that many
compounds displayed higher potency against SaPC or LmPC than against RePC
(described in Chapter 4). The screen performed at UWM did reveal more potential hits
for inhibitors of LmPC (~3 hits/1,000 compounds) than of RePC (see Figure A6). The
screen was not applied to the detection of potential activators, based on the absence of
any observed activators in the screening results against RePC. Unfortunately, the hits
could not be confirmed in secondary assays because the compounds were not made
available for follow up studies. Synthesizing these potential hit compounds would have
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required a major investment of resources and the compounds themselves were no longer
stored by the laboratory that performed the initial synthesis (Frankowski et al. 2011).
Nevertheless, these efforts to screen a modest-sized ~10 000 compound library
demonstrated that the assay itself is highly suitable as a primary screen in a high
throughput setting. An overview of the screening process is diagrammed in Figure 3-14.
Figure 3-14. Screening Process for Pyruvate Carboxylase Small Molecule Effectors

Figure 3-14. Screening process for pyruvate carboxylase small molecule effectors.
A small library of mechanistic, oncology, natural product and diversity sets (total
of 2,954 compounds) were obtained through the National Cancer Institute Developmental
Therapeutics Program (NCI DTP) (http://dtp.cancer.gov). The NCI DTP compounds
were screened for inhibitors of SaPC (see Figure 3-15A). The activity of SaPC enabled
an increased signal to noise ratio in the FVB assay when compared to LmPC, requiring
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less enzyme for screening (10 µg/mL for SaPC versus 50 µg/mL for LmPC). As
previously discussed, compounds from the displayed higher potency against SaPC or
LmPC than against RePC (described in Chapter 4), thus SaPC was the most appropriate
target for the NCI DTP screen. Approximately 20 hit compounds were identified (greater
than 80% inhibition) from the mechanistic, oncology, natural product and diversity sets.
A total of 15 hit compounds were obtained from the NCI DTP for follow up studies.
These 15 compounds were selected based on their a-keto acid functional group as related
to the rational drug design project described in Chapter 4 or based on chemical features
that were common to multiple hit compounds. For example, in Figure 3-15C, Compounds
70 and 71 display this similar scaffold that is highlighted in teal. While a majority of the
hit compounds came from the mechanistic and diversity set, two hit compounds were
identified from the oncology set: cisplatin and oxaliplatin. Cisplatin was also
reproducibly identified as a PC inhibitor in the LOPAC screens against RePC (see Figure
3-13A), lending further confidence to the reliability of this assay in identifying genuine
PC inhibitors. While cisplatin is not a promising lead compound for further studies due to
its promiscuity (Lee et al. 2017), it served as additional validation that the FVB assay can
consistently detect valid inhibitors across multiple screens.
From the dose-dependent response of the 15 selected hit compounds, 7 were
identified as having IC50 values < 10 µM, indicating the potential of the inhibitors to be
used as first-generation small molecule inhibitors of PC (see Figure 3-15). Of the 7 potent
compounds, five were identified from the mechanistic set (compounds 60, 61, 69, 70 and
71) and two were identified from the diversity set (compounds 65 and 66). However,
subsequent analysis of the NCI DTP compounds through mass spectrometry and nuclear
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magnetic resonance (NMR) demonstrated that all of the hit compounds were impure
(work done in collaboration with the Chemistry Department at Marquette University) and
were therefore unreliable hit compounds to continue to pursue. While it may have seemed
promising that the hit compounds all had IC50 values < 10 µM and decent IC50 curves, it
was difficult to determine what component of the compounds were causing inhibition due
to the compound impurity. The compounds from NCI DTP are sourced as an open
chemical repository, meaning the compounds have been donated from various academic
and industrial sources. The NCI DTP cannot guarantee the quality of the compounds as
they have not been reanalyzed by the NCI DTP for the purity or accuracy of the
compound structure. Despite the inability to pursue reliable screening results, a
recommended process for screening large libraries and hit compound follow up are
described in Chapter 5 and could lead to a successful future direction in a HTS discovery
project for novel inhibitors of PC.
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Figure 3-15. NCI DTP Screen Against SaPC

Figure 3-15. NCI DTP screen against SaPC. A) Screening data for inhibition of the NCI
DTP compound library. The dashed line represents 2× standard deviation of all the data.
Hit compounds were identified as resulting in inhibition greater than 2´ the standard
deviation, which corresponds to greater than 80% inhibition. The hit threshold limit is
usually expressed as 3× the standard deviation away from the mean of all the data.
However, this was lowered to 2× so that there were a number of reasonable hits that
could be followed up on in the secondary assays. B) Dose dependent response of the 7
NCI DTP confirmed hit compounds. Compound 60 (black), Compound 61 (grey),
Compound 65 (periwinkle), Compound 66 (pink), Compound 69 (blue), Compound 70
(red), and Compound 71 (green). The error bars represent the standard deviation of the
signal across eight wells. C) Chemical structures of the compounds and the
corresponding IC50 values. Compounds containing the a-keto functional group are
highlighted in red (Compounds 61, 65 and 66) while compounds selected based on their
shared chemical scaffold are highlighted in teal (Compounds 70 and 71).
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3.4 Discussion
A novel, fixed time assay for PC has been developed that is reliable, sensitive and
robust. The assay monitors the production of OAA through the formation of a colored
adduct between OAA and the commercially available diazonium salt of FVB. This offers
a simple assay to detect PC activity through monitoring the increase in absorbance at 530
nm. The assay can be utilized as an alternative method to coupled-enzyme assays to
detect PC activity. Additionally, the assay can readily be transitioned to a multi-well plate
format where the reagent stability, accuracy and reproducibility is ideal for use in highthroughput screening of small molecule libraries for both activators and inhibitors of PC
activity.
While diazonium salts have previously been used to detect the production of
OAA, they have not specifically been applied to assay PC activity. Diazonium salts such
as Fast Red KL, Fast Ponceau L and Fast Violet B have been used to detect OAA
production from aspartate transaminase (Lombarts and Peters 1971, Babson et al. 1962b,
Amador and Salvatore 1971, Sax and Moore 1967). Fast Violet B, in particular, has also
been utilized to assess phosphoenolpyruvate carboxylase activity and has previously been
optimized in a microtiter plate assay (Norris, Atkinson, and Smith 1975, Cockburn et al.
1990). Fast Violet B was selected as the optimal diazonium salt to assay PC activity
based the stability of the FVB-OAA color adduct, the low signal to noise ratio of OAA
with pyruvate, and the amenability of FVB to be transitioned to a 96-well plate format.
The choice of Fast Violet B over other diazonium salts in this assay is based on several
unique features. Fast Violet B has been demonstrated to be stable over an optimal pH
range for PC activity with the addition of either EDTA or detergent (pH 7.0-7.5)
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(Cockburn et al. 1990, Babson et al. 1962b, Lombarts and Peters 1971, Scrutton,
Olmsted, and Utter 1969). Alternatively, Fast Red KL and Fast Ponceau L were most
stable over a pH range of 4.2- 4.6 (Lombarts and Peters 1971, Sax and Moore 1967,
Babson et al. 1962b, Amador and Salvatore 1971). While acidic Fast Red KL or Fast
Ponceau L could potentially be added in the current protocol following PC inactivation,
the acidic conditions would have the potential to promote PC precipitation and
aggregation which could obscure the signal to noise window of the assay (Scrutton,
Olmsted, and Utter 1969). Additionally, previous studies demonstrated that Fast Violet B
had a broad absorption peak between 490-540 nm compared to the narrower absorption
peaks of Fast Red KL and Fast Ponceau L (455-467 nm respectively)(Sax and Moore
1967, Lombarts and Peters 1971). As previously described, many assay components
absorb at lower wavelengths. Thus, selecting a diazonium salt with a higher wavelength
serves to maximize the signal to noise ratio of the assay. Lastly, FVB has previously been
used in a microtiter plate-based assay for phosponenolpyruvate carboxylase, indicating
that it is amenable to the smaller reaction volumes typical of a high throughput screening
assay.
The FVB-based assay is capable of accurately measuring steady state kinetics in
PC, consistent with a study by Amador and Salvatore (1971) that compared the activity
of aspartate aminotransferase measured by FVB and Fast Ponceau L to the rates
determined by a MDH coupled-enzyme assay. Thus, the FVB fixed-time assay is not
only an ideal primary assay to use in a HTS program, but it can also be employed as an
alternative to the coupled-enzyme assay typically used for standard kinetic measurements
of PC activity. In instances where assay conditions interfere with the coupled-enzyme,
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the FVB assay is an ideal alternative assay to measure PC activity. A prime example is
when small molecule effectors also inhibit/activate MDH or LDH, precluding accurate
initial velocity determinations in PC. Oxalate, for example, inhibits both PC and the
coupling enzyme, LDH (Novoa et al. 1959). Several additional a-keto acids are inhibitors
of PC (Lietzan and St Maurice 2013b) and serve as a promising scaffold for rational drug
design, as described in Chapter 4. However, MDH and LDH have been shown to reduce
aromatic a-keto acids (Friedrich et al. 1987). These examples highlight the importance of
developing additional enzyme assays that are free of secondary coupling enzymes that
might otherwise be subject to cross-reactivity.
While it has many advantages, the FVB assay also has several limitations that
must be carefully considered. It has previously been demonstrated that FVB also forms a
color adduct with a-ketoglutarate (Sax and Moore 1967) and occasionally produced false
positives due to ketosis in serums (Amador and Salvatore 1971). Therefore, FVB has the
potential for cross-reactivity with nucleophilic compounds. Additionally, FVB reacts
with high concentrations (> 250 µM) of acetyl CoA and CoA, resulting in a decrease in
absorbance of the FVB-OAA color adduct (see Figure A8). Thus, small molecule
activators may be difficult to identify if their interference with FVB-OAA colored adduct
formation offsets their enhancement of PC activity. This may be one reason why PC
activators were not observed in the LOPAC screen. It is also likely, however, that it is
simply more difficult to find activators of PC as allosteric ligands are generally more
difficult to detect in HTS (Alt 2016). Allosteric activators, like acetyl Co-A, have very
specific interactions for PC (Adina-Zada, Zeczycki, and Attwood 2012, Zeczycki,
Menefee, Jitrapakdee, et al. 2011), meaning that even the slightest modification to acetyl
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CoA can cause a complete change in the degree of activation. For example, RePC was
activated 6-fold by acetyl CoA while it was only activated 2-fold by CoA (see Table A3).
If allosteric activators are not specific for PC in the screening process, they may exhibit a
small to negligible change in the assay signal.
Lastly, consideration should be given to determining the appropriate
concentration of substrates to be used in the FVB assay when it is being applied either to
kinetic measures or being used as a HTS primary screen. Here, the assay has been
performed at 2 mM pyruvate, which is less than the saturating concentrations of 5 – 20
mM pyruvate, depending on the source of the PC enzyme. This sub-saturating
concentration of pyruvate maximizes the signal to noise ratio of the assay for RePC but,
notably, has not been optimized for LmPC or SaPC. The concentration of the substrates in
an assay can impact the number and type of inhibitors that are identified in a screening
process (Acker and Auld 2014, Yang, Copeland, and Lai 2009). In particular, the assay
substrate concentrations should be considered in relationship to their KM values, as this
will influence the type of inhibitors that are identified. For example, a competitive
inhibitor is mutually exclusive with the substrate. Alternatively, uncompetitive inhibitors
bind only after the substrate binds to enzyme. At saturating substrate concentrations,
there is a higher substrate occupancy in the active site, increasing the likelihood of
finding uncompetitive inhibitors and decreasing the likelihood of finding competitive
inhibitors. It was determined by Yang et al. that performing inhibitor screens at substrate
concentrations near to the KM value is ideal to optimize the identification of competitive,
non-competitive and uncompetitive inhibitors (Yang, Copeland, and Lai 2009). This
could explain in part why there was a higher percentage of inhibitor hits from the screen
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against SaPC compared to RePC or LmPC. The SaPC KM value for pyruvate is 2 mM,
equal to the substrate concentration that was used in the FVB assay. The SaPC screen
may, therefore, have detected a wider range of inhibitors on account of the pyruvate
concentration matching the KM value for SaPC. The pyruvate KM value for LmPC and
RePC is 0.68 mM and 0.75 mM, respectively (see Table A2). In screens directed against
these enzymes, the 2 mM pyruvate concentrations were higher than the pyruvate KM
values for RePC and LmPC. It is possible, therefore, that those screens were biased
toward uncompetitive inhibitors at the exclusion of a wider range of inhibitor types, such
as competitive inhibitors.
The increased number of hit compounds from the NCI DTP screen may be a
result of the low quality of compounds in the screen. A large number of hit compounds
from the NCI DTP screen were determined to be impure. Compound degradation or
uncertainty may be a more prominent feature of the NCI DTP library for reasons
previously described, resulting in a higher degree of non-specific inhibition. Ultimately, it
is difficult to draw direct comparisons on the hit rate between three separate screens that
used RePC (UWM), LmPC (UWM) and SaPC (NCI DTP), given that different screens
and enzymes were used. Interestingly, while RePC and LmPC have similar KM values for
pyruvate, they had quite different hit rates despite being screened against the same
library. This suggests that individual PC enzymes may have varying susceptibilities to
small molecule inhibition. This issue is investigated further in Chapter 4. Regardless,
prior to embarking on any future screening projects it will be important to consider the
substrate concentrations, the KM values of the substrates, the type of inhibitors that are
desired and the source of the enzyme.
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In conclusion, a novel-fixed time assay to detect PC activity has been established.
This assay can be used to screen for small molecule effectors of PC or as an alternative
method to measure steady state enzyme kinetics. The development and validation of this
assay has enabled a HTS procedure and is extensively used to assess inhibitors in the
rational drug design project described in Chapter 4. The small molecules that are
discovered and developed through these projects can be used as valuable biochemical
tools to further investigate the regulation, structure and the role PC plays in certain types
of diseases and infections.

62
CHAPTER 4: A STRUCTURE-BASED DRUG DESIGN APPROACH TO
DEVELOPING PYRUVATE CARBOXYLASE INHIBITORS
4.1 Introduction
PC is an important anaplerotic enzyme that catalyzes the conversion of pyruvate
to OAA in a wide range of organisms (Jitrapakdee et al. 2008). Studies have linked PC
activity to a number of diseases and infections including certain types of cancer, type 2
diabetes, and listeriosis that are sustained as a result of aberrant or essential PC
expression in cells (Schar et al. 2010, Kumashiro et al. 2013, Cheng et al. 2011). PC has
been implicated in these diseases as a result of studies using genetic tools such as
knockouts, antisense oligonucleotides, and siRNAs that target the PC gene (Schar et al.
2010, Cheng et al. 2011, Hasan et al. 2008, Kumashiro et al. 2013). While genetic
manipulations of PC have validated it as a target for the treatment of these diseases and
infections, genetic tools alone are unable to identify the precise mechanistic role that PC
plays in vivo.
PC is a protein scaffold for a number of metabolic enzymes (Fahien, Davis, and
Laboy 1993), has a moonlighting function that is important in the assembly of the
peroxisomal enzyme, alcohol oxidase (Huberts et al. 2010), interacts with proteins
important in the mitochondrial antiviral signaling pathway (Cao et al. 2016), and binds to
the pleiotropic protein, prohibitin (Vessal et al. 2006). Thus, a reduction in PC expression
levels is likely to impact multiple cellular systems. It is, therefore, difficult to clearly
establish whether the phenotypes observed in response to genetic manipulation of PC are
a result of changes in PC catalytic activity or of changes in peripheral metabolic and/or
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cell signaling pathways. Additionally, genetic tools can only be utilized in vivo and
cannot be applied to study the structure or regulation of PC in vitro.
The development of specific and potent small molecule effectors of PC has the
potential to expand the limited range of chemical probes currently available to study PC
both in vitro and in vivo. Small molecules have the advantage of altering specific
catalytic functions of PC without reducing/eliminating the gene product from the cellular
system, thus precluding unintentional effects on other metabolic and signaling enzymes
in the cell. To date, attempts to use small molecule effectors to study PC directly in
cellular studies have made use of non-specific inhibitors of PC expression/activity, all of
which have the potential to interact with other metabolic enzymes (Choi et al. 2017,
Sureka et al. 2014, Whiteley et al. 2017, Ferrandina et al. 1997, Farfari et al. 2000,
Flamez et al. 2002, Wilmanski et al. 2017).
Phenylacetate, in particular, has been applied in studies of insulin release and a
substantial amount (>5mM) is needed to partially inhibit PC and decrease insulin
secretion (Farfari et al. 2000, Lu et al. 2002). At these concentrations, it is anticipated that
many cellular systems will be affected by the addition of phenylacetate (Harrison et al.
1998, Di Benedetto et al. 2001), such as the induction of cell cycle arrest (Park et al.
2004) and inhibition of nitric oxide synthase (Pahan et al. 1997). Other compounds such
as 1α,25-dihydroxyvitamin D, downregulate PC expression in oncogene transfected
breast epithelial cells (Wilmanski et al. 2017), but it is unknown if the compound directly
affects PC activity. In certain bacteria like L. monocytogenes and L. lactis, cyclic-di-AMP
is an allosteric regulator that decreases PC activity with a KD value of 8 µM (Sureka et al.
2014), making it one of the most potent inhibitors of PC to be documented. However,

64
even with a relatively potent compound like c-di-AMP that has been used both in vivo
and in vitro, it is difficult to conclude on the direct and specific role PC plays in bacterial
metabolism as it bind to a broad range of proteins (Commichau et al. 2015).
Like most metabolic studies, a single methodology to study PC both in vivo and in
vitro is insufficient to definitively characterize the role PC plays not only in L.
monocytogenes, but in other systems as well. This highlights the value of expanding the
biochemical toolkit to study PC both in and outside the cellular context. The method we
have taken to expand the ways in which to study PC is through the development of potent
and specific small molecule effectors of PC activity. Since the HTS approach is still
being developed, a SBDD approach that specifically targeted the unique CT domain of
PC has been implemented. The BC domain is conserved across biotin-dependent
enzymes, while the CT domain structures of biotin-dependent enzymes are unique for the
various substrates that are utilized throughout the enzyme family (Tong 2013). By
targeting the CT domain of PC rather than the BC domain, small molecules effectors of
PC are more likely to be specific for PC and limited in their interactions with other
biotin-dependent enzymes.
To initiate a SBDD project, structures of pyruvate, 3-bromopyruvate (3BP),
oxalate and 3-hydroxypyruvate (3HP) bound in the CT domain of RePCDBCDBCCP
(Lietzan and St Maurice 2013b) (see Figure 4-1), were applied to discover novel
inhibitors of PC. Oxalate, oxamate 3HP and 3BP are a-keto acids that are all bound in
the active site in an orientation similar to that of pyruvate (see Section 1.2 for a review of
pyruvate binding in the CT domain) (Lietzan and St Maurice 2013a, Lietzan, Lin, and St
Maurice 2014) . Oxalate is a noncompetitive inhibitor with respect to pyruvate with a Ki
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value of 70 µM for yeast PC (Ruiz-Amil et al. 1965), 50-130 µM for rat liver PC
(McClure et al. 1971) and 12 µM for chicken liver PC (Scrutton, Olmsted, and Utter
1969). 3HP is a noncompetitive inhibitor with respect to pyruvate with a Ki value of 5.4
mM for Thiobacillus novellus PC (Charles, Willer, and Schafer 1984). To the best of our
knowledge, 3BP has never been kinetically characterized as an inhibitor of PC. While the
structure of 3BP bound in the CT domain of PC suggests it is likely to be a competitive or
noncompetitive/mixed type inhibitor, prior studies did not kinetically determine
inhibition of 3BP with PC (Lietzan and St Maurice 2013b).
Based on the specific interactions of the a-keto acids with the catalytic amino
acids in the CT domain, it was hypothesized that a-keto acids discovered through the
SBDD project would be specific competitive or noncompetitive/mixed type inhibitors for
the unique CT domain of PC. Reversible small molecule inhibitors can either be
competitive, uncompetitive, noncompetitive or mixed type (Ring, Wrighton, and
Mohutsky 2014). Competitive inhibitors can only bind to the enzyme and prevent the
binding of a substrate while uncompetitive inhibitors can only bind to the enzymesubstrate complex and prevent product formation/release. Alternatively, noncompetitive
inhibitors can bind to both the enzyme and enzyme-substrate complex with equal affinity
(Ring, Wrighton, and Mohutsky 2014) (see Figure 4-2).
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Figure 4-1. Structures of a- Keto Acid Substrates and Inhibitors of PC

Figure 4-1. Structures of a- Keto Acid Substrates and Inhibitors of PC. Pyruvate (green;
pdb i.d. 3bg5-SaPC) (orange; pdb i.d. 4jx5-RePC), oxalate (pink; pdb i.d. 4mfd-RePC), 3bromopyruvate (teal; pdb i.d. 4mim-RePC) and 3-hydroxypyruvate (yellow; pdb i.d.
4mfe-RePC) have previously been structurally characterized in the CT domain of RePC
and SaPC. The metal ion is either Zn2+ or Mn2+, depending on the organism. PC from
bacteria and yeast predominantly utilize Zn2+, while PC from vertebrates prefer Mn2+
(Lietzan and St Maurice 2013a)
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Figure 4-2. Possible Modes of Inhibition of a Small Molecule with Respect to
Pyruvate in PC

Figure 4-2. Possible modes of inhibition of a small molecule with respect to pyruvate in
PC. There four modes of inhibition that are possible for an inhibitor of PC with respect to
pyruvate. Small molecule inhibitors can either be competitive, uncompetitive,
noncompetitive or mixed type. The Lineweaver-Burk plots shown are an example of the
double-reciprocal plots of the enzyme kinetics that demonstrate the four distinct patterns
of competitive, noncompetitive/mixed and uncompetitive inhibition.
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Over 200 compounds have been found, developed and screened for PC inhibition
through SBDD. The FVB assay was the primary assay utilized for the initial screening of
the compounds. If the compounds inhibited PC in the primary assay, they were
transitioned to the secondary assays that included the MDH and LDH assay. Compounds
that were the most potent were kinetically and structurally characterized (see Figure 4-3
for the screening process overview). Using SBDD, we have discovered and developed
several promising first generation small molecule inhibitors of PC.
Figure 4-3. PC Assays and Rational Drug Design Screening Overview

Figure 4-3. PC assays and rational drug design screening overview. A) The FVB assay
served as the initial primary assay to detect inhibitors of PC and was thoroughly
described in Chapter 3. The secondary coupled enzyme assays were used to assay
specific PC domain activity. The MDH assay measures pyruvate carboxylation while the
LDH assay measures OAA decarboxylation in the CT domain. B) Diagram of the
screening flow process. The inhibition of metalloenzymes in the screening flow will be
mentioned in the discussion of this chapter as well as in Chapter 5 as a future secondary
assay.

69
4.2 Methods
4.2.1 Collaborations and Contributions
Many of the compounds described in this chapter were synthesized by the
Donaldson and Dockendorff laboratories in the Marquette University Chemistry
Department. Compounds 1-85, oxalate, 3-bromopyruvate and 3-hydroxypyruvate were
ordered either through the NCI DTP or Sigma-Aldrich. Compounds numbered 86 and
greater were synthesized in the Dockendorff and Donaldson laboratories. The synthetic
efforts were led by graduate students Daniel Burkett and Ricardo Rosas, and included
several undergraduate students, most notably Anson Bautista and Ryan Engel. An online
Excel spreadsheet is maintained by the St. Maurice and Donaldson labs to track the
original of the compounds, the identity of the synthetic chemist, and the inhibition results,
can be located through the ME(D)3 group sharepoint site. Mallory Mews (MM), working
under my mentorship and supervision, contributed to the determination of many of the
IC50 values described in this chapter. In all cases, these contributions are clearly noted in
the relevant tables and figures. As it will be indicated (*) refers to the IC50 values that
were solely collected by MM, whereas, (**) refers to compounds that had been originally
screened by the author of this dissertation, Brittney Wyatt (BW) and followed up on by
MM.
4.2.2 Screening compounds for inhibition using the primary FVB assay
The FVB assay in the 384-well plate format was utilized as the primary assay to
screen for small molecule inhibitors of PC. The 384-well plate procedure has been
described thoroughly in Chapter 3. To determine whether the compounds interfered with
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formation of the FVB-OAA colored adduct itself, the procedure was slightly modified.
Instead of the addition of 15 µL enzyme, 15 µL of OAA was added to a final
concentration of 200 µM in the assay. This functioned to assess the possible interference
of the compounds with forming an FVB-OAA colored adduct at 530 nm. All other steps
were identical to the previously described FVB assay protocol.
4.2.3 Pyruvate Carboxylation MDH Assay
The carboxylation of pyruvate in full-length PC (SaPC, LmPC and RePC) was
measured by coupling the formation of OAA to the reaction catalyzed by MDH, which
converts OAA to malate and oxidizes NADH to NAD+ (see Figure 3-1). This can be
readily observed by measuring the change in absorbance of NADH at 340 nm. All MDH
assays were performed at 22 °C in 96-well plate format for a total reaction volume of 200
µL. Assay conditions consisted of 100 mM Tris (pH 7.8), 7 mM MgCl2, 150 mM KCl
and 0.005% Triton x-100. The procedure for the 96-well plate MDH assay was as
follows: 1) addition of 20 µL PC to a final concentration of 10 µg/mL-30 µg/mL
depending on PC activity, 2) addition of 20 µL of compound to varying final
concentrations, 3) addition of 20 µL of MDH to a final concentration of 20 U/mL, and
lastly 4) addition of 140 µL of substrates to initiate the reaction (pyruvate, HCO3-, ATP
and NADH to a final concentration of 12 mM, 25 mM, 2.5 mM and 0.25 mM
respectively). For Ki determinations, the procedure was slightly modified as follows: 1)
addition of 20 µL SaPC to a final concentration of 10 µg/mL, 2) addition of 20 µL of
compound to varying final concentrations, 3) addition of 20 µL of MDH to a final
concentration of 20 U/mL, 4) addition of 20 µL of pyruvate to varying final
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concentrations and 5) addition of 120 µL of substrates to initiate the reaction (HCO3-,
ATP and NADH to a final concentration of 25 mM, 2.5 mM and 0.25 mM respectively).
To account for possible compound inhibition of MDH, the procedure was modified as
follows: 1) addition of 20 µL OAA to a final concentration of 30 mM, 2) addition of 20
µL of compound to varying final concentrations, 3) addition of 20 µL of MDH to a final
concentration of 0.275-0.25 U/mL, and 4) addition of 140 µL of substrates to initiate the
reaction (pyruvate, HCO3-, ATP and NADH to a final concentration of 12 mM, 25 mM,
2.5 mM and 0.25 mM respectively). Reagents were dispensed manually by a hand-held,
multi-channel micropipette and absorbance measurements were recorded at 340 nm with
a Multiskan Ascent spectrophotometer (Thermo). Initial velocity rates were analyzed
using an Excel template, further described in the 4.2.6 Data Analysis section.
4.2.4 An LDH-based assay to measure oxamate-induced decarboxylation of
oxaloacetate
The CT domain specific decarboxylation of OAA in in full-length (SaPC) and
truncated (SaPCDBCDBCCP) PC was measured by coupling the formation of pyruvate to
the reaction catalyzed by LDH, which reduces pyruvate to lactate and oxidizes NADH to
NAD+. This can be readily observed by measuring the change in absorbance of NADH at
340 nm. All LDH assays were performed at 22 °C in 96-well plate format for a total
reaction volume of 200 µL. Assay conditions consisted of 100 mM Tris (pH 7.8) and
0.005% Triton x-100. The procedure for the 96-well plate LDH assay was as follows: 1)
addition of 20 µL PC to a final concentration of 100 µg/mL-200 µg/mL depending on PC
activity, 2) addition of 20 µL of compound to varying final concentrations, 3) addition of
20 µL of LDH to a final concentration of 10 U/mL, and lastly 4) addition of 140 µL of
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substrates that included oxamate, OAA and NADH to a final concentration of 0.5 mM,
0.2 mM and 0.25 mM, respectively. To account for possible compound inhibition of
LDH or compound reduction by LDH, the procedure was modified as follows: 1)
addition of 20 µL pyruvate to a final concentration of 50 mM, 2) addition of 20 µL of
compound to varying final concentrations, 3) addition of 20 µL of LDH to a final
concentration of 0.05-0.1 U/mL, and 4) addition of 140 µL of NADH to a final
concentration of 0.25 mM. Reagents were dispensed manually by a hand-held, multichannel micropipette and absorbance measurements were recorded at 340 nm with a
Multiskan Ascent spectrophotometer (Thermo). Initial velocity rates were analyzed using
an Excel template, further described in the 4.2.8 Data Analysis section.
4.2.5 Cloning of Domain Truncation Mutations of SaPCDBC and
SaPCDBCDBCCP
To create SaPC variants that could be applied in both the LDH assay and
crystallization studies, a PCR cloning approach was taken to remove the BC domain
(SaPCDBC) and BC/BCCP domain (SaPCDBCDBCCP). All amino acids are labeled
according to a T-Coffee alignment (Notredame, Higgins, and Heringa 2000) of the SaPC
sequence compared to the sequences of other PC enzymes from various organisms. For
the BC domain truncation (SaPCDBC), it was determined that Ile458 represented the Cterminal end of the BC domain based on the X-ray crystal structure of SaPC (pdb i.d. =
3bg5). The SaPCDBC construct therefore begins at Gln459 and this construct contains the
allosteric domain, the CT domain and the BCCP domain. The gene encoding SaPCDBC
was cloned into the pET-28a-(His)8-TEV expression vector as follows: a ~2.3 kbp
fragment was PCR amplified from the wild-type SaPC pET-28a-(His)8-TEV template
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using the primers 5’- CGCTGCAGCAGCCGTCTCTAGAT -3’ (forward; PstI restriction
enzyme) and 5’- GCGCTCGAGTCAGTCAGTTGCTTT-3’ (reverse; XhoI restriction
enzyme). Primers were synthesized by Integrated DNA Technologies (Coralville, IA).
The PCR amplified fragment and a pET-28a-(His)8-TEV expression vector were digested
with PstI / XhoI restriction enzymes and digested samples were gel purified. Samples
were ligated, and clones with the expected insertion were selected by colony PCR.
The SaPCDBCDBCCP construct was generated by the same procedure with
several modifications. Since the BC domain truncation was identical to SaPCDBC, the
SaPCDBCDBCCP construct began at Gln459 as well. To account for the BCCP removal, it
was determined that Asn1061 represented the C-terminal end of the allosteric domain. The
construct therefore ended at Asn1061 and a stop codon, TGA, was incorporated at residue
1062 in the primer design. This construct contains the CT domain and the allosteric
domain. The gene encoding SaPCDBCDBCCP was cloned into the pET-28a-(His)8-TEV
expression vector as follows: a ~1.8 kbp fragment was PCR amplified from the wild-type
SaPC pET-28a-(His)8-TEV template using the primers 5’CGCTGCAGCAGCCGTCTCTAGAT -3’ (forward; PstI restriction enzyme) and 5’GCGCCTCGAGTCAATTTTCATCTTT -3’. (reverse; XhoI restriction enzyme). Primers
were synthesized by Integrated DNA Technologies (Coralville, IA). The PCR amplified
fragment and a pET-28a-(His)8-TEV expression vector were digested with PstI / XhoI
restriction enzymes and digested samples were gel purified. Samples were ligated, and
clones with the expected insertion were selected by colony PCR. All clones were verified
by sequencing of the complete gene by Functional Biosciences Inc.

74
4.2.6 X-ray crystallography of SaPCDBC with Compound 98 and 17
SaPCDBC was crystallized in the apo form as well as co-crystallized with
Compound 17. The crystallization conditions for the apo crystals were as follows: 22%
MePEG 2K, 84 mM MgSO4 and 250 mM ammonium tartrate. The crystallization
conditions for co-crystallization with Compound 17 were as follows: 26% MePEG 2K,
84 mM MgSO4 and 250 mM ammonium tartrate. For co-crystallization, Compound 17
was dissolved in 10 mM Tris (pH 7.8), 150 mM KCl, 3 mM MgCl2, 5% (v/v) glycerol
and diluted into a 17.7 mg/mL SaPCDBC protein solution to a final concentration of 10
mM. Crystals were grown by adding 4 µL of crystallization solution to 4 µL of protein
solution that were situated either on siliconized glass cover slips for hanging drop vapor
diffusion or on pedestals for sitting drop vapor diffusion. The well volume of each plate
for all crystallization conditions was 250 µL. Diffusion chambers were sealed using
vacuum grease. Rectangular crystals grew to full size (~270 µm × 100 µm × 60 µm)
after two weeks. The apo crystals were transferred to cryo conditions that contained
18.2% MePEG 2K, 58.8 MgSO4, 175 mM ammonium tartrate, 5% ethylene glycol and 215 mM of Compound 98. Apo crystals were soaked for 24 hours before being transferred
to the cryo condition substituted with 20% ethylene glycol and flash cooled in liquid
nitrogen for data collection. Crystals co-crystallized with Compound 17 were transferred
to the cryo condition with 20% ethylene glycol and 10 mM of Compound 17 before being
flash cooled in liquid nitrogen. X-ray diffraction data were collected at the Advanced
Photon Source (APS, Argonne, IL) beamline LS-CAT (Life Science Collaborative
Access Team) 21-ID-F on a Mosaic 300 CCD detector at wavelength 0.97872 Å.
Diffraction images were processed using HKL2000 (Otwinowski and Minor 1997). The
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structures were determined by molecular replacement using SaPC (pdb 3bg5) as the
search model with Phaser (McCoy et al. 2007). Following molecular replacement, a
single round of refinement was performed with REFMAC (Vagin et al. 2004) followed
by manual model building with COOT (Emsley and Cowtan 2004).
4.2.7 Computational Docking
A computational docking study was performed to assess the predicted CT domain
binding location and relative affinity of the most potent small molecule inhibitors (IC50
values < 30 µM). As there are two conformational states of the CT domain that have been
crystallized, the docking study was designed to consider both the open and closed
conformation of the CT domain. To assess the predicted binding of the compounds in the
CT domain of SaPC in the closed conformation, the pdb file of SaPC (3bg5) with
pyruvate was modified. The pdb file was trimmed to include only Chain C of the CT
domain (residues ~495-1091, pdb labeling) and excluded the BCCP domain from Chain
D that extended biotin in to the CT domain active site of Chain C. The exclusion of the
BCCP domain is due to the possible steric hindrance of biotin in the active site that may
affect the predicted binding of the compounds. In addition to the CT domain, pyruvate
and the metal ion were included in the modified pdb file. As the original SaPC (3bg5) did
not include any water molecules in the published crystallized structure, a water molecule
that is in close proximity to the metal ion from an overlaid RePCDBCDBCCP structure
(4jx5) was added to the modified pdb file as well. This water molecule is often observed
to be bridging the interaction between the metal ion and carbonyl oxygen of pyruvate
(Lietzan and St Maurice 2013b). The docking program treated water molecules as
displaceable and that parameter was kept as crystallization with the compound, 3BP (pdb
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4mim), suggests a binding mode that displaces the water molecule and directly interacts
with the metal ion (Lietzan and St Maurice 2013b). In summary, the model for the closed
conformation of SaPC included the CT domain of Chain C, a bound metal ion, pyruvate
and water molecule. This modified pdb file was applied in all computational docking
studies mentioned in this chapter, unless otherwise stated. Other modifications were
made to this pdb file such as the removal of the water and/or metal ion and the inclusion
of the biotin in the CT domain for additional assessment. The docking results from those
studies are listed in the Appendix, Section B.
To assess the predicted binding of the compounds in the CT domain of SaPC in
the open conformation, the pdb file of SaPCDBC co-crystallized with Compound 17
(unpublished) without bound pyruvate was modified. The crystal structure of SaPCDBC
co-crystallized with Compound 17, was determined to be an appropriate model as it
demonstrated an open conformation of the CT domain. With several rounds of refinement
there was no clear electron density for Compound 17 in the active site, resulting in a
crystal structure of SaPCDBC in the open conformation and no bound ligand. The pdb
file was trimmed to contain only Chain A of the CT domain (residues ~495-1091, pdb
labeling) and included the metal ion, water and pyruvate molecules from the overlaid
structure of the modified closed conformation pdb file described above.
Docking studies were performed with both the closed and open conformations of
the CT domain through an automated docking program called FORECASTER (Molecular
Forecaster) (Therrien et al. 2012). This web-based program identified the position of
pyruvate in the CT domain active site, removed pyruvate and subsequently docked the
compounds within a cavity zone of the binding site (Corbeil, Englebienne, and Moitessier
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2007). The compounds used in the docking study were built using Chemdraw
(PerkinElmer) and saved as MDL Molefiles. Through the FORECASTER web-based
application, a workflow (“Docking- 2D Molecules to a Rigid Protein (pdb)”) was
selected that converted the 2D MDL Molefiles to 3D molecules and the pdb file to a mol2
file. Protein Rotamer Elaboration and Protonation based on Accurate Residue Energy, or
PREPARE, was utilized as part of the FORECASTER workflow. This software prepared all the
atom files from the pdb files for suitable mol2 files. In addition to preparing the pdb files,
PREPARE identified pyruvate in the pdb file by the residue name (PYR), chain location (A
for open or C for closed conformation), and residue number (2001). The protein mol2
was subsequently processed by PROtein Conformational Ensemble System Setup, or
PROCESS, in the FORECASTER workflow to dock the 3D compounds in the binding site of
the CT domain. The center of the binding site was defined by the center of pyruvate
present in the active site. After the removal of pyruvate from the active site, a sphere with
a radius of 15 Å was applied as the default for establishing the binding site cavity.
FORECASTER utilized a genetic algorithm/hybrid matching algorithm to dock the
compounds within the established cavity site. Docking scores were reported from
FORECASTER as the predicted binding energy (DG) and following computational docking,
the lowest energy pose was visualized in Pymol.
4.2.8 Data Analysis
The IC50 values were determined by fitting the data to Equation 7 from Chapter 3.
An IC50 value is the concentration at which an inhibitor reduces the rate of the enzymatic
reaction by 50% and is dependent on the substrate concentrations. The Cheng-Prussof
Equation can be used to estimate a true binding constant or Ki value (Yang, Copeland,
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and Lai 2009). The Cheng-Prussoff Equation for a competitive inhibitor was used to
estimate the Ki values of compounds from RePC, LmPC and SaPC:
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Experimental Ki values were determined using global nonlinear regression in
Graphpad Prism. This allowed multiple data sets to be simultaneously fitted to the desired
equation by minimizing the sum and sum of squares for all data sets and data points,
respectively. The model that was used to determine the Ki value of a competitive inhibitor
was:
[t]

𝐾z{|} = 𝐾z × V1 + D \

[9]

o

Y=

?@AB × ~

[10]

•€( )~)
(DE

Where [I] was the inhibitor concentration and was set as an individual parameter for all
data sets. X and Y refer to the substrate concentration and enzyme activity respectively.
Vmax, KM and Ki parameters were shared and a best-fit for the entire data set was
determined. To determine the mixed-type inhibition of oxalate the model used was:
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Where [I] was the inhibitor concentration and was set as an individual parameter for all
data sets. X and Y refer to the substrate concentration and enzyme activity respectively.
Vmax, KM, Ki, and a parameters were shared and a best-fit for the entire set of data was
determined.
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To determine initial velocity rates for the MDH and LDH assays in the 96-well
plate format, the average slope and standard deviations in units of

<:;
;‰G

were calculated for

96-well plate reader data output from a Multiskan Ascent spectrophotometer (Thermo).
<:;

Beer’s Law was used to convert ;‰G to

µcaŠ
c>‹

with a calculated path length for the 96-well

plates:
abs = c × ε × l

[14]

Where c is the concentration of the enzyme, e is the extinction coefficient for PC (6220
M-cm-) and l is the path length. As the enzyme activity was recorded in 96-well plates
and not in 1 mL cuvettes, the path length in 1 mL cuvettes (1 cm) could not be used for
the 96-well plate. To determine the path length in the 96-well plates, the following ratio,
Equation 15, was derived based on the absorbance and concentration of NADH in the 1
mL cuvettes and 96-well plate format. The absorbance of 0.25 mM of NADH in 1 mL
quartz cuvettes recorded at 340 nm in a UV- 1800 spectrophotometer (Shimadzu
Scientific Instruments) was represented by:
abs GŽ•‰HH‰ = c•9‘’ × ε × l , where l= 1 cm
Rewritten:
c•9‘’ =

abs GŽ•‰HH‰
ε × 1 cm

The absorbance of 0.25 mM NADH in the 96-well plate format with 200 µL recorded at
340 nm in a Multiskan Ascent spectrophotometer was represented by:
abs “‰ŠŠ = c•9‘’ × ε × l , where l= unknown
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As the NADH measured in both formats was prepared from the same stock of NADH, it
can be assumed that the concentration of NADH was equal between the 1 mL cuvette and
96-well plate. Therefore, abswell can be rewritten as:
𝑎𝑏𝑠 —˜™™ = U

𝑎𝑏𝑠 š›œ˜••˜
] × e × l
e × 1 cm

Rewritten:
<:;žrff

l = V<:; Ÿ

¡r¢¢r

\ cm

[15]

Where l was determined to be 0.43 cm in the 96- well plates with a 200 µL volume.
4.3 Results
4.3.1 Inhibition of SaPC, LmPC and RePC by oxalate, 3-hydroxypyruvate and
3-bromopyruvate
Based on the structural studies of pyruvate, oxalate, 3HP and 3BP bound in the
same orientation in the CT domain of PC (Lietzan and St Maurice 2013b), it was
hypothesized that a-keto acids would act as substrate analog inhibitors. Oxalate, 3HP and
3BP were confirmed to inhibit RePC, LmPC and SaPC in the 384-well plate FVB assay
(see Figure 4-4). Oxalate was the most potent inhibitor for all three bacterial enzymes,
with IC50 values of 140 µM, 16 µM and 2 µM for RePC, LmPC and SaPC, respectively
(see Table 4-1). Oxalate did not interfere with the formation of the FVB-OAA colored
adduct. 3BP was found to also inhibit the bacterial enzymes with IC50 values of 1 mM, 20
µM and 300 µM for RePC, LmPC and SaPC, respectively, while 3HP slightly inhibited
the activity of the bacterial enzymes with IC50 values of 2 mM, 1 mM and 600 µM for
RePC, LmPC and SaPC, respectively. All IC50 values are consistent with published Ki
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values for oxalate (12-150 µM, (Ruiz-Amil et al. 1965)) and 3HP ( 5.4 mM (Charles,
Willer, and Schafer 1984)).
This is the first documented report of IC50 values for 3BP inhibition of bacterial
PC, with a range of 20 µM -1 mM based on results from the FVB assay. However, as
discussed in Chapter 3, the FVB assay may be prone to false positives, as the FVB
diazonium salt has the potential to cross-react with nucleophilic compounds (Amador and
Salvatore 1971). 3BP in particular, interfered with the FVB-OAA colored adduct with a
similar dose response to SaPC (see Figure 4-4A). Therefore, the IC50 values determined
with 3BP may not be accurate in the FVB assay. As the inhibition of 3BP has never
previously been characterized for PC, 3BP was transitioned to the MDH assay for IC50
despite the modest inhibition reported in the FVB assay and due to the interference with
colored adduct formation at concentrations >200 µM. Due to the potent inhibition of
oxalate with SaPC, it was also transitioned to the MDH assay to confirm the IC50 values.
Based on the >500 µM IC50 values for all tested bacterial PC enzymes with 3HP and the
slight inhibition of the FVB-OAA colored adduct at 1 mM, it was determined that 3HP
did not warrant further analysis in the MDH assay.
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Figure 4-4. IC50 Determination for Substrate-Analog Inhibitors of Bacterial PC in
the FVB Assay

Figure 4-4. IC50 determination for substrate-analog inhibitors of bacterial PC in the FVB
assay. For all plots, the RePC inhibited reaction is represented by the green line, the
LmPC inhibited reaction is represented by the purple line, the SaPC inhibited reaction is
represented by the teal line and the FVB-OAA colored adduct inhibition is represented by
the black line. In all panels, the error bars represent the standard deviation across eight
wells. A) The IC50 values for 3BP were 1 mM, 20 µM and 300 µM for RePC, LmPC and
SaPC respectively. The FVB-OAA colored adduct was also inhibited by 3BP with a
similar dose response as SaPC. B) The IC50 values for 3-HP were 2 mM, 1 mM and 600
µM for RePC, LmPC and SaPC respectively. The FVB-OAA colored adduct was also
inhibited by 3-hydroxypyruvate but not to the same extent as 3BP. C) The IC50 values for
oxalate were 140 µM, 16 µM and 2 µM for RePC, LmPC and SaPC respectively. The
FVB-OAA colored adduct was not inhibited by oxalate.
In the MDH assay, the IC50 values for oxalate were 51 µM, 21 µM and 3 µM for
RePC, LmPC and SaPC respectively while the IC50 values for 3BP were 140 µM, 1.1 µM
and 51 µM for RePC, LmPC and SaPC respectively (see Figure B1). Using the IC50
values determined in the MDH assay and an assumption of competitive inhibition, the Ki
values for oxalate and 3BP could be estimated using Equation 8. Based on the structural
evidence that oxalate and 3BP were bound in the CT domain active site in the same
orientation as pyruvate, the assumption of competitive inhibition with respect to pyruvate
was considered to be reasonable. Additionally, as demonstrated in Section 4.3.4, oxalate
was determined be a mixed type inhibitor that strongly favored competitive inhibition.
The estimated Ki values for oxalate were 140 µM, 1.1 µM and 0.43 µM for RePC, LmPC
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and SaPC respectively while the estimated Ki values for 3BP were 7.3 µM, 3 µM and
0.43 µM for RePC, LmPC and SaPC respectively. The Ki value for oxalate was
determined kinetically for SaPC in Section 4.3.4 demonstrating that the predictive Ki
(0.43 µM) value was consistent with the kinetically determined Ki value (0.29 µM).
Based on these results, PC enzymes from different species may have varying sensitivity
to certain small molecule inhibitors. Due to the apparent increased sensitivity of SaPC to
the inhibitors in the FVB and MDH assay, the remaining studies in this chapter were
completed with SaPC.
Table 4-1. IC50 Values for oxalate, 3BP and 3HP as determined using the FVB and
MDH assays
Signal
Compound
Assay
RePC
LmPC
SaPC
Interference
FVB
1 .0mM
Yes
20 µM
300 µM
3-Bromopyruvate
MDH
1.0 mM
No
7.0 µM
**51 µM
***Ki
--140 µM
1.1 µM
7.1 µM
FVB
No
140 µM
16 µM
2 µM
Oxalate
MDH
No
51 µM
21 µM
3 µM
***Ki
--7.3 µM
3 µM
0.43 µM
3-Hydroxypyruvate
FVB
2 mM
1 mM
Yes
600 µM
**Indicates compound was initially screened by BW and evaluated by MM
***Predicted Ki values from Equation 8 based on the IC50 values from the MDH assay.
4.3.2 Scaffold Selection for CT Domain a-Keto Acid Compounds
Crystal structures with various a-keto acid substrate analogs bound suggest that
the CT domain active site of PC is structured to accommodate bulkier functional groups
at the C-2 or C-3 position. Several a-keto acid containing compounds, modified at the C3 position, were evaluated for inhibition of PC activity in order to assess the potential for
this functional group to serve as a scaffold for PC inhibitor development. The FVB assay
was utilized to determine IC50 values in the initial assessment of a-keto acid derivatives.
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Aromatic a-keto acids, such as phenylpyruvic acid (Compound 96), were among the
most promising of the a-keto acid compounds (see Table 4-2), with an IC50 value of 240
µM. The importance of the aromatic ring of phenylpyruvic acid can be demonstrated with
a cyclohexyl ring substitution (α-oxo-cyclohexanepropanoic acid, Compound 140) that
greatly diminished potency. Even slight modifications to the core structure of
phenylpyruvic acid such as the removal (phenyglyoxylic acid, Compound 20) or addition
(2-oxo-4-phenylbutanoic acid, Compound 93) of a carbon between C-2 and the aromatic
ring resulted in a substantial reduction in inhibition. However, the addition of a hydroxyl
group in the para position of the aromatic ring greatly decreased the IC50 value (67 µM)
of 4-hydroxyphenylpyruvic acid (Compound 17) and demonstrated the ability of the
phenylpyruvic acid scaffold (Compound 96) to be modified for more potent inhibitors of
PC.
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Table 4-2. Scaffold Selection for PC Small Molecule Inhibitors
Compound

Structure

FVB Assay IC50 Value

O

Compound 89

OH

>2 mM

OH

>1 mM

O

O

*Compound 140
O
O

OH

Compound 20

>3 mM

O
O

Compound 18

OH

>3 mM

OH
O
OH

Compound 93

>2 mM

O
O

**Compound 96

OH

240 µM

O
O

**Compound 17

OH
HO

67 µM

O

* Indicates compound had only been evaluated by undergraduate researcher MM
**Indicates compound was initially screened by BW and evaluated by MM
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4.3.3 An Initial Structure Activity Series Centered on Aromatic Ring
Substitutions of Phenylpyruvic Acid.
The CT domain of PC is a member of the broader DRE-TIM (Asp-Arg-Glu triplet
in the TIM barrel fold) metallolyase protein superfamily (Forouhar et al. 2006). All
members of this superfamily catalyze reactions that proceed through a stabilized enolate
intermediate. The CT domain reaction mechanism proceeds through a stabilized
enolpyruvate intermediate that subsequently becomes carboxylated to form OAA. It is
promising, then, that phenylpyruvic acids are inhibitory to PC given their propensity to
exist predominately in the enol form in DMSO (Sciacovelli et al. 1976). To further
evaluate the characteristics contributing to inhibition, an initial structure activity
relationship (SAR) study was evaluated for a series of aromatic ring substitutions that
probed the effect of para, meta and ortho substituted aromatic groups (see Table 4-3).
These compounds were evaluated using both the primary FVB and secondary MDH
assays in order to confirm and compare the individual IC50 values.
Para and meta substituted phenylpyruvic acids are both known to exist
predominantly in the enol form while ortho substituted phenylpyruvic acids prefer the
keto form (Takai et al. 1998, Carpy, Haasbroek, and Oliver 2004). Consistent with these
chemical features and our hypothesis that compounds with enol-like characteristics will
have enhanced potency for PC, aromatic compounds substituted in the ortho position 2nitrophenylpyruvic acid (Compound 19) and 3-(2-bromophenyl)-2-hydroxy-2-propanoic
acid (Compound 115)) had higher IC50 values than their para- or meta-substituted
counterparts. There does not seem to be a preference for para- vs. meta-substituted
phenylpyruvic acids, suggesting that the enol character at C-2, rather than the steric fit, is
the most significant contributor to inhibition strength among phenylpyruvic acid
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derivatives. However, only the bromo and methyl substituents were available for direct
comparison of para- vs. meta-substitution.
To further investigate the electronic nature of the inhibitors, a Hammett plot was
generated for a large series of para-substituted phenylpyruvic acids. A Hammett plot
reports on the linear free energy relationship between structure and activity by plotting
the electronic properties of the substitutions against the effect on the reaction (Hammett
1935). In particular, Hammett substituent constants (s) were reported and plotted against
the log IC50 values of the compounds from the MDH assay (Hansch, Leo, and Taft 1991)
(see Figure 4-5). There was a clear linear relationship between the para substituent
constants and the log IC50 values as demonstrated by the Hammett plot. The positive
slope of the Hammett plot indicates that the inhibition of the PC reaction was affected by
the electronic properties of the substitutions, such that electron donating groups tended to
enhance inhibition while electron withdrawing groups were not as effective. However,
the linear regression of the line was not forced through 0,0 indicating that there may be
other factors contributing to the potency of the compounds. While the compounds
designed through the SAR study were not the most potent inhibitors discovered through
SBDD and did not require additional follow-up studies, the compounds provided several
informative insights into the development of potent inhibitors. First, the electron donating
properties of the para substituted aromatic a-keto acids may have an impact on the
potency of designed compounds and second, these studies provided additional evidence
that the CT domain may be specifically targeted as the compounds demonstrate enol-like
characteristics.
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Table 4-3. Aromatic Ring Substitution Structure Activity Relationship of PC
Inhibitors
R1

O

Aromatic a-keto acids ring substitutions
R1= Ortho position
R2= Para position
R3= Meta position

OH
O

R2
R3

Compound

R1

R2

R3

IC50 FVB µM

IC50 MDH µM

s

96

H

H

H

240

130

0

19

NO2

H

H

>2 mM

>2 mM

0.71

*110

H

NO2

H

>1 mM

>1 mM

0.778

*115

Br

H

H

>1 mM

>1 mM

NA

**97

H

Br

H

200

81

0.232

*108

H

H

Br

30

8.8

0.32

*112

H

H

CH3

360

23

-0.069

**114

H

CH3

H

210

140

-0.170

*120

H

Cl

H

280

220

0.227

*106

H

OCH3

H

170

56

-0.268

*119

H

B(OH)2

H

150

77

0.12

*109

H

CF3

H

67

96

0.54

*107

H

F

H

100

30

0.062

**17

H

OH

H

67

22

-0.37

**117

H

CH3

CH3

98

38

NA

Color sections represent identical R constituents at different aromatic ring substitute
positions
* Indicates compound had only been evaluated by undergraduate researcher MM
**Indicates compound was initially screened by BW and evaluated by MM

89

Figure 4-5. Para Hammett Substituent Constants (σ) Relationship to IC50 Values

Figure 4-5. Para Hammett substituent constants (σ) relationship to IC50 values. IC50 X
refers to the IC50 values of the various tested compounds compared as a ratio to the IC50
value of Compound 96 (130 µM). Compound 96 (red) represents the σ value of 0.0 as the
compound does not contain any para, meta or ortho substitutions. The Hammett plot
demonstrates a positive linear relationship (R2=0.52) with the reported σ values and IC50
values determined from the MDH assay. The compounds represented are as followed:
Compound 110 (lime green), Compound 120 (pink), Compound 97 (orange), Compound
119 (grey), Compound 17 (green), Compound 114 (blue), Compound 106 (black),
Compound 109 (teal) and Compound 107 (purple).
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4.3.4 Potent First Generation Small Molecule Inhibitors of PC
The initial SAR study validated the promising inhibitory potential of a-keto acids
and established that enolic character contributes meaningfully to inhibitor potency. As a
consequence, additional a-keto acids, with increased steric bulk, were tested for PC
inhibition in the MDH assay. This included a-oxo-2-quinolinepropanoic acid (Compound
98) and benzene-1,4-dipropanoic acid (Compound 122) (See Table 4-4). PC tolerated the
additional bulk of the quinoline-derived compound as evidenced by the 8 µM IC50 value
for Compound 98, representing the most potent inhibitor of PC developed through
SBDD. The high affinity of Compound 98 may derive from the quinolinyl nitrogen,
which is capable of forming an intramolecular hydrogen bond to stabilize the enol form
of this compound (see Figure 4-6). The most potent compounds, oxalate and Compound
98, and representative compounds from SAR, 4-hydroxyphenylpyruvic acid (Compound
17) and 2-hydroxy-3-(4-methylphenyl)-2-propenoic acid (Compound 114) were
advanced for further structural and kinetic analysis. Compound 17 and 114 were selected
due to their low IC50 values (22 µM and 17 µM respectively) in the MDH assay and for
their low Hammett substituent constant (-0.37 and -0.17) compared to the other SAR
compounds. The structural and kinetic analysis included determination of the Ki value
and mode of inhibition, secondary LDH assays, X-ray crystallography and docking
studies.
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Figure 4-6. Intramolecular Hydrogen Bonding in Compound 98

O
OH
N

H

O

Figure 4-6. Intramolecular hydrogen bonding is proposed to stabilize the enol form of
Compound 98.
Table 4-4. Ki and Docking Values for Select Small Molecule Inhibitors of PC

Compound

Structure

IC50 MDH µM

Ki µM

Docking
Closed/
Open

51

***7

-28/-37

23

***3

-44/-65

22

***3

-25/-42

17

2.4
***2.4

-22/-43

8

0.74
***1.1

-36/-35

3

0.29
***0.43

-22/-42

O

3BP

Br

OH
OH

122

O

OH

OH

HO

OH
O

O

**17

OH
OH

HO

O

**114

OH
OH
O

98

OH
N

Oxalate

OH

HO

OH

HO

OH

**Indicates compound was initially screened by BW and evaluated by MM for IC50
values only. All docking and Ki determinations were made by BW.
***Predicted Ki values from Equation 8 based on the IC50 values from the MDH assay.
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While the compounds described above were assumed to target the CT domain of
PC and directly outcompete the substrate, the IC50 values were unable to determine
whether these inhibitors are directly targeting the CT domain and were unable to assess
the mode of inhibition (competitive, noncompetitive, mixed-type, etc.). As described in
Section 4.2.5, a truncated form of SaPC was generated that lacked the BC and BCCP
domain (SaPCDBCDBCCP) to facilitate inhibition assays of the CT domain in isolation,
via a LDH coupled enzyme assay. The LDH assay measures the rate of oxamate-induced
OAA decarboxylation in the CT domain. Oxamate promotes OAA decarboxylation by
accepting the carboxyl group from OAA to form pyruvate and carbamyl oxamate
(Lietzan, Lin, and St Maurice 2014). If a-keto acids specifically inhibit the CT domain of
PC, we would expect to see inhibition of SaPCDBCDBCCP via the LDH coupled enzyme
assay. As demonstrated in Figure 4-7A (black columns), the CT domain enzyme activity
is inhibited in the presence of oxalate, as expected. Compound 98 also inhibited the CT
domain reaction, but to a lesser extent. Surprisingly, Compound 17 enhanced the CT
domain reaction. While oxamate accelerates the decarboxylation of OAA, it is also an
inhibitor of both LDH and PC (Lietzan, Lin, and St Maurice 2014, Zeczycki, Maurice,
and Attwood 2010, Zeczycki, St. Maurice, and Attwood 2010). Consequently, oxamate
was removed from the LDH assay (grey columns) resulting in decreased overall reaction
rates. Surprisingly, in the absence of oxamate, both Compound 98 and 17 appeared to
enhance the rate of OAA decarboxylation. These results suggested possible crossreactivity with the LDH coupling enzyme. To further investigate this possibility, LDH
(without PC present) was assayed in the presence of these compounds. It was determined
that Compound 17 inhibited LDH at concentrations greater than 1 mM (see Figure 4-7B)
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and, furthermore, acted as substrates for LDH (see Figure 4-7C). Consistent with these
observations, it has previously been demonstrated that LDH is able to directly reduce
aromatic a-keto acids in the presence of NADH (Friedrich et al. 1987). Compound 17
was progressed towards crystallization studies as high concentrations of the compound
can be easily dissolved in crystallization solutions, but due to its interactions with LDH,
were removed from further kinetic studies. These findings greatly complicate the use of
an LDH-coupled assay to assess CT domain specific inhibition in PC and lead to the
conclusion that the LDH assay is inappropriate for assessing CT domain inhibitors of PC.
Alternative methods were, therefore, required in order to clarify the target site of
inhibition.
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Figure 4-7. LDH Assay Inhibition and Substrate Range

Figure 4-7. LDH assay inhibition and substrate range. A) Initial determination of
compound inhibition in the presence of the indicated compound and 0.5 mM oxamate,
0.2 mM OAA, 0.25 mM NADH and 100 µg/mL SaPCDBCDBCCP is represented by the
black columns. The grey columns represent compound inhibition in the absence of
oxamate and in the presence of the indicated compounds and 0.2 mM OAA, 0.25 mM
NADH and 100 µg/mL SaPCDBCDBCCP. B) Direct inhibition of LDH by individual
compounds was determined in the presence of 0.05 U/mL of LDH in the presence of 50
mM pyruvate and 0.25 mM NADH. At high concentrations, Compound 17 showed
evidence of LDH inhibition. C) The ability of LDH to use the compounds as substrates
was determined with 0.05 U/mL of LDH in the presence of 0.25 mM NADH. Compound
17, in particular, is readily reduced by LDH.
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Based on our hypothesis that the compounds are competitive inhibitors with
respect to pyruvate, Ki values, predictive Ki values and the mode of inhibition were
determined for the compounds described in Table 4-4 (see Figure B2 and B3). Oxalate is
known to bind in the CT domain of PC and was used as comparison. Oxalate was a
mixed type inhibitor that strongly favored competitive inhibition with a Ki value of 0.29
µM. The a value derived from a global fit of the data to Equation 12 indicated that
oxalate is primarily a competitive inhibitor with respect to pyruvate. The a values from
the mixed-type model can determine the degree to which the inhibitor changes the
affinity of PC for pyruvate. If the a value is 1, then the inhibitor has no influence on the
affinity of pyruvate, resulting in classic noncompetitive inhibition. As the a value
approaches 0, the inhibitor will significantly increase the affinity of PC for pyruvate,
resulting in uncompetitive inhibition. As the a value approaches infinity, the inhibitor
will significantly decrease the affinity of PC for pyruvate, resulting in competitive
inhibition. In the case of oxalate, the a value was very large, indicating that the inhibitors
strongly favored competitive inhibition. These results differ from previous reports of
classic noncompetitive inhibition of PC by oxalate with respect to pyruvate (Ruiz-Amil et
al. 1965). The differences are attributed to the substantially higher purity of PC relative to
what was available in 1965 and our results are reinforced by the convincing structural
evidence that oxalate is bound in the pyruvate binding site at the CT domain of PC
(Lietzan and St Maurice 2013b). Thus, we are confident that our Ki value and mode of
inhibition are accurate. As an additional measure to assess whether our procedure for
determining Ki values was accurate, the mode of inhibition for oxalate with respect to
ATP was determined. Oxalate was a mixed-type inhibitor with respect to ATP, with a Ki
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value of 2.5 µM and a value equal to 0.92 strongly favoring a noncompetitive mode of
inhibition.
Compounds 98 and 114 were determined to be competitive inhibitors with respect
to pyruvate and noncompetitive inhibitors with respect to ATP (see Figure 4-8, B2 and
B3). The Ki values for pyruvate inhibition are reported in Table 4-4 with Compound 98
being the most potent inhibitor, with a Ki value of 0.74 µM. The predictive Ki values were
determined for Compound 98 (1.1 µM) and Compound 114 (2.4 µM). As the predictive
Ki values were consistent with the kinetically determined Ki values, and due to the
consistent competitive inhibition mode for oxalate, Compound 98 and Compound 114,
competitive predictive Ki values were mathematically determined for 3BP (7 µM),
Compound 17 (3 µM) and Compound 122 (3 µM). These results indicate that these
compounds directly compete with pyruvate in the CT domain active site. Furthermore,
their binding affinity is not altered by the presence of ATP binding in the BC domain
active site. Consistent with our hypothesis, a-keto acids specifically target the pyruvate
binding site in the CT domain of PC.

97
Figure 4-8. Compound 98 is Competitive with Respect to Pyruvate and
Noncompetitive with Respect to ATP

Figure 4-8. Compound 98 is competitive with respect to pyruvate and noncompetitive
with respect to ATP. Oxalate is a mixed type inhibitor with respect to pyruvate (strongly
favors competitive inhibition) and mixed type with respect to ATP (strongly favors
noncompetitive inhibition). A) Global fit of Compound 98 as a competitive inhibitor with
respect to pyruvate, Ki value = 0.74 µM. B) Lineweaver-Burk plot demonstrating
competitive inhibition of Compound 98 with respect to pyruvate. C) Lineweaver-Burk
plot demonstrating noncompetitive inhibition of Compound 98 with respect to ATP, Ki
value = 5.2 µM. D) Global fit of oxalate as a mixed type inhibitor with respect to
pyruvate, Ki value = 0.29 µM. E) Lineweaver-Burk plot demonstrating mixed inhibition
of oxalate with respect to pyruvate. F) Lineweaver-Burk plot demonstrating mixed
inhibition of oxalate with respect to ATP, Ki value = 2.5 µM.
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Substantial efforts were dedicated to X-ray crystallography with Compounds 17
and 98 with the goal of directly visualizing these high affinity compounds bound in the
CT domain of PC. These efforts included soaking and co-crystallization crystallization
attempts with full-length, DBC and DBCDBCCP variants of SaPC, LmPC and RePC
(these efforts are outlined in Appendix C). The most promising crystallization conditions
included the reproduction of RePCDBCDBCCP crystals (Lietzan and St Maurice 2013b)
from Lietzan et al. and SaPCDBC crystals that were refined through a PC-specific general
screen developed from previously published crystallization conditions of PC. The
refinement of the RePCDBCDBCCP crystals were never progressed to X-ray diffraction
at the Advance Photon Source (APS) as they did not diffract past ~5-6 Å. The SaPCDBC
crystals however, diffracted to ~3-2.3 Å and were progressed to X-ray diffraction at the
APS. Data were collected on various crystals that were either co-crystallized with
Compound 17 or soaked with Compound 98 (described in Section 4.2.6). Those
crystallization attempts with SaPCDBC were deemed unsuccessful as the crystal
structures did not reveal significant electron density of any small molecules in the CT
domain active site. However, as the SaPCDBC structure was consistent with previous
structures that highlighted the CT domain in the open conformation (Lietzan and St
Maurice 2013a, St Maurice et al. 2007), the structure was utilized as an important
structure in subsequent docking studies.
As an alternative approach to structural characterization, docking studies were
performed to computationally predict the binding affinity of the most potent inhibitors for
the CT domain of PC, and to visualize the predicted binding site. Several considerations
such as the conformation of the CT domain and the enol/keto form of the compounds
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were accounted for in the docking studies. As mentioned in the introduction, the CT
domain has been crystallized in two conformations, the open and closed conformation.
Without pyruvate bound, the CT domain is in the open conformation (Lietzan and St
Maurice 2013a). Upon the binding of pyruvate, the CT domain adopts a closed
conformation that promotes the binding of carboxybiotin (Lietzan and St Maurice 2013a)
(see Figure 4-9). As the crystal structure of SaPCDBC was determined to be the open
conformation, it was utilized as the comparison to the closed conformation of the CT
domain in SaPC (pdb i.d. 3bg5). As a majority of the kinetic studies described in this
chapter were assayed with SaPC, these structures were determined to be the most
appropriate. Based on a surface view of the CT domain tunnel in the closed
conformation, the active site is less accessible relative to the open conformation (see
Figure 4-9). For the more sterically bulky compounds, this can be expected to affect their
docking score and, thus, docking was performed against both conformations.
Additionally, the enol/keto form was considered for docking with the most potent
compounds. As shown in Figure 4-10, docking with the enol and keto form of Compound
98 in the open conformation, closed conformation and closed conformation with biotin
present all resulted in varying poses within the CT domain. Due to the importance of the
enolic characteristics of the compounds, all compounds were docked in their enol form
(docking scores are recorded in Table 4-4) unless otherwise stated. Docking scores
account for hydrogen bonds, Coulombic and Van der Waal interactions (Pagadala, Syed,
and Tuszynski 2017), with a more negative docking score correlating with a higher
predicted binding affinity.
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To investigate the accuracy of the predictive binding poses of the compounds
through docking, the docking poses of pyruvate bound in CT domain were compared to
the crystal structures of pyruvate bound in the closed conformation (see Figure 4-11).
While there are some variances in the binding orientation of pyruvate crystallized with
RePCDBCDBCCP (Lietzan and St Maurice 2013a) and SaPC (Xiang and Tong 2008a) in
the closed conformation, all structures show that the carboxyl moiety of pyruvate forms a
salt bridge Arg621 and the carbonyl oxygen of pyruvate is within hydrogen bonding
distance of Arg548, Gln552 and oriented towards the Mn2+/Zn2+ metal ion (see Figure 411A and B). Surprisingly, the docking poses of pyruvate in the closed conformation and
closed conformation with biotin present did not demonstrate the same orientation of
pyruvate as the crystal structures (see Figure 4-11C). However, when the Mn2+/Zn2+
metal ion was removed, the docking poses of pyruvate did align with the orientation of
pyruvate in the crystal structures (see Figure 4-11D). This indicated that the carboxyl
moieties in the docking program will be preferentially coordinated with the Mn2+/Zn2+
metal rather than the active site amino acids.
To assess whether it was possible to remove the Mn2+/Zn2+ metal for all docking
experiments for more accurate docking poses, Compound 98 was docked in the closed
conformation without the metal ion. Regardless if the metal ion was removed or not, the
a-keto acid group was oriented towards the water and metal ion, while the aromatic rings
were positioned near the catalytic amino acids (see Figure 4-11E). Additionally, when the
metal ion was overlaid, it was apparent that the compound was occupying the same space
as the metal ion and it was decided that the metal ion would remain present in all docking
studies. Ultimately, the pyruvate docking controls demonstrated that there is a clear
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difference in the way the docking software predicts how the a-keto acids bind to how
they are oriented in the crystal structure.
As Compound 98 was the most potent compound discovered from SBDD, it was
studied further in the docking program in both the closed conformation and closed
conformation with biotin present. Those two conformations were selected due to the
completely different predictive binding orientations of Compound 98 in the CT domain.
Based on the docking structure in the closed conformation, the nitrogen in the quinoline
group was predicted to be within hydrogen bonding distance of Thr882 and Gln552, while
the a-keto acid group was predicted to coordinate with an ordered water molecule, the
active site metal and the guanidinium group of Arg548 (see Figure 4-12A-C). All three
amino acids are conserved in PC while Gln552/ Arg548 are conserved within the broader
DRE-TIM metalloenzyme family that catalyze reactions that proceed through an enol
intermediate (Forouhar et al. 2006). Additionally, the aromatic rings of Compound 98
occupy the space that biotin has been shown to occupy in several X-ray crystal structures
(Xiang and Tong 2008a) (see Figure 4-12C). Alternatively, the docking of Compound 98
in the closed conformation with biotin present seems to suggest that the orientation of
Compound 98 was impacted by the presence of biotin. This docking pose had a similar
orientation as the a-keto acid group of pyruvate, but the aromatic ring coordination with
the water and metal ion were unusual. The nitrogen in the quinoline compound was
within hydrogen bond distance of Gln552 while the carboxyl moiety of the compound
formed a salt bridge with Arg621. The carboxyl moiety of Compound 98 does not interfere
with the binding location of biotin. Until a crystal structure can elucidate the true binding
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orientation of Compound 98, the docking studies are useful in visualizing the predictive
spatial availability of the CT domain with bound compounds in various conformations.
Figure 4-9. Cartoon and Surface View of the CT Domain in the Open and Closed
Conformation

Figure 4-9. Cartoon and surface view of the CT domain in the open and closed
conformation. Conformational changes were determined by the overlay of full length
SaPC (closed conformation, pbd i.d. 3bg5) and SaPCDBC (open, conformation,
unpublished) as described in Section 4.2.5. In all panels the open conformation is
represented by the blue cartoon and surface view and the closed conformation is
represented by the green cartoon and surface view. Pyruvate is represented by the yellow
stick model, water by the red sphere and the metal Mn2+/Zn2+ ion by the grey sphere. A)
Cartoon representation of the CT domain in the closed and open conformation. Upon
pyruvate binding, the CT adopts a closed conformation and several a-helices shift ~5 Å
towards the center of the CT domain. B) Surface representation of the open conformation
with the overlay of pyruvate from the closed conformation. C) Surface representation of
the same view of pyruvate in the closed conformation highlighting the less accessible
active site.
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Figure 4-10. Different Docking Poses of the Enol and Keto Form of Compound 98

Figure 4-10. Different docking poses of the enol and keto form of Compound 98. In the
right panels, the keto or enol forms of Compound 98 were docked in either the open
conformation (periwinkle), closed conformation (green) or closed conformation with
biotin present in the CT domain (grey). Crystallized pyruvate is represented by the yellow
stick model. A) Structure of the keto form of Compound 98 and the various positions of
the compound docked in the CT domain. B) Structure of the enol form of Compound 98
and the various positions of the compound docked from the same view as the keto form.
The Mn2+/Zn2+ metal ion is represented by the grey sphere and the displaceable overlaid
water molecule is represented by the red sphere.
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Figure 4-11. Crystallized and Docked Pyruvate Orientation in the CT Domain

Figure 4-11. Crystallized and docked pyruvate orientation in the CT domain. A) Crystal
structure of private (yellow) bound in the CT domain of SaPC. Upon the binding of
pyruvate, the CT domain adopts a closed conformation where the carboxyl moiety of
pyruvate forms a salt bridge Arg621 and the carbonyl oxygen of pyruvate is within
hydrogen bonding distance of Arg548 and Gln552. These residues are responsible for
stabilizing the enolpyruvate intermediate that is formed when biotin transfers CO2
through a proton shuttle to pyruvate via Thr882. In the closed conformation, Tyr628 forms a
hydrogen bond with Asp590. B) Comparison of pyruvate bound in SaPC crystal structure
(yellow) and RePC (periwinkle). C) Comparison of pyruvate docked in the closed
conformation (pink) and closed conformation with biotin present (purple). D)
Comparison of pyruvate docked in the closed conformation (pink) and the closed
conformation with biotin present with the removal of the metal ion. E) Compound 98
docked in the closed conformation with the removal of the metal ion. The metal ion was
overlaid to demonstrate the steric clash of Compound 98 with the metal.
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Figure 4-12. Docking Pose of Compound 98 in the Closed Conformation of the CT
Domain

Figure 4-12. Docking pose of Compound 98 in the closed conformation of the CT
domain. Panels A-C represent Compound 98 that was docked in the closed conformation
without biotin present. Panels D-F represent Compound 98 that was docked in the closed
conformation with biotin present. In all images, the water is represented by the red sphere
and the Mn2+/Zn2+ metal ion is represented by the grey sphere. A) Forward view of
Compound 98 and the a-keto acid group orientation towards the water and metal ion. B)
The nitrogen in the quinoline compound is within hydrogen bond distance of Gln552 and
Thr882. C) The aromatic rings of Compound 98 occupy the binding location of biotin. D)
Forward view of Compound 98 and the a-keto acid group orientation towards the
catalytic amino acids while the aromatic rings coordinate with the water and metal. E)
The nitrogen in the quinoline compound is within hydrogen bond distance of Gln552 while
the carboxyl moiety of the compound forms a salt bridge with Arg621. F) The carboxyl
moiety of Compound 98 does not interfere with the binding location of biotin.
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4.4 Discussion
The inhibitors described in this chapter, developed using SBDD, have produced
relatively high affinity small molecule fragments that can serve as a foundation for the
ongoing development of specific and potent small molecule inhibitors of PC. We have
determined that a-keto acids are amenable scaffolds that can be modified to
accommodate increased steric bulk, leading to increasingly potent inhibitors.
Phenylpyruvic acids, in particular, served as the core scaffold that demonstrated
increased potency and provided initial evidence that the enol tautomer is a more potent
inhibitor. It was originally hypothesized that the enol tautomer of the compounds would
result in more potent inhibitors as they would mimic the enolpyruvate intermediate and
therefore act as a transition state analogue. As such, it was predicted that the a-keto acid
inhibitors would orient in a similar position as pyruvate and the various a-keto acid
substrate analogues that had previously been crystallized in the CT domain (Lietzan and
St Maurice 2013b). This includes the binding of the inhibitor such that the carboxylic
moiety of the compound would form a stabilizing salt bridge with the guanidine group of
Arg621 and the carbonyl oxygen of the a-keto acid would be within hydrogen bonding
distance of Arg548 and Gln552. It is through these catalytic amino acids that the
enolpyruvate intermediate is stabilized and so, hypothetically, should the enolic
inhibitors.
As mentioned in Section 4.3.3, phenylpyruvic acids are predominately in the enol
form in DMSO and deuterated NMR solutions (Sciacovelli et al. 1976, Takai et al. 1998).
However, the inhibition of the compounds that were assessed in our assays only
contained a maximum of 5% DMSO and represented the inhibition of PC in an aqueous
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solution. Indeed, studies have demonstrated that the enol-keto tautomerization of
phenylpyruvic acids are highly dependent on the solvent, temperature, pH and para, meta
and ortho substitution groups of the phenylpyruvic acids (Takai et al. 1998, Sciacovelli et
al. 1976, Carpy, Haasbroek, and Oliver 2004, Geratz 1965, KNOX and PITT 1957,
Yamaji and Saito 2018, Larsen and Wieczorkowska 1974). In particular, the transition of
the enol to keto tautomer has been demonstrated to progress rapidly in water (Takai et al.
1998) such that the keto form dominates 95% of the solution in water (Sciacovelli et al.
1976).
There is evidence that the para, meta and ortho substitutions of phenylpyruvic
acids influence the enol-keto tautomer form in various solutions (Larsen and
Wieczorkowska 1974, Takai et al. 1998). In deuterated NMR solutions such as CD3CN,
regardless of the electron donating or withdrawing group that was substituted in the para
or meta position, the enol form dominated while the electron withdrawing groups in the
ortho position favored the keto form (Takai et al. 1998). The para and meta aromatic ring
substitutions from our study demonstrated that they contributed to lower IC50 values
when compared to ortho substitutes, providing initial evidence that the enol tautomer was
important in the potency of the inhibitor. Again, the inhibition studies were done in an
aqueous assay buffer and not CD3CN, thus those studies do not explain why we see a
clear trend in the increased potency of the compounds that contain electron donating
groups in the para position. Intuitively, this trend does not seem consistent with the
formation of the anionic intermediate, enolpyruvate, that is stabilized in the CT domain
reaction (Zeczycki et al. 2009). However, as previously reported by Larsen et al., there is
evidence that an electron donating group, such as an hydroxyl group in the para position
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of phenylpyruvic acid, promotes the enol form in an aqueous solution (17%) compared to
the unsubstituted phenyl pyruvic acid (10%) (Larsen and Wieczorkowska 1974). The
Hammett plot therefore may provide some insights into the enol-keto form of the
inhibitors. If the electron donating properties of the para substitutions do increase the
enol form of the compounds in an aqueous solution, then the positive slope of the
Hammett plot is consistent with the hypothesis that the enol tautomer is important in the
inhibition of the CT domain reaction.
As Larsen et al. demonstrated, the para substitution did not demonstrate a 100%
enol tautomer solution. Therefore, the enol-keto ratio could have an impact on several of
the SBDD studies described in this chapter. First, if the enol form is the predominate
tautomer that results in potent inhibition and it is present in only ~10-20 % of the
solution, then the kinetically determined Ki values are likely an underestimation of the
true Ki values from the form of the compound that inhibits the reaction. Second, the enolketo ratio could have a significant impact on the success of crystallization studies. As
mentioned in Section 4.3.4, we were unable to crystallize the compounds with SaDBC.
This may be due to the unexpected lower concentration of the enol compound that is able
to bind in the CT domain and thus impact the saturation of the compound present in the
crystallization conditions.
Based on the original hypothesis, the compounds have been proposed to have
enhanced potency due to enolic characteristic that mimic the enolpyruvate intermediate
transition state. However, the visualization of the predictive binding orientation of the
compounds docked in the CT domain have provided an additional explanation as to why
the enolic characters of the compounds may be important in the inhibition of PC. In a
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majority of the docking poses, the a-keto acid moiety directly coordinates with the metal
ion and does not form any stabilizing bonds with the key catalytic amino acids. Enol
intermediates can be stabilized through coordination with metals, and certain enzymatic
reactions are accelerated with an enolate/enol and metal intermediate (Ming 2009). In
particular, metal-enolate bonds are more stable than metal-keto bonds (Ming 2009). This
coordination with the metal ion highlights the potential of the compounds to specifically
inhibit the CT domain reaction through the metal ion as an enol tautomer.
It has been recognized that docking is a predictive model (Chen 2015) and based
on the inability of the docking software to correctly dock pyruvate in an orientation
similar to the crystal structure, we realize that the models may not be an accurate.
However, the docking studies did allow us to visualize the compounds bound in the CT
domain. This was beneficial as the docking studies demonstrated that it was spatially
unlikely that the bulkier compounds such as Compound 98, could sterically orient such
that their a-keto groups are oriented similarly to pyruvate. Due to docking studies
prediction that the a-keto acid moiety directly coordinates with the metal ion, it raised
new concerns that these compounds may act as promiscuous metal chelators against a
range of metalloenzymes.
Nearly one third of all proteins are estimated to be metalloenzymes (Day and
Cohen 2013) (Valdez et al. 2014). Metalloenzyme inhibitors are commonly hydroxamic
acids or carboxylic acids that coordinate to the active site metal (Day and Cohen 2013).
There are concerns that these metalloenzyme inhibitors are indiscriminate, but several
recent studies by Day et al. and Chen et al. demonstrate that this might be a broad
misconception. Day et al. concluded that metalloenzyme inhibitors are indeed specific for
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their intended targets and do not demonstrate off-target activity, even at high
concentrations (Day and Cohen 2013). Chen et al. followed this study by rudimentarily
creating an in vivo like environment by assaying multiple metalloenzymes in the presence
of inhibitors. They demonstrated that the potency of metalloenzyme inhibitors was not
affected by the presence of other metalloenzymes.
It is hopeful that our compounds are not broad binding, metal chelators or nonspecific inhibitors in general. It is reassuring to note that our most potent compound
(Compound 98) does not display nonspecific inhibition against MDH or LDH, nor is it
used as a substrate by LDH. Both MDH and LDH utilize substrates such as OAA
(Bernstein and Everse 1978) and pyruvate (Coulson and Rabin 1969) respectively,
similarly to PC. If the compounds were promiscuous inhibitors for enzyme reactions that
utilize the same CT domain substrates as PC, then it may be expected to see inhibition
with both MDH and LDH. While it is still very possible that these compounds are nonspecific for PC and have broad binding capabilities, these initial results are promising for
future compound development.
In lieu of a crystal structure, the docking studies may be able to provide a
foundation for future compound development and to elucidate possible inhibition
interactions, with the caveat that these are only predictive models. It has been previously
shown that competitive inhibitors of PC can promote carboxybiotin decarboxylation in
the CT domain of PC (Goodall et al. 1981). While pyruvate binding is not required for
biotin decarboxylation, the CT domain needs a ligand to be bound in the active site in
order for biotin to access to the CT domain active site (Xiang and Tong 2008a, Attwood,
Tipton, and Cleland 1986). Inhibitors that promote carboxybiotin decarboxylation are
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fluoropyruvate, hydroxypyruvate, oxamate and glyoxylate (Goodall et al. 1981). Notably,
these are all a-keto acids. Inhibitors that do not promote carboxybiotin decarboxylation
are propionate, lactate and acetaldehyde that lack either the carboxyl or carbonyl group
(Goodall et al. 1981). When pyruvate binds in the CT domain, the active site loop adopts
a closed conformation and a salt bridge forms between the carboxyl moiety and Arg621
(Lietzan and St Maurice 2013a). This rearranges an active site loop and repositions Tyr628
in the active site. Biotin binding is promoted in the closed conformation, with the
thiopene ring of biotin positioned directly above the repositioned aromatic ring of Tyr628
to form a sulfur-p interaction that contributes directly to biotin binding (Lietzan and St
Maurice 2013a, Xiang and Tong 2008a). There is support for such sulfur-p interaction in
the literature, where it has been proposed that divalent sulfides near the plane of aromatic
rings will stabilize protein ligand complexes (Reid, Lindley, and Thornton 1985,
Maveyraud et al. 1996). Based on this information and the docking poses of Compound
98 bound in the CT domain, I have developed several possible models that may describe
the mechanism of inhibition and why Compound 98 in particular is the most potent
compound discovered thus far:
Model #1: Compound bindsà Closed Loopà Compound Aromatic p-p Interaction
with Tyr628
Compound 98 outcompetes pyruvate and binds in the open conformation of the CT
domain. Like previously known inhibitors of PC, it promotes the closed loop
conformation. In this position, the aromatic rings of Compound 98 and Tyr628 are within
distance for p-p interactions (~ 3.2 A). Since the aromatic rings are positioned in the
same location as biotin, carboxybiotin is unable to access the CT domain active site.
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Model #2: Compound bindsà Closed Loopà Biotin Bindsà Compound Aromatic
p-p Interaction with Tyr628 and Compound Aromatic p-sulfur interaction with

Biotin
Compound 98 outcompetes pyruvate and binds in the open conformation of the CT
domain. It promotes the closed loop conformation. In this position, the aromatic rings of
Compound 98 and Tyr628 are within distance for p-p interactions. Carboxybiotin is still
able to access the CT domain active site, but the thiopene ring of biotin is positioned near
the aromatic rings of Compound 98 to form an p electron cloud and contribute to
carboxybiotin binding. The interactions of Compound 98 and carboxybiotin may impact
the movement of the BCCP domain, thus interfering with enzyme activity. With this
model, it may be possible for the compounds to become carboxylated and utilized as a
substrate for PC (see Figure 4-13).
Figure 4-13. Proposed Mechanism for the CT Domain Carboxylation of Aromatic
Phenylpyruvic Acids

Figure 4-13. Proposed Mechanism for the CT Domain Carboxylation of Aromatic
Phenylpyruvic Acids
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Model #3: Compound bindsà Open Loopà Biotin Binds (?)à Compound
Aromatic p-sulfur interaction with Biotin (?)
Compound 98 outcompetes pyruvate and binds in the open conformation of the CT
domain. It does not promote the closed loop conformation. The change from the open to
closed conformation is based on studies that utilized smaller a-keto acids such a
pyruvate, 3BP and 3HP (Lietzan and St Maurice 2013b) that demonstrate the importance
of the position of the carboxylic acid of the a-keto acids. If the docking poses are correct
in predicting that the a-keto acids are coordinating with the metal ion and not with the
catalytic amino acids, then there would be no “signal” for the CT domain to adopt the
closed conformation. While the docking poses for Compound 98 do indicate that it can
bind both the open and closed conformation with equal probability, this might not be the
case, especially for sterically bulkier compounds. In this position, the aromatic rings of
Compound 98 and Tyr628 are not within distance for p-p interactions. Carboxybiotin may
still able to access the CT domain active site if random movements allow it to come in to
contact with the CT domain and position the thiopene ring near the aromatic rings of
Compound 98 to form a p electron cloud and contribute to carboxybiotin binding. The
interactions of Compound 98 and carboxybiotin may impact the movement of the BCCP
domain, thus interfering with enzyme activity. However, based on this model, there
would be no ligand-induced biotin binding pocket in the CT domain.
4.5 Future directions
To assess the mechanism of inhibition with regards to the models described, a
crystal structure is needed. A crystal structure would provide additional insight into if the
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compounds promote the closed conformation or remain bound in the open conformation.
Additionally, a crystal structure would highlight the preferred orientation of the
compounds in the CT domain and provide a measure to assess the accuracy of the
docking poses. The inhibitory effect of the enol or keto form of the compounds should be
an emphasis for future compound designs as the keto-enol ratio may impact the docking
studies (Martin 2009), X-ray crystallography and the potency of the compounds. A NMR
study of the compounds prepared in assay buffer could determine the percent of enol vs
keto tautomer present as well as the effect the electron donating groups have on the
stabilization of the enol tautomer in an aqueous solution that represents our kinetic
conditions. The confidence in establishing the enol-keto tautomer preference of the
compounds in our system would greatly direct the future studies on the most appropriate
crystallization conditions to utilize such as the percent of DMSO that will enhance the
enol form without affecting crystallization, what compounds prefer the enol form and the
appropriate concentration of the compounds to use for crystallization. Lastly, NMR
studies could also eliminate or confirm the ability of the compounds to be carboxylated
by PC as a substrate.
Other experiments such as the effect of amino acid mutations of Tyr628 and
Lys1119 in isothermal titration calorimetry (ITC) or fluorescent polarization (described in
Chapter 5) binding studies could be implemented to assess the hypothetical role of the
aromatic p interactions as described in the models. Direct binding rather than enzyme
activity would have to be utilized as Tyr628 and Lys1119 are important in the catalysis of
the PC reaction and display reduced enzyme activity when mutated (Lietzan and St
Maurice 2013a, Lietzan, Lin, and St Maurice 2014). Tyr628 is hypothesized to be
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important in p-p interactions between the aromatic ring of tyrosine and the compounds.
Mutating tyrosine to phenylalanine, another aromatic amino acid, would hypothetically
have no effect on the binding of the compounds to the CT domain. However, mutating
tyrosine to alanine, an amino acid with a methyl side chain, should decrease the binding
affinity of the compounds for the CT domain of PC if Tyr628 was important in the binding
of the compounds. Lys1119 is the residue that biotin is tethered to in the BCCP domain
(Lietzan et al. 2011) and hypothesized to interact with the compounds via an p electron
cloud stabilization. Mutating the lysine to glutamine would maintain the spatial size of
lysine but prevent the covalent linkage of biotin and determine whether or not biotin
specifically contributes to the binding of the compounds. Alternatively, binding studies
with a DBCCP truncation where the BCCP domain is removed and therefore lacks biotin
could also be applied in these studies.
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CHAPTER 5: DISCUSSION
This dissertation describes the development, validation and implementation of
several innovative methods that have been used to discover novel small molecule
inhibitors of PC. Through the validation of the FVB fixed time assay, a procedure for
screening numerous small molecule effectors has been established that will provide the
platform for future HTS endeavors. In combination with HTS, a SBDD project has been
implemented in collaboration with the Donaldson and Dockendorff laboratories in the
Marquette University Chemistry Department. This rational approach of developing small
molecule inhibitors for PC has led to the establishment of the most potent inhibitors of
PC to be documented. These first-generation compounds have the potential to be
optimized as specific and potent tools to study the structure, regulation and the role PC
plays in certain types of diseases and infections.
5.1 PC as a Small Molecule Target
PC expression has been linked to several diseases such as breast cancer (Christen
et al. 2016) and type 2 diabetes (Hasan et al. 2008), as well as certain bacterial infections
like listeriosis (Schar et al. 2010). Small molecules that are developed in vitro to elucidate
the effect of the small molecules on the structure and regulation of PC also have the
potential to be translated to in vivo studies. Specific and potent small molecules for PC
can be used to further study the role of PC in those diseases and infections. By expanding
the tools in which to study PC through both approaches, the small molecules developed
with the techniques described in this dissertation have the potential to be utilized as the
foundation for future drug development against PC.
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5.1.1 Application of Small Molecule Effectors to in Vitro Studies
As demonstrated by the SBDD and HTS projects, bacterial enzymes exhibited
varying sensitivity in vitro to 3BP, 3HP and oxalate in the FVB assay and MDH assay.
Generally, SaPC was more sensitive to the compounds followed by LmPC. The least
sensitive enzyme was RePC. This trend was commonly observed in most cases where
compounds were tested against all three bacterial enzymes. As described in Chapter 3,
the difference in IC50 values may be due to differences in KM values for pyruvate among
the various bacterial PCs. However, this is insufficient to explain the difference in
inhibitor potency between RePC and LmPC that have around the same KM values for
pyruvate. IC50 values are not measures of direct binding constants and only represent the
concentration of the inhibitor at which the enzymatic reaction is 50% inhibited (Yang,
Copeland, and Lai 2009). These values are dependent on the binding affinity of the
inhibitor, the KM value of the substrate, the concentration of the substrates and the mode
of inhibition. Ki values represent true dissociation constants and offer a more precise
representation of the relative binding affinities amongst various bacterial PC enzymes.
The estimated Ki values from the MDH assay do support the notion that bacterial
PC may have varying sensitives to CT domain inhibitors in vitro. SaPC had the lowest
estimated Ki with oxalate (0.43 µM), LmPC had the lowest estimated Ki with 3BP (1.1
µM) while RePC had the highest Ki value with oxalate (140 µM). It is reassuring to note
that the predictive Ki value of oxalate (0.43 µM) in SaPC aligned well with the kinetically
determined Ki value in SaPC (0.29 µM). In a previous study, the KD of oxalate for the CT
domain of RePC was determined to be 130 µM (Lietzan and St Maurice 2013b),
providing evidence that the estimated Ki values are accurate and that species-specific
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inhibition in bacterial PC is possible. Additionally, when comparing structural overlays
of the open conformation of the CT domain in SaPCDBC (unpublished), LmPC (pdb i.d.
4qsl, (Sureka et al. 2014)) and RePC (pdb i.d. 2qf7, (St Maurice et al. 2007)), there are
slight shifts in the helices lining the CT domain tunnel such that RePC appears to have a
tighter tunnel than LmPC or SaPC (see Figure B4). SaPC appears to have the most open
CT domain that may allow it to bind a variety of compounds with greater flexibility.
Other studies have also demonstrated that inhibitors can regulate enzyme activity and
have varying degrees of inhibition based on species specificity (Kishor et al. 2013,
Lawrence et al. 2008, Kruger and Overington 2012). For example, methionine
aminopeptidases (MetAPs) are essential enzymes that are found in most organisms and
the increased activity of MetAPs have been correlated to certain bacterial infections and
cancer (Kishor et al. 2013). MetAPs are difficult to target due their conserved active sites.
However, despite this conserved protein structure, Kishor et al. designed species-specific
inhibitors of M. tuberculosis, E. faecalis and human MetAPs through SAR studies. The
results in this dissertation chapter highlight the possibility that compounds can be
discovered in vitro that are species-specific for bacterial PC and could be a promising
direction for the development of future antimicrobial agents.
Small molecule effectors can elucidate structural and kinetic information on the
regulation of PC activity in vitro. Through the SBDD project, the most potent small
molecule inhibitors of PC activity to be documented have been discovered and
developed. The compounds have been assessed in various in vitro methods such as IC50
determinations, SAR studies and kinetic assays that have determined the mode of
inhibition and Ki values of the most potent compounds. These compounds are aromatic a-
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keto acids and are competitive with respect to pyruvate, indicating that they are targeting
the unique CT domain of PC. There is a demonstrated positive relationship between the
potency and the enol-like characteristics of the compounds. The enol form of the
compounds is hypothesized to either: 1) mimic the stabilizing enolpyruvate intermediate
or 2) coordinate with the Mn2+/Zn2+ metal ion of the CT domain. In the absence of a
crystal structure, it is difficult to elucidate the exact mechanism of inhibition. A crystal
structure in particular, would be able to determine if the compounds induce the closed
conformation in the CT domain and whether or not coordination with the metal ion or the
mimic of a transition state intermediate is the preferred inhibition mechanism. A crystal
structure could give insight into how the enol form of the compounds are important in
inhibition. For example, if the compounds do not induce the closed conformation of the
CT domain then what specific amino acids are important in the coordination of the enol
compounds in the active site?
The aromatic a-keto acid inhibitors discovered in this dissertation not only have
the potential to be utilized as valuable in vitro tools to study the structure and regulation
of PC but may also be applied to study other enzymes that catalyze reactions that proceed
through a stabilizing enol-intermediate if they are not specific for PC.
Phosphoenolpyruvate carboxykinase (PEPCK) catalyzes the reversible conversion of
phosphoenolpyruvate to OAA with GTP through a enolpyruvate intermediate (Yang,
Kalhan, and Hanson 2009) (Hanson and Patel 1994). PEPCK can also use ITP for
catalysis but not ATP, displaying nucleotide specificity that has been hypothesized to be
a function of the tautomerization of the keto and enol form of the guanosine and inosine
nucleotide purine ring (Yang, Kalhan, and Hanson 2009). Studies have demonstrated that
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the guanosine and inosine nucleotides prefer the keto tautomer in solution, but the
binding pocket of PEPCK has been proposed to impose selectivity for the enol tautomer
(Yang, Kalhan, and Hanson 2009). If the keto:enol ratio of the compounds discovered in
this dissertation is important in PC inhibition, the compounds may be a useful tool in
probing the binding pockets of enzymes like PEPCK that also catalyze reactions that
proceed through an enol-intermediate. However, as the goal of the chemical probe
development project is to develop potent and specific small molecule inhibitors of PC, it
would be hopeful that the small molecules discovered through SBDD would not be
specific for PEPCK. Regardless, the possibility of assessing the enol-like characteristics
of the compounds in enzymes like PEPCK for either selectivity against PC or as a study
on enol intermediates could be informative for in vitro studies.
5.1.2 Application of Small Molecule Effectors to in Vivo Studies
Small molecule inhibitors of PC are not only important tools that can aid in
understanding the regulation of PC in vitro, but can also be utilized in cell-based assays
to study the role of PC in certain types of diseases and infections, such as cancer and
listeriosis respectively. While we have not assessed our most potent hit compounds in
vivo, small molecules such as 3BP have previously been applied in other studies as
anticancer drugs (Dasari and Tchounwou 2014, Pedersen 2012). Prior to this dissertation,
3BP had been structurally characterized as a PC inhibitor (Lietzan and St Maurice
2013b), but previous studies did not determine an IC50 value of 3BP for PC. As described
in Chapter 4, 3BP was found to inhibit SaPC, RePC and LmPC activity with IC50 values
of 51 µM, 1 mM and 7 µM respectively. Given the importance of PC in certain types of
cancers (Lao-On, Attwood, and Jitrapakdee 2018) and the use of 3BP (Pedersen 2012) as

121
an anticancer drug, it highlights the possibility of the compounds discovered in this
dissertation to be applied to cell-based assays that assess the role of PC in cancer.
3BP is a highly reactive electrophilic alkylator that may have many interactions
with various metabolic targets (Shoshan 2012). For example, 3BP is thought to inhibit
succinate dehydrogenase (Pereira da Silva et al. 2009), glyceraldehyde-3-phosphate
dehydrogenase (Pereira da Silva et al. 2009, Dell'Antone 2009, Ganapathy-Kanniappan et
al. 2010) and can be used as a substrate by LDH (Dell'Antone 2009). Additionally, it is
an inhibitor of isocitrate lyase (Pham et al. 2017). Based on the results from Chapter 4, it
is now a known inhibitor of another important metabolic enzyme, PC. Despite the many
possible and known metabolic targets of 3BP, it has been used in studies as an anticancer
drug that is surprisingly specific for tumor cells and demonstrates limited toxicity in
noncancerous cells (Ko et al. 2004, Shoshan 2012, Attia et al. 2015, Yun et al. 2009). For
example, when treated with 30 µM of 3BP, AS-30D HCC cells (cells used to model
hepatocellular carcinoma) viability decreased from 100% to 10%, while noncancerous
hepatocytes remained unaffected (Ko et al. 2004). However, it appears the sensitivity of
cancer cells to 3BP is not universal and depends on the cancer cell line.
In particular, 3BP has been shown to be an effective anticancer drug in cancer cell
lines where PC is highly expressed. 3BP has been used to study tumor reduction in
combination with tamoxifen (a drug that is standard endocrine therapy for breast cancer)
(Attia et al. 2015) and cancer cell toxicity in breast cancer cell lines (Kwiatkowska et al.
2016, Wu et al. 2014, Xintaropoulou et al. 2015). It was found that breast cancer cell
lines with a high metastatic profile such as MDA-MB-231 cells, were more sensitive to
3BP treatment than the noninvasive tumorigenic MCF-7 breast cancer cell lines
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(Kwiatkowska et al. 2016). This is interesting because PC is highly expressed in MDAMB-231 breast cancer cell lines and not in MCF-7 cells lines (Phannasil et al. 2015).
Additionally, 3BP has selective toxicity to cells with KRAS and BRAF mutations that are
related to colorectal, pancreatic, melanoma and lung cancer (Yun et al. 2009). KRAS
mutations in particular are commonly associated with non-small cell lung cancer
(NSCLC) (Roman et al. 2018, Riely, Marks, and Pao 2009). In combination with
rapamycin (inhibitor of mTOR, a positive regulator of the Warburg effect), 3BP was
shown to have enhanced antitumor efficacy for NSCLC cell lines (Zhang et al. 2015).
Given the importance of 3BP toxicity in certain cancer cell lines that have high PC
expression and the research in this dissertation that demonstrates that 3BP inhibits PC, a
more thorough understanding of 3BP inhibition of PC could greatly benefit future in vivo
studies on the role PC plays in cancer metabolism as 3BP is currently in transition
towards clinical trials (Ko et al. 2012) .
5.1.3 Application of Small Molecules as Drugs
The compounds discovered in this dissertation were not developed with the
intention of being progressed through a drug development project, but to be utilized as
the foundation for chemical probes that can be applied to in vivo and in vitro studies.
Currently, the discovery of small molecule effectors of PC is in the hit development
stage. We have implemented several methods such as HTS and SBBD, that have
developed the first-generation small molecule inhibitors of PC. We are screening and
assessing for hit compounds that can be progressed towards lead compound optimization.
If the future goal of this project is to eventually transition to a drug discovery program,
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then several considerations should be made with regards to the target selection and
compound hit refinements while the project is still in the hit generation stage.
An emphasis has been placed on potent and specific small molecule effectors of
PC throughout this dissertation. This is not only important for in vivo assays, but also
important for future drug development. Drugs should be designed to obtain maximum
safety and efficiency with the lowest dosage of drug (Teague and Valko 2017). In
particular, the drugability of a target should be carefully considered (Bleicher et al. 2003).
Drugability is the ability of a target to be effectively regulated by a small molecule
effector that has been developed with these properties in mind: absorption, distribution,
metabolism, excretion and pharmacokinetics (ADME/PK) (Eddershaw, Beresford, and
Bayliss 2000). ADME/PK studies assess the chemical bioavailability of the compounds
in various tissues, the transfer ability of the compounds from body compartments, the
breakdown and removal of the compounds from the body, as well as the toxicity of the
compounds (Bleicher et al. 2003, Eddershaw, Beresford, and Bayliss 2000).
The steps of drug development are: 1) Hit generation where targets and hits are
identified, 2) lead generation where hits are refined, 3) lead optimization where leads are
refined and 4) clinical development (see Figure 5-1) (Bleicher et al. 2003). Target
selection is important in the outcome of hit development. Hits are progressed to leads by
comprehensive evaluation of the chemical integrity, SAR studies and ADME/PK studies
of the compounds (Eddershaw, Beresford, and Bayliss 2000). Rigorous and educated
selections on hit and lead compounds at each stage will help decrease the high risk of
attrition as the compounds progress through the drug development stages. While SAR
studies described in Chapter 4 have demonstrated that the enol form of the compounds
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may be important in the inhibition of PC, there have been no comprehensive chemical
evaluations of the most potent compounds, such as ADME/PK studies, as we are still in
the hit generation stage. Some examples of ADME/PK studies that could be utilized with
compounds that are eventually transitioned to lead generation are metabolite toxicity
assessment with liver microsomes (Jia and Liu 2007) or intestinal permeability evaluation
in a cell-based Caco-2 model (Li 2001).
Figure 5-1. Drug Discovery and Development Workflow

Figure 5-1. Drug discovery and development workflow. Robust selection of compounds
at every stage of drug development will decrease the high attrition rates of compounds
that are removed in drug development projects. We are currently at the hit generation
stage (Bleicher et al. 2003) .
5.1.4 PC as a Drug Target
An ideal drug target should have a demonstrated role in the pathophysiology of a
disease, an available structure, the ability to be assayed in a HTS and differing expression
levels throughout the body (Gashaw et al. 2012). PC meets many of the requirements of a
good drug target, as PC expression is increased in certain types of cancers (Christen et al.
2016), is essential for L. monocytogenes virulence (Schar et al. 2010) and is differentially
expressed in certain tissues (Jitrapakdee et al. 2008). Importantly, PC can now be assayed
in a validated FVB-based HTS. In particular, SaPC, LmPC and RePC are bacterial PC
enzymes that have been purified and assayed in the HTS and SBDD projects. Several

125
concentrated efforts have also been made to purify human PC (HsPC) as a target to
screen potential inhibitors against. Unfortunately, there has been limited success in
purifying active, soluble HsPC from an E. coli bacterial expression system in our
research laboratory.
Attempts were made to increase the solubility of full-length HsPC with an Nterminal tagged maltose binding protein (MBP). MBPs are one of the most effective
solubilizing agents for proteins that improperly fold or aggregate in bacterial expression
systems (Sun, Tropea, and Waugh 2011). Despite the addition of the MBP, a majority of
the purified full-length HsPC was aggregated and less than 1 mg of purified protein was
collected (compared to ~40 mg of SaPC). However, the enzyme was slightly active with
a specific activity of 4.4 µmol min- mg- in the presence of acetyl CoA (see Figure C2).
Additionally, when the MBP tagged HsPC was utilized in the FVB assay in the presence
of acetyl CoA, it had a Z-factor of 0.74 (see Figure C3). Other efforts were made to
purify active and soluble HsPC protein with a BC domain truncation (HsPCDBC) and
while ~3 mgs of protein were purified (see Figure C1), the protein was inactive as it had
no OAA decarboxylation activity in the LDH assay. As demonstrated by Xiang et al.,
while full-length expression of HsPC in E. coli resulted in aggregated protein,
crystallization of active HsPCDBC was successful (Xiang and Tong 2008a). It is
unknown, then, exactly why our HsPCDBC protein was inactive. It may have been due to
a protein purification error or due to the lack of protein purification optimization for
HsPCDBC.
The difficulties of purifying active, soluble full-length HsPC in a bacterial
expression system may be due to eukaryotic post-translational modifications that do not
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occur in E. coli but are essential for human protein structure and activity (Schein 1991). It
may also be due to differences in codon bias (Quax et al. 2015) between human and
bacteria that affect translation. As it was difficult to purify enough active HsPC for the
HTS and SBDD projects, it was not used as the target PC enzyme for the studies
described in this dissertation. Instead, bacterial PC enzymes such as RePC, LmPC and
SaPC were utilized in both HTS and SBDD with an emphasis on SaPC in SBDD. SaPC
shares 49% sequence similarity with HsPC and the CT domain structures of both SaPC
and HsPC, when overlaid, differ by only 0.6 Å rms (Xiang and Tong 2008a). There is,
however a slight difference in the C-terminal extension of the CT domain in HsPC
compared to SaPC (Xiang and Tong 2008a). Additionally, in comparing the open and
closed conformation of SaPC with the available structures of RePC (open and closed) and
LmPC (closed) in preparation for the docking studies, it was noticed that there are only
slight shifts in the helices lining the CT domain tunnel such that RePC appears to have a
tighter tunnel than LmPC or SaPC (~2.5 Å rms difference between SaPC and RePC).
Overall, all CT domain structures of bacterial and human PC enzymes are very similar.
Based on the structural similarity of HsPC, LmPC, RePC and SaPC it might be
assumed that the selection of the PC target does not matter for HTS, SBDD or future drug
discovery efforts. It may be assumed that screening against SaPC for example, will result
in hit compounds that will also be hit compounds for LmPC or HsPC. However, as it has
been demonstrated in this dissertation, bacterial enzymes exhibited varying sensitivity to
3BP and oxalate. Generally, SaPC was more sensitive to the compounds followed by
LmPC, providing some evidence that species specific inhibition in bacterial PC is
possible. It has been established that PC isolated from S. aureus and L. monocytogenes
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can be differentially regulated by an allosteric inhibitor, c-di-AMP (Sureka et al. 2014).
Sureka et al. confirmed that c-di-AMP is a potent allosteric inhibitor of LmPC and not
SaPC, as the c-di-AMP binding site is not present in SaPC (Sureka et al. 2014). This
highlights the importance of target selection in HTS as it is a nonbiased approach to
discovering small molecule effectors of PC that may then reveal novel, species specific
binding locations. It may be possible that screening against SaPC will reveal novel
binding locations that are SaPC specific and not LmPC or HsPC specific.
If the goal of the HTS project is to eventually be utilized as the foundation for a
drug development program that specifically targets PC, then the most ideal PC drug
target should be selected for screening. As a reminder, an ideal drug target is one that can
be assayed in a HTS and has a demonstrated role in the pathophysiology of a disease
(Gashaw et al. 2012). Bacterial PCs could be utilized as drug targets for antibiotic drug
development while human PC could be a drug target for cancer therapy. If the goal is to
develop drugs that will act as antibiotics against bacterial PC, then considerations should
be made in to which bacterium in particular is being targeted, and how to limit off target
effects against human PC. If the goal of the program is to discover compounds that will
target human PC for future cancer therapy, then purification and utilization of human PC
is essential as screening against bacterial PC may not result in inhibitors that are specific
for human PC. In both instances, a protocol for purifying human PC, or at the very least
mammalian PC, will need to be established. Methods such as HsPC purification from
insect cells using the baculovirus system (Petchampai et al. 2004), mammalian PC
extraction from either sheep or pig liver (Rylatt, Keech, and Wallace 1977, KhewGoodall et al. 1991, Warren and Tipton 1974), or purification of recombinant HsPC from
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293T kidney cells (Jitrapakdee, Walker, and Wallace 1999) should be considered as
future directions for purifying human or mammalian PC.
Due to the difficulties of purifying sufficient amounts of human PC for HTS,
combined with the relative ease of purifying bacterial PC, and the importance of PC in
certain bacterial infections, a future drug development program should focus on bacterial
PC as the ideal drug target. Both LmPC and SaPC could be potential drug targets as they
have been found to be important in the virulence of L. monocytogenes (Sureka et al.
2014) and S. aureus (Benton et al. 2004) respectively. In particular, LmPC has a unique
allosteric binding location (c-di-AMP) and due to the interrupted TCA cycle of L.
monocytogenes (Schar et al. 2010) (Section 1.1.4), it may have other unique binding
locations that have evolved to regulate LmPC in the interrupted TCA cycle of L.
monocytogenes. These novel binding locations could be discovered through HTS and
may be able to provide the foundation for LmPC specific antibiotics. Given the rise of
antibiotic resistant bacteria (Gillings et al. 2008) and the limited number of antibiotics
that have been developed recently (Fischbach and Walsh 2009), targeting central
metabolic enzymes like PC may a possible direction for the future of antibiotic drug
development (Haag, Velk, and Wu 2012, Murima, McKinney, and Pethe 2014).
Targeting metabolic enzymes may bypass the antibiotic resistant pathways that bacteria
have currently established against existing antibiotics (Haag, Velk, and Wu 2012). This
is not a novel idea or unheard of direction as drugs like trimethoprim (TMP), Prontosil
and Bedaquiline all target bacterial metabolic enzymes that have human homologs
(Murima, McKinney, and Pethe 2014). TMP inhibits bacterial dihydrofolate reductase
(DHFR) magnitudes higher than the human counterpart through cooperative binding of
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TMP and a DHFR-cofactor, nicotinamide adenine dinucleotide phosphate (Baccanari and
Kuyper 1993, Kwon, Higgins, and Rabinowitz 2010). Bedaquiline is another example of
an antibiotic that displays targeted selection for the bacterial enzyme over the human
enzyme as mycobacterium ATP synthase is at least 20,000´ more sensitive to
Bedaquiline than the human ATP synthase (Haagsma et al. 2009).
5.2 Future Directions for Pyruvate Carboxylase Small Molecule Effector Discovery
In addition to the contribution of this dissertation work towards the discovery of
specific and potent chemical probes for PC, it also describes the development of a
diazonium based, HTS assay. The FVB assay can not only function as a HTS assay for
PC, but also has the potential to be used as a HTS for other enzymes that utilize or
produce OAA, much like how FVB was originally used to detect phosphoenolpyruvate
carboxylase and aspartate transaminase activity (Sax and Moore 1967, Cockburn et al.
1990, Lombarts and Peters 1971, Norris, Atkinson, and Smith 1975, Babson et al. 1962a).
Enzymes such as MDH, phosphoenolpyruvate carboxykinase and OAA decarboxylase
could benefit from the optimization of a fixed time assay that can measure OAA levels
(Minárik et al. 2002, Yang, Kalhan, and Hanson 2009, Sender et al. 2004). In particular,
phosphoenolpyruvate carboxykinase is an important enzyme that maintains blood glucose
levels and has been identified as a potential drug target for diabetes and obesity
(Matsuoka et al. 2015). Currently, the FVB assay is utilized as the primary screen in both
the HTS and SBBD projects that are described in this dissertation.
With regards to HTS, libraries of compounds are initially screened in the FVB
assay with a single point determination in 384-well plates (each single well contains one
compound), whereas in the SBDD project, rationally designed compounds are initially
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evaluated with a dose dependent response in the FVB assay. If a compound has been
identified as a potential hit compound either in HTS or SBDD, the IC50 value of the
compound is confirmed in both the FVB and secondary MDH assay (96-well plates).
Potent compounds (IC50 <30 mM) that do not inhibit MDH, are kinetically characterized
by their mode of inhibition and Ki values via the 96-well MDH assay. The MDH assay
was specifically chosen to determine Ki values as it records initial velocity measurements.
From Equation 10 and 13 in Section 4.2.8, those initial velocities are used to determine Ki
values. The FVB assay can be utilized to determine initial velocity measurements as well,
but it requires precise manual inactivation of the enzyme with EDTA over numerous time
points and is more labor intensive than the MDH assay. As the LDH assay was
determined to be an inappropriate secondary assay to assess aromatic a-keto acid
inhibition of PC, it has been removed from the screening process. However, a recently
optimized secondary assay has been established as a future secondary assay that
could assess the broad metal binding capabilities of the compounds against carbonic
anhydrase (Day and Cohen 2013). This metalloenzyme assay was optimized in 96-well
plates by undergraduate researcher, Mallory Mews. The assay may give some insight into
whether or not a compound is a promiscuous metal chelator. This assay will only be used
for the most potent and promising inhibitors that have been thoroughly characterized as it
is estimated to cost $14/plate to test against carbonic anhydrase.
Depending on the number of compounds that are tested in the future through both
the HTS and SBDD projects, as well as the number of researchers dedicated to evaluating
the compounds, the screening flow may have to be altered. For example, we receive on
average one compound per week from our collaborators. This rate is very manageable for
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an undergraduate researcher to assess the dose dependent response in both the FVB and
MDH assay each week. If this rate were to increase (hypothetically to 10
compounds/week), it would be recommended that the researcher test the compounds at
50-100 µM in the FVB assay and confirm potential hits with a dose dependent response
in the MDH assay. As more promising and potent hits are discovered, the limits for
progressing compounds to the secondary assays should be reevaluated to reflect the needs
of the project. In particular, potential hit compounds from HTS may become too
numerous to manage effectively with the current screening procedure and the
development of additional secondary assays may be essential in developing a robust HTS
program in conjunction with SBDD. For the remainder of this discussion, I will highlight
potential resources and areas for improvement for the HTS and SBDD projects.
5.2.1 Future Assay Development
Compounds from SBDD and HTS displayed higher potency against SaPC than
against LmPC or RePC, thus SaPC was the most appropriate PC enzyme that was utilized
in the FVB and MDH assays. However, for future assay development, consideration
should be given to determining the appropriate concentration of substrates based on the
PC enzyme (SaPC, RePC, LmPC etc.) that is being targeted in the assay. The subsaturating concentration of 2 mM pyruvate in the FVB assay is optimal for maximizing
the signal to noise ratio of the assay in RePC, but it has not been optimized for SaPC and
LmPC. The concentration of the substrates in an assay can impact the number and type of
inhibitors that are identified in a screening process (Acker and Auld 2014, Yang,
Copeland, and Lai 2009). The FVB assay in particular, should be modified to maximize
the signal to noise ratio (Glickman 2004) while also considering the KM value (Yang,
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Copeland, and Lai 2009) of pyruvate for each selected enzyme in HTS. Intuitively it
might be thought that as competitive inhibitors are generally more specific for enzyme
active sites (Acker and Auld 2014), then the assay should be modified to have pyruvate
concentrations below the KM value to increase the number of hits that may be competitive
inhibitors (Yang, Copeland, and Lai 2009) for the unique CT domain of PC. However,
noncompetitive inhibitors may be more preferable to discover in a screening approach as
those compounds generally bind at evolutionary less conserved allosteric sites and
increase selectivity of the compound for the target (Lindsley 2014). At all concentrations
of pyruvate, there should be the ability to identify noncompetitive inhibitors, therefore,
pyruvate concentrations below the KM value may be selective for both competitive and
noncompetitive inhibitors.
Depending on the number of hits that are routinely identified from HTS and
SBDD, a series of additional secondary assays must be established (Janzen 2014). These
secondary assays should ideally eliminate compounds that are either false positives or
compounds that target the conserved BC domain of PC. With these secondary assays in
place, the majority of the compounds that are progressed to dose dependent response
assays to confirm IC50 values will be compounds that: 1) inhibit the PC reaction and 2)
target the unique CT domain of PC.
The LDH assay measures the rate of oxamate-induced OAA decarboxylation in
the CT domain and was utilized to facilitate inhibition assays of the CT domain in
isolation. However, it was determined that several compounds inhibited LDH at
concentrations greater than 1 mM and, furthermore, that some compounds act as
substrates for LDH. These findings greatly complicate the use of an LDH-coupled assay
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to assess CT domain specific inhibition in PC and lead to the conclusion that the LDH
assay is inappropriate for assessing CT domain inhibitors of PC. While the FVB assay
procedure is currently designed to measure pyruvate carboxylation and can be an
alternative to the MDH coupled-enzyme assay, it could possibly be modified to assay
OAA decarboxylation to pyruvate as an alternative to the LDH coupled-enzyme assay.
This would be a beneficial secondary assay that could specifically assay the CT domain
reaction of PC.
To initiate the reaction, OAA would act as the substrate for the PC reaction
instead of the substrates that are used in the pyruvate carboxylation reaction (ATP,
bicarbonate and pyruvate). The assay would have to be optimized with and without
oxamate to determine if the substrate is necessary in this modified FVB assay. As
oxamate promotes OAA decarboxylation by accepting the carboxyl group from OAA to
form pyruvate and carbamyl oxamate (Lietzan, Lin, and St Maurice 2014), it greatly
increases the rate of the reaction. However, as the FVB assay is a fixed-time assay, if the
rate of the reaction is slow, the time to enzyme inactivation can be extended to increase
the signal to noise background. Instead of measuring the increase of FVB-OAA colored
adduct formation as for the pyruvate carboxylation assay, the decrease in absorbance of
the FVB-OAA colored adduct would be measured to report on OAA conversion to
pyruvate. Additionally, truncated versions of PC (DBC) could be applied in the assay so
only the CT domain is contributing to the reaction. Hits that are not true inhibitors of the
CT domain reaction would be identified by the decrease in FVB-OAA colored adduct
absorbance.
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In addition to the modified OAA decarboxylation FVB assay, other secondary
HTS assays that utilize ATP cleavage or fluorescent polarization could be developed to
assess CT domain inhibition. To assay if the compounds are inhibiting the conserved BC
domain of PC, a standard coupled ATPase assay with urea carboxylase (UC) could be
optimized for HTS. This assay measures the initial rate of ATP cleavage from the
conserved BC domain of UC with several coupled enzymes that include pyruvate kinase
and LDH (Lin, Boese, and St Maurice 2016). If a compound inhibits the ATP cleavage
reaction, it should be removed from follow up studies as it is an inhibitor that targets the
BC domain from UC or a possible inhibitor of the coupled-enzymes, pyruvate
kinase/LDH. Regardless if the inhibition is due to the inhibition of the BC domain from
UC or due the inhibition of pyruvate kinase/LDH, the compound is not specific for the
CT domain of PC as it can target other enzymes as well. However, LDH has been shown
to reduce aromatic a-keto acids (Friedrich et al. 1987) and we have demonstrated that
Compound 17 is utilized as a substrate by LDH, thus LDH may mask any inhibition in
this assay. A control should then be established in the secondary assay that measures the
possible reduction of the compounds by LDH. This control would include LDH, the
compound and NADH. If LDH reduces the compound and oxidizes NADH to NAD+, this
can be readily observed by measuring the change in absorbance of NADH at 340 nm.
Fluorescent polarization (FP) is a technique that could expand the ability to assess
the binding of small molecules to the BC or CT domains of PC. FP is a method that
utilizes the fluorescent properties of a compound based on the orientation of the
compound in solution relative to excited and emitted polarizing light (Lea and Simeonov
2011, Huang and Aulabaugh 2016). For example, if a fluorescent small molecule is not
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bound to PC and is constantly rotating in space, when it is excited by plane-polarized
light, the emitted light will become depolarized. If a fluorescent small molecule is bound
to PC, the movement of the small molecule becomes more limited and when it is excited
by plane-polarized light, the emitted light will be polarized. This technique can be used
with various PC domain truncations that could assess the binding of fluorescent small
molecules to either the BC domain or CT domain. For small molecules that are not
fluorescent, competition assays could be established with fluorescent compounds that are
known to bind to PC. For example, Compound 98 is a fluorescent small molecule due to
its conjugated aromatic rings and could be used to determine if a more potent inhibitor
was outcompeting it from the CT domain.
5.2.2 Future Directions in HTS
Based on the previous experiences of HTS from Chapter 3, it is recommended
that future screening be performed with libraries from which potential hits can be pursued
and confirmed in secondary assays. For example, we were unable to follow up on
potential hit compounds from the screens performed at UWM due to the compounds were
not made available for follow up studies. Synthesizing those potential hit compounds
would have required a major investment of resources and the compounds themselves
were no longer stored by the laboratory that performed the initial synthesis (Frankowski
et al. 2011). Or in the case of the NCI DTP library, NMR studies demonstrated that all of
the hit compounds were impure.
While there are a wide range of libraries that are currently available commercially
and through academic investigators, only several have been briefly highlighted. The
research group of Dr. Matt Scaglione at the Medical College of Wisconsin currently has a
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library consisting of ~40,000 compounds and funding for a technician to train other
researchers on the HTS instruments. The Scaglione library consists of the NCI DTP
Diversity IV set, a Life Chemical Diversity set (35,200 compounds), and a FDA
approved drug set. The High Throughput Analysis Laboratory at Northwestern
University also has a wide range of chemical libraries that can be utilized for HTS. The
High Throughput Analysis Laboratory can provide a ChemDiv Structural-Diversity set
(30,000 compounds), ChemBridge Drug-Like set (20,000 compounds), the Kozmin
Library (7000 compounds), and the Silverman Collection (custom library) to potential
collaborators. Lastly, the Molecular Libraries Probe Production Centers Network
(MLPCN) is an organization that partners with investigators that have developed novel
assays and have been approved to screen their library of compounds through an
application process. The MLPCN library consists of 350,000 chemically diverse
compounds with the additional support of medicinal chemists that optimize the validated
hits from the screens (Roy et al. 2010).
5.2.3 Future Directions in Structure Based Drug Design
The SBDD project has resulted in the discovery of the most inhibitors of PC
activity to be documented. As determined in Chapter 4, Compound 98 and para
substituted phenylpyruvic acids such as Compounds 17 and 114 are the most promising
hit compounds to be developed thus far. These inhibitors are competitive with respect to
pyruvate, contain aromatic a-keto acids and are hypothesized to inhibit the CT domain
reaction based on their enolic characteristics either by mimicking the enolpyruvate
intermediate or coordinating with the metal ion in the CT domain. Several compounds
have been designed centered on observations made through the docking, SAR and Ki
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determination studies. As Compound 98 is currently our most potent compound with a Ki
value of 0.74 µM, the structure of the compound was used as a scaffold for Compound A
and Compound B (see Table 5.1). The scaffold was modified with the addition of a fused
aromatic ring (Compound A) or linked aromatic ring (Compound B). The docking studies
suggest that aromatic p-p interactions between the compounds and Tyr628 may be a
possible coordination that is occurring. It is hypothesized that an additional aromatic ring
would increase the predictive binding affinity of the compound. However, aromatic
compounds are prone to solubility issues due to p-p interactions between the compound
molecules (Ritchie and Macdonald 2009), thus a carbon link was introduced in
Compound B to mitigate those possible effects. A study by Ritchie et al. suggests that the
more aromatic rings (specifically more than three) that are in a drug candidate, the more
likely it will face drug attrition (Ritchie and Macdonald 2009). While the compounds that
contain multiple aromatic rings may not be ideal drug candidates, they would be
beneficial to use in competitive FP assays to assess the binding of compounds that are not
fluorescent.
Lastly, the importance of the enol form was considered for future compound
development. As it had been demonstrated by the Hammett plot in Figure 4-5, the lower
the s value, the lower the IC50 value. Electron donating groups may promote the enol
form of the compounds in aqueous solutions (Larsen and Wieczorkowska 1974) and
therefore may be better inhibitors. Compound C is a NH2 para substituted phenylpyruvic
acid with a s value of -0.66. The lowest para substituted s value that has been currently
tested is -0.37 (Compound 17, IC50 value of 22 µM). The hypothetical future compounds
were docked in the open conformation of the CT domain of SaPCDBC. As a majority of
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predictive docking poses suggest, the compounds are not oriented in the same position as
pyruvate and thus are unlikely to promote the closed conformation of the CT domain.
The docking scores do not predict that Compound A, B or C will bind with greater
affinity than previously docked compounds and the docking poses suggest that
Compound C would coordinate more closely to the metal ion than A or B (see Figure 52). Despite the increased bulk of the additional aromatic ring, the docking poses predict
that the Compound A and B would still be able to access the CT domain, however, the
poses do not suggest any p-p interactions would occur.
Table 5-1. Hypothetical Future Compound Designs
Structure

Docking Score

Compound A
O

-36
OH

N

OH

Compound B
O

-36
OH

N

OH

Compound C
O

-35
OH

H 2N

OH
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Figure 5-2. Docking Poses of the Hypothetical Future Compounds

Figure 5-2. Docking poses of the hypothetical future compounds. Compound A is
represented by the pink stick model, Compound B by the yellow stick model and
Compound D by the green stick model. The compounds were docked in the open
conformation of the CT domain of SaPCDBC that is represented by the periwinkle
cartoon model.
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5.2.4 Future Directions in Cell-Based Assays
To expand the direction of the project towards cell-based assays, several
possibilities for testing well validated, stable and soluble compounds in assays for
antimicrobial and anticancer activity are briefly described. Minimum inhibitory
concentration (MIC) assays are standardized assays that can assess the antimicrobial
activity of compounds (Wiegand, Hilpert, and Hancock 2008). MIC assays could be
applied to determine the MIC of the compounds with L. monocytogenes, S. aureus, and
E. coli cultures. As PEPC replaces the function of PC by converting PEP to OAA in
enteric bacteria, PC is not present in E. coli (Jitrapakdee et al. 2008), and would serve as
the control for compounds that display PC specific antimicrobial activity. Dr. Ming You
at the Medical College of Wisconsin has published several studies that have investigated
the cell toxicity and anticancer effects of 3BP with NSCLC (Zhang et al. 2015, Zhang et
al. 2012) and may be a resource for testing the compounds in cytotoxicity assays such as
the MTT (3-(4, 5-dimethylthiazolyl-2)-2, 5-diphenyltetrazolium bromide) assay (Zhang
et al. 2012). MTT is reduced by metabolically active cells and can be utilized in a
colorimetric assay to measure cell viability and proliferation (van de Loosdrecht et al.
1994).
The NCI DTP is also another option to screen the compounds against cancer cell
lines as the program offers a free NCI-60 human tumor screen that will screen mailed
compounds against 60 cancer cell lines. The compounds are assessed for potential
anticancer properties, unique inhibition profiles and are compared to submitted
compounds that have been previously analyzed. In particular, the DTP has a total of 9
NSCLC cell lines, 7 breast cancer cell lines that include MCF-7 (low PC expression) and
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MDA-MB-231 (high PC expression) cancer cell lines (Shoemaker 2006). As PC is
known to have varying expression levels in certain cancer cell lines, this screen in
particular could demonstrate if the compounds: 1) have anticancer activity and 2) are
possibly specific for cancer cell lines that have high PC expression.
5.3 Conclusion
PC is an important metabolic enzyme that has been implicated in a wide range of
diseases and infection. Despite the importance of PC in these diseases and infections,
there are no specific and potent small molecule effectors available to study the structure,
regulation and specific role of PC in the cellular context. The methods developed in this
dissertation aimed to discover novel and potent small molecule effectors of PC activity.
The research presented in this dissertation describes a novel fixed time assay that has
been developed based on the reaction of the diazonium salt, FVB, with the final product
of the PC catalyzed reaction, OAA. This assay has been validated and can screen
numerous compounds in both HTS and SBDD projects. Through SBDD, potent inhibitors
that are specific for the CT domain reaction of PC have been discovered and developed.
These compounds can be utilized as the foundation for specific and potent chemical
probes of PC and have the potential to benefit a wide range of in vivo and in vitro studies.
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APPENDIX A: Fast Violet B Assay Optimization and Validation

Figure A1. Reagent Stability at Varying Temperatures

Time from preparation (min)

Time from preparation (min)

Figure A1. Reagent stability at varying temperatures. For both A and B, the background
signal (black) is the inactivated PC reaction with 12.7 mM EDTA. The reaction signal
(teal) is the PC reaction in the absence of added effectors. The activation signal (orange)
is the PC reaction in the presence of acetyl CoA (0.25 mM). The inactivation signal
(blue) is the PC reaction in the presence of the inhibitor, oxalate (5 mM). A) Reagents
used in the FVB-based assay are not stable in all reactions for up to 8 hours at when kept
on ice. B) All reagents used in the FVB-based assay are stable in all reactions for up to 8
hours at 22° C. Due to the stability of the reagents at 22° C, assay optimization
progressed with the reagents being kept at 22° C for the duration of all validation
experiments.
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Table A1. Validation Checklist for Plate Uniformity Assessment as Determined by
(Sittampalam et al. 2012)

Meets
Criteria?
Intra-Plate Tests

Check manually for drift/ edge effects in all
plates
All max (HI) signal CV’s < 20 %
All mid signal (unnormalized) CV’s < 20 %
All normalized mid signal (mid %) SD’s < 20
All min (LO) SD’s < Min (max (HI) SD, mid SD)
All SW’s >2
All Z’ Factors > 0.4 (and < 1; must pass one of 6
or 7)

96-well
3-Day
Inh.

96-well
2-Day
Act.

384-well
3-Day Inh.

Yes

Yes

Yes

Yes
Yes
Yes
Yes
Yes

Yes
Yes
Yes
Yes
Yes

Yes
Yes
Yes
Yes
Yes

Yes

Yes

Yes

Yes
Yes

Yes
Yes

Yes
Yes

Inter-Plate Tests
All within-day fold shifts < 2
All Average (between-)Day fold shifts < 2
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Figure A2. 96-Well Plate Format Procedure Optimization to 384-Well Plate Format

Figure A2. 96-Well Plate Format Procedure Optimization to 384-Well Plate Format
The background signal (black) is the inactivated PC reaction with 12.7 mM EDTA. The
reaction signal (teal) is the PC reaction in the absence of added effectors. The activation
signal (orange) is the PC reaction in the presence of acetyl CoA (0.25 mM). The
inactivation signal (blue) is the PC reaction in the presence of the inhibitor, oxalate (5
mM). The 96-well plate procedure was followed as described in Figure 3-4, except all
volumes were reduced by half so that the final volume was 60 µL. Consistent absorbance
values were observed for all reactions across the entire plate demonstrating that the 96well plate format could be modified to 384-well plate format with high signal variance
and low error.

170
Figure A3. 384-Well Plate Uniformity Assessment for Inhibition

Figure A3. Inhibition plate uniformity validation tests for RePC with oxalate in the 384well plate format. Uniformity tests show consistent signals across all plates and across
multiple days. There are no edge or drift effects in the plates and all statistical measures
are acceptable. 3-day inhibition plate uniformity assessment with 5 mM oxalate for the
minimal signal (blue diamonds), 90 µM oxalate for the middle signal (pink squares) and
the uninhibited PC reaction for the maximal signal (green triangles). The plate uniformity
validation test provided additional support for the robustness of the 384-well plate
format.
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Figure A4. 384-Well Plate FVB Assay LOPAC Screen

Figure A4. Results from the LOPAC (Library of Pharmacologically Active Compounds)
screens. A) Absorbance signals for individual plate controls, with 250 µM acetyl CoA
(pink squares) served as the activated reaction, PC reaction in the absence of effectors
(purple squares) served as the unaltered reaction and 5mM oxalate (blue squares) served
as the inhibited reaction. B) 3 plates in the LOPAC screen had excellent Z-factors, while
one did not. C) Screening data for the plates that were run in the LOPAC screen for A
and B in percent of inhibition. The two hit compounds that were consistently identified
across all three screens in the 96-well plate format, cisplatin and pyriplatin (Figure 3-12),
are the two compounds with the highest percent of inhibition (>90%). It was promising to
observe the same two consistent hits appear in both plate formats and these results
indicate that the 384-well plate can be used in screening larger libraries with RePC.
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Figure A5. University of Wisconsin-Milwaukee Screening Against RePC

Figure A5. Results from the University of Wisconsin-Milwaukee screens against RePC
A) Absorbance signals for individual plate controls, with 250 µM acetyl CoA (pink
squares) served as the activated reaction, PC reaction in the absence of effectors (purple
squares) served as the unaltered reaction and 5mM oxalate (blue squares) served as the
inhibited reaction. B) All 33 plates in the screen had excellent Z-factors except for the
first plate. C) Screening data for the plates that were run in the screen for A and B in
percent of activation. All results indicate that the 384-well plate format for the FVB assay
can be used to screen larger libraries of compounds. Despite screening a larger library,
there were still unremarkable results for potential activating hit compounds.
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Figure A6. Comparison of University of Wisconsin-Milwaukee Screening Against
RePC and LmPC.

Figure A6. Comparison of University of Wisconsin-Milwaukee Screening Against RePC
and LmPC.
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Table A2. KM Values of Pyruvate Under Varying Conditions with PC from Different
Species
KM
(mM)

KM with Acetyl
CoA
(mM)

KM with CoA
(mM)

0.75 ± 0.2

0.35 ± 0.03

1.2 ± 0.1

Listeria monocytogenes

0.68 ± 0.02

0.64 ± 0.04

0.30 ± 0.06

Staphylococcus aureus

2.0 ± 0.2

0.56 ± 0.03

0.58 ± 0.1

PC Origin
Rhizobium etli

Table A3. kcat Values of PC from Different Species with Varying Allosteric
Activators
kcat
(min-)

kcat with
Acetyl CoA
(min-)

kcat with CoA
(min-)

Rhizobium etli

140 ± 4

910 ± 13

240 ± 6

Listeria monocytogenes

30 ± 2

160 ± 2

120 ± 2

Staphylococcus aureus

250 ± 10

1400 ± 16

1300 ± 2

PC Origin
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Figure A7. FVB-OAA Colored Adduct Decrease in Absorbance with Increasing
Concentrations of CoA.

Figure A7. FVB-OAA Colored Adduct Decrease in Absorbance with Increasing
Concentrations of CoA. The interference of CoA with the FVB-OAA colored adduct was
first observed when increasing titrations of CoA or acetyl CoA resulted in a decrease in
the activation signals in the FVB assay at high concentrations of the activator. This had
previously never been documented before, so a series of controls were established.
Increasing CoA concentrations decreased the FVB-OAA colored adduct absorbance
(teal) in the presence of 300 µM OAA and standard assay conditions (blue). Even at 250
µM, the concentration that is used in the FVB assay for activation controls has a slight
decrease in absorbance. The error bars represent the standard deviation of the signal
across eight wells.
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APPENDIX B: Structure Based Drug Design

Figure B1: IC50 Determination for Substrate-Analog Inhibitors of Bacterial PC in
the MDH Assay

Figure B1. IC50 determination for substrate-analog inhibitors of bacterial PC in the MDH
assay. For all plots, the RePC inhibited reaction is represented by the green line, the
LmPC inhibited reaction is represented by the purple line, the SaPC inhibited reaction is
represented by the teal line and the FVB-OAA colored adduct inhibition is represented by
the black line. In all panels, the error bars represent the standard deviation across eight
wells. A) The IC50 values for oxalate were 51 µM, 21 µM and 3 µM for RePC, LmPC
and SaPC respectively. B) The IC50 values for 3BP were 1 mM, 7 µM and 51 µM RePC,
LmPC and SaPC respectively. The SaPC IC50 value was determined by Mallory Mews
and was not included in this graph.
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Table B1. Aromatic Ring Substitution SAR of PC Inhibitors and Percent of
Inhibition of the Assay Signal at 1 mM or 200 µM
R1

O

Aromatic a-keto acids ring substitutions
R1= Ortho position
R2= Para position
R3= Meta position

OH
O

R2
R3

FVB 1mM/ 200 µM MDH 1mM/ 200 µM
%
%

Compound

R1

R2

R3

96

H

H

H

6/-10

78/0

19

N2O

H

H

ND

ND

110

H

N2O

H

ND

ND

115

Br

H

H

ND

ND

97

H

Br

H

45/-10

9/0

108

H

H

Br

28/-11

ND/0

112

H

H

CH3

21/-10

74/13

114

H

CH3

H

18/-10

10/-3

120

H

Cl

H

36/-12

12/2

106

H

OCH3

H

25/-10

ND/-15

119

H

B(OH)2

H

34/-10

-48/17

109

H

CF3

H

20/-10

ND/-11

107

H

F

H

35/-12

78/23

17

H

OH

H

64/-10

9/-17

117

H

CH3

CH3

14/-11

-17/3

*Color sections represent identical R constituents at different aromatic ring substitute
positions
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Table B2. Additional Docking Scores with Various Protein PDB Files

Compound

Biotin

Metal

No
Metal

Metal
and H2O

Metal,
H2O and
Open
Conf.

-

-45

-24

-22/-25

-24/-42

+

-40

-25

-25/-24

---

-

-41

-24

-28/-42

-37-18

+

-38

-25

-37/-27

---

-

-40

-20

-42/-44

-40/-40

+

-41

-24

-43/-43

---

-

-20

-17

-22/ND

-20/ND

+

-19

-18

-21/ND

---

-

-42

-17

-36/-31

-35/-38

+

-22

-15

-17/-22

---

-

-31

---

-22

-35

+

-35

---

-18

---

-

-56

---

-44

-49

+

-33

---

-39

---

Pyruvate
OHO

O

3-Bromopyurvate
Br

OH

HO

O

3-Hydroxypyruvate
O
HO

OH
OH

Oxalate
HO

OH

HO

OH

Ki= 0.29, IC50= 3
Compound 98
O
OH
N

OH

Ki= 0.74, IC50= 8
Compound 114
O
OH
OH

Ki= 2.4, IC50= 17
Compound 122
O
OH
HO

OH
OH

O

Ki= TBD, IC50= 23
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Compound 42
O
O

OH

-

-40

---

-37

-38

+

-39

---

-39

---

-

-9

---

-12

-22

+

-4

---

-8

---

-

-14

---

-19

-22

---

-10

---

OH

O

Ki= TBD, IC50= 160
Compound 103
O
O
N

OH

Ki= 140, IC50= TBD
Compound 101
HO

O
O

N
H

O

Ki= , IC50=
+
-9
* The slash (/) refers to the enol/keto docking scores
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Table B3. Enol and Keto Docking Scores of Pyruvate, Compound 17 and
Compound 110
Compound

Closed

Closed with
Biotin

Open

-46

-25

-22

-25

-25

-42

-37

-32

-38

-39

-41

-37

-44

-47

-40

-41

-39

-35

Pyruvate-keto
OH
O
O

Pyruvate-enol
OH
HO
O

17-keto
O

OH
O
HO

17-enol
O

OH
OH
HO

110-keto
O

OH
O
NO2

110-enol
O

OH
OH
NO2

Compound 110= EWG (s 0.778, IC50= >1000 µM), keto
Compound 17= EDG (s -0.37, IC50=22 µM), enol
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Figure B2. Oxalate, Compound 98, Compound 114 and Compound 103 are
Noncompetitive with Respect to ATP

Figure B2. Oxalate, Compound 98, Compound 114 and Compound 103 are
noncompetitive with respect to ATP. Left panels are global fits and right panels are
Lineweaver-Burk plots. A) Oxalate is a mixed type inhibitor (strongly favors
noncompetitive inhibition), Ki value = 2.5 µM. B) Compound 98 is a noncompetitive
inhibitor, Ki value = 5.2 µM. C) Compound 114 is a noncompetitive inhibitor, Ki value =
29 µM. D) Compound 103 is a noncompetitive inhibitor, Ki value = 740 µM.
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Figure B3. Oxalate, Compound 98, Compound 114 and Compound 103 are
Competitive with Respect to Pyruvate

Figure B3. Oxalate, Compound 98, Compound 114 and Compound 103 are competitive
with respect to pyruvate. Left panels are global fits and right panels are Lineweaver-Burk
plots. A) Oxalate is a mixed type inhibitor (strongly favors competitive inhibition), Ki
value = 0.29 µM. B) Compound 98 is a competitive inhibitor, Ki value = 0.74 µM. C)
Compound 114 is a competitive inhibitor, Ki value = 2.4 µM. D) Compound 103 is a
competitive inhibitor, Ki value = 141 µM.
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Figure B4. Cartoon Representation of SaPC, RePC and LmPC CT Domain Active
Site in the Open Conformation.

Figure B4. Cartoon representation of SaPC, RePC and LmPC CT domain active site in the
open conformation. Structural overlays of the open conformation of the CT domain in
SaPCDBC (unpublished, blue), LmPC (pdb i.d. 4qsl- green (Sureka et al. 2014)) and
RePC (pdb i.d. 2qf7-orange (St Maurice et al. 2007)), there are slight shifts in the helices
lining the CT domain tunnel such that RePC appears to have a tighter tunnel than LmPC
or SaPC.
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APPENDIX C: Protein Purification and Crystallization Attempts

Cloning of Domain Truncation Mutations of LmPCDBC, LmPCDBCDBCCP and
HsPCDBC

All cloning methods for LmPCDBC, LmPCDBCDBCCP and HsPCDBC proceeded
through the same method described in Section 4.2.5. For the BC domain truncations,
Lys458 and Lys490 were determined represented the C-terminal end of the BC domain of
LmPC and HsPC respectively. For the LmPCDBCDBCCP truncation was determined that
Asn1059 represented the C-terminal end of the allosteric domain. The construct therefore
ended at Asn1059 and a stop codon, TGA, was incorporated at residue 1060 in the primer
design. All BC and BC/BCCP domain truncations were cloned into the pET-28a-(His)8TEV expression vector from PCR amplified from the wild-type LmPC pET-28a-(His)8TEV template or wild-type MBP-HsPC pKLD116 (see Section 5.1.4). All clones were
verified by sequencing of the complete gene by Functional Biosciences Inc. The forward
and reverse primers for LmPCDBC, LmPCDBCDBCCP and HsPCDBC were as followed:

LmPCDBC:
5’- GCCTGCAGCATATTCGCGACCGT- 3’ (forward; PstI restriction enzyme)
5’- GCGCGCTCGAGTCAAATTCTGTTTAC- 3’ (forward; XhoI restriction enzyme)
LmPCDBCDBCCP:
5’- GCCTGCAGCATATTCGCGACCGT- 3’ (forward; PstI restriction enzyme)
5’- CGCCTCGAGTCAGTTCATATCTTGGAT - 3’ (forward; XhoI restriction enzyme)
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HsPCDBC:
5’- CGCATATGCGGCCTGCACAG - 3’ (forward; NdeI restriction enzyme)
5’- ATGCGGCCGCTCACTCGATCTC - 3’ (reverse; NotI restriction enzyme)

Protein purification of LmPCDBC, LmPCDBCDBCCP and HsPCDBC followed the
methods outlined in Chapter 2 with LmPC, SaPC, SaPCDBC and SaPCDBCDBCCP.

Figure C1. Protein Purification SDS Gel of HsPCDBC

Figure C1. Protein purification SDS gel of HsPCDBC. ~ 3 mgs of 2.5 mg/mL HsPCDBC
was collected following the protein purification method outlined in Chapter 2. 1) Marker,
2) total fraction, 3) insoluble fraction, 4) soluble fraction 5) Ni2+ column run through after
the addition of protein to the column, 6) after 300 mL of lysis and wash buffer was
applied to the column to remove nonspecific protein, 7) eluted protein from the Ni2+
column, 8) Q-Sepharose run through after the addition of protein to the column and 9)
eluted protein from the Q-Sepharose column with a molecular weight ~ 80 kDa as
expected.

186
Figure C2. Specific Activity of MBP-HsPC

Figure C2. Specific activity of MBP-HsPC. MBP- HsPC was co-expressed from a
modified pKLD116 vector (designed by Ann Menefee, previous post-doctoral researcher)
with a pCY216 vector encoding E. coli biotin protein ligase (BirA) in E. coli HMS cells.
After elution from the Ni2+-NTA Profinity resin column in Ni2+-affinity chromatography
(represented by the first SDS gel), the soluble protein was isolated from the aggregated
by fast protein liquid chromatography (FPLC). The aggregated protein eluted in fractions
7-12 with very little specific activity. The active form of the enzyme eluted in fractions
13-17. The purified, active and soluble protein is represented by the SDS-gel
corresponding to the 150 kDa bands from each fraction. The highest specific activity of
HsPC in the presence of acetyl CoA when isolated from the soluble protein was 4.4 µmol
min- mg- while the specific activity of the aggregated protein was 0.19 µmol min- mg-.
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Figure C3. Activity of MBP-HsPC in the FVB Assay

Figure C3. Activity of MBP-HsPC in the FVB assay. The activity of MBP-HsPC purified
from FPLC (fractions 13-17 collected from Figure C2) and MBP-HsPC collected before
FPLC (Ni2+-affinity chromatography) was measured in the FVB assay in the presence of
EDTA (black), the unaffected reaction in the presence of assay buffer (grey) and in the
presence of acetyl CoA (green). The FPLC samples demonstrated higher specific activity
in Figure C2, but were not as active as the protein samples before FPLC in the FVB
assay. The Z-factors for activation were 0.74 and 0.72 for the FPLC purified MBP-HsPC
and for the Ni2+-affinity chromatography purified MBP-HsPC respectively.
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Compound Crystallization Conditions of Hit Refinements

A variety of hit RePC, LmPC and SaPC crystals were refined from crystallization
conditions in hanging drop/sitting drop vapor diffusion and batch crystallization. These
conditions were pursued in the hopes of crystallizing PC with small molecule
compounds. The most promising crystals were diffracted on SaPCDBC crystals, and data
was collected as described in Chapter 4 (see Table C1). General screening solutions from
the St. Maurice research laboratory (144 conditions) were successful in the establishment
of several hit conditions for RePC, LmPC, SaPC, SaPCDBC and SaPCDBCDBCCP. The
most successful refinements based on those hit conditions are listed in Table C2.
However, the general screen was not successful in identifying crystals for LmPCDBC and
LmPCDBCDBCCP. Due to the unsuccessful screening of LmPC truncation crystals, a PC
general screen was created based on published crystallization conditions (see Table C3).
The PC general screen did not result in crystal hits for LmPC, but resulted in numerous
hits for SaPC truncations.
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Table C1. Data Collection and Refinement Statistics
Xtal371
Compound 17
P42212

Xtal 363
(Compound 98)
P4212

a, b, c (Å)

125.9, 125.9, 97.5

126.9, 126.9, 97.1

a, b, g (°)

90, 90, 90

90, 90, 90

Resolution range, Å

50.00-2.30

44.87-2.88

(3.00-2.95)

(2.98-2.88)

Redundancy

5.96 (5.22)

5.84 (4.25)

Completeness (%)

99.8 (98.0)

98.1 (84.6)

Unique Reflections

13475

18253

Rmerge (%)

0.223 (0.581)

0.255 (0.744)

Average I/s

4.8 (1.9)

4.1 (1.0)

Space Group
Cell Dimensions

Refinement: In Progress
Rcrystal

0.2690

0.2368

Rfree

0.3155

0.2889

Xtal371 is SaPCDBC co-crystallized with 10 mM Compound 17
Xtal363 is SaPCDBC soaked with 15 mM Compound 98
(highest bin)
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Table C2. Refined Crystallization Hits for PC

RePC
Protein [ ]
Method
Refined
condition
Compound
Crystal
morphology

Additional
Techniques

10.8 mg/mL
Sitting/hanging drop
vapor diffusion
50-100 mM CaCl2
12% PEG 4K
140 mM MES
pH 6.0
200- 400 µM TNPATP
Large, clustered, thin
3D plates, ~ 1 cluster
per drop
Stocks of TNP-ATP
were prepared under
red light and plating
the protein with the
crystallization
conditions were
performed under red
light

RePC
DBCDBCCP
15 mg/mL
Batch under oil
345 mM TMACl
11% PEG 8K
100 mM Bis Tris
pH 6.0
apo

LmPC
11.7 mg/mL
Sitting/hanging drop
vapor diffusion
170-200 mM
NaMalonate
16% PEG 8K
100 mM TEA pH 7.5
10 mM CoA
10 mM CoA with 10
mM Compound 17

Medium, individual
spherical crystals, ~5
per drop

Large, broken crystals
~1 crystal per drop

---

Crystallized well in
both hanging and
sitting, appeared to do
well with the addition
of compounds other
than CoA
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Table C3. The BW PC General Screen
1
200 mM Am.
Tartrate
A

0% PEG
3350
15% PEG
3350

B

200 mM Am.
tartrate
10% PEG
3350

C

100 mM Bis
Tris pH 6

2

3

4

200 mM
Am.
Tartrate

200 mM
Am.
Tartrate

200 mM
Am.
Tartrate

200 mM
Am.
Tartrate

5% PEG
3350
15% PEG
3350

10% PEG
3350
15% PEG
3350

15% PEG
3350
15% PEG
3350

20% PEG
3350
15% PEG
3350

25% PEG
3350
15% PEG
3350

200 mM
Am.
phospate
15% PEG
3350

200 mM
Am.
thiocynate
15% PEG
3350

100 mM
Am.
chloride
10% PEG
8K

100 mM
Am.
sulfate
16% PEG
3350

200 mM
Na citrate

100 mM
TE pH 8

100 mM
Bis-Tris
6.5

200 mM
Am.
Tartrate

18% PEG
3350
200 mM Na
acetate

84 mM
MgSO4

84 mM
MgSO4

D
100 mM
Hepes 7.5

100 mM
Hepes 7.5

200 mM
Am.
Tartrate
100 mM
Hepes 7.5

A1-A6
200 mM Ammonium tartrate constant
0-25% PEG 3350
C1-C6, D1-D6
Varying PEGs
Varying pH
Varying salts

6

200 mM
Am.
Tartrate

100 mM
100 mM Bis
Bis Tris pH Tris pH 7
6.5
84 mM
100 mM
MgSO4
Am.
tartrate
18%
18%
MePEG 2K MePEG 2K

200 mM Am.
tartrate

5

350 mM
TMACl
18%
18%
MePEG 2K MePEG
2K
84 mM
MgSO4
200 mM
MgSO4
200 mM
Am.
200 mM
Tartrate
Am.
Tartrate

B1-B6
15% PEG 3350
Varying salts

19% PEG
3350

100 mM
Bis-Tris
7.0
18%
MePEG
2K
200 mM
Am.
Tartrate

